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Introduction to the thesis 
 
General info development taxanes 
 Over forty years ago, samples of the Taxus brevifolia, the pacific yew tree, 
were screened by the National Cancer Institute (NCI) for anticancer activity. 
Screening indicated that an extract from the tree possessed activity against 
tumour cell lines. Paclitaxel the active compound of the extract, was isolated 
in its pure form in 1969.(1) The mechanism of action was not described until 
1979 when Schiff and Horwitz discovered its unique mechanism of 
cytotoxicity.(2) In contrast to other mitotic agents, paclitaxel and docetaxel 
promoted the assembly of tubulin and stabilised the resulting microtubules. 
Clinical studies with paclitaxel started in 1983. At the same time French 
researchers produced semisynthetic derivatives of baccatin III, an extract 
from the needles of the European yew Taxus baccata, and modified it with a 
chemically synthesised side chain. Docetaxel emerged from these efforts and 
entered clinical trials in 1990.(3) 
 Drug vehicle, drug-interactions, tissue penetration and age are all factors 
affecting drug pharmacokinetics, and are the focus of this thesis. 
 
Vehicle selection 
 A major difficulty in the development of both paclitaxel and docetaxel 
was their insolubility in water. Paclitaxel as currently formulated (Taxol), is 
dissolved in a vehicle containing Cremophor EL (CrEL) and alcohol. CrEL, a 
non-ionic surfactant, is a polyoxyethylated castor oil. Docetaxel (Taxotere) 
is currently formulated in polysorbate 80 (Tween 80), an oleate ester of 
sorbitol. Though the vital role that pharmaceutical excipients have in drug 
formulation has been neglected, it is now well recognised that excipients can 
result in adverse effects(4) and have the potential to cause drug 
interactions.(5) This is reviewed in the second chapter of this thesis. 
Investigations in the disposition of Tween 80 are outlined in the third 
chapter.  
 
Interaction 
 In this thesis the influence of other chemical compounds on the 
pharmacokinetics (PK) of paclitaxel and docetaxel is investigated. The 
overexpression of the transmembrane drug transporter P-glycoprotein (P-gp) 
plays an important role in pharmacokinetics and clinical drug resistance.(6,7) 
Numerous clinical trials have been performed to develop inhibitors of P-gp 
with the aim to overcome drug resistance.(8) Unfortunately, the combination 
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of anticancer agents and P-gp inhibitors necessitated significant dose 
reduction of the anticancer drugs due to a substantial rise in serious side 
effects.(9) Intended modulation of paclitaxel by co-administration of the 
potent P-glycoprotein inhibitor valspodar was studied with specific focus on 
the PK of the unbound fraction of paclitaxel to explore the interaction 
between these drugs that are both substrates of the cytochrome P450 
isozyme 3A (CYP3A). 
 Docetaxel is also primarily metabolised by CYP3A. Due to significant 
interindividual differences in CYP3A activity docetaxel PK is subject to large 
interindividual differences.(10) In patients with prostate cancer this 
anticancer drug is combined with ketoconazole because both drugs are 
known to have anti-prostate cancer properties.(11) Unfortunately, 
ketoconazole is a potent CYP3A inhibitor. Therefore, this combination is 
likely to have undesirable clinical consequences due to a much slower 
metabolising rate of docetaxel in the presence of this inhibitor. A more 
desirable side-effect of this drug combination is possibly the reduction of 
interindividual variation in docetaxel PK, leading to a more predictable 
toxicity profile and allowing optimal dosing strategy whilst maintaining 
cytotoxic efficacy. 
 
CSF Penetration 
 Although the brain is among the best perfused organs in the body, most 
drugs do not accumulate into the brain due to the blood brain barrier (BBB). 
In patients treated for MBC with docetaxel a high incidence of isolated 
central nervous system (CNS) metastasis was noted, suggesting that the CNS 
might be a sanctuary site for malignant cells during chemotherapeutic 
treatment. On the other hand, several studies suggested that the BBB might 
be disrupted in the presence of metastasis, suggesting the possibility of 
penetration of the cytotoxic agent. We performed a PK study on penetration 
of docetaxel in the cerebrospinal fluid (CSF).   
 
Elderly 
 Elderly patients with cancer are not only less likely to receive 
chemotherapy, they are similarly underrepresented in clinical trials, despite 
the fact that more then 50% of all new patients with breast and lung cancer 
are older than 65 years.(12,13) This is leading to an important treatment bias 
against older cancer patients. In an effort to assess the PK, toxicity and 
responses of older patients with cancer to taxane treatment we conducted 
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several studies to investigate the effects of both paclitaxel and docetaxel in 
these patients. 
 
References 
 
1.  Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., and McPhail, A. T. Plant antitumor 
agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor 
agent from Taxus brevifolia. J.Am.Chem.Soc., 93: 2325-2327, 1971. 
2.  Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro 
by taxol. Nature, 277: 665-667, 1979. 
3.  Ringel, I. and Horwitz, S. B. Studies with RP 56976 (taxotere): a semisynthetic 
analogue of taxol. J.Natl.Cancer Inst., 83: 288-291, 1991. 
4.  Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A. Cremophor EL: the 
drawbacks and advantages of vehicle selection for drug formulation. Eur.J.Cancer, 37: 
1590-1598, 2001. 
5.  Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Nonlinear 
pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle 
Cremophor EL. Cancer Res., 56: 2112-2115, 1996. 
6.  Juliano, R. L. and Ling, V. A surface glycoprotein modulating drug permeability in 
Chinese hamster ovary cell mutants. Biochim.Biophys.Acta, 455: 152-162, 1976. 
7.  Chaudhary, P. M. and Roninson, I. B. Expression and activity of P-glycoprotein, a 
multidrug efflux pump, in human hematopoietic stem cells. Cell, 66: 85-94, 1991. 
8.  Sonneveld, P., Durie, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, 
R., Lowenberg, B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma 
by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 340: 
255-259, 1992. 
9.  Fracasso, P. M., Westervelt, P., Fears, C. L., Rosen, D. M., Zuhowski, E. G., Cazenave, 
L. A., Litchman, M., Egorin, M. J., Westerveldt, P., and Fears, C. A. Phase I study of 
paclitaxel in combination with a multidrug resistance modulator, PSC 833 
(Valspodar), in refractory malignancies. J.Clin Oncol, 18: 1124-1134, 2000. 
10.  Bruno, R., Hille, D., Riva, A., Vivier, N., Bokkel Huinnink, W. W., van Oosterom, A. T., 
Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V., Rigas, J. R., Seidman, A. D., 
Chevallier, B., Fumoleau, P., Burris, H. A., Ravdin, P. M., and Sheiner, L. B. 
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in 
patients with cancer. J.Clin.Oncol., 16: 187-196, 1998. 
11.  Van Veldhuizen, P. J., Reed, G., Aggarwal, A., Baranda, J., Zulfiqar, M., and 
Williamson, S. Docetaxel and ketoconazole in advanced hormone-refractory prostate 
carcinoma: a phase I and pharmacokinetic study. Cancer, 98: 1855-1862, 2003. 
12.  Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., Jr., and Albain, K. S. 
Underrepresentation of patients 65 years of age or older in cancer- treatment trials. 
N.Engl.J.Med., 341: 2061-2067, 1999. 
13.  Trimble, E. L., Carter, C. L., Cain, D., Freidlin, B., Ungerleider, R. S., and Friedman, 
M. A. Representation of older patients in cancer treatment trials. Cancer, 74: 2208-
2214, 1994. 
  
Chapter 2 
Pharmacological effects of formulation vehicles: 
implications for cancer chemotherapy 
A.J. ten Tije,1 J. Verweij,1 W.J. Loos,1 A. Sparreboom1,2 
1Department of Medical Oncology, Erasmus MC - Daniel den Hoed 
Cancer Center, Rotterdam, the Netherlands; 2National Cancer 
Institute, Bethesda, Maryland, USA 
Clinical Pharmacokinetics 42: 665-685, 2003 
Chapter 2 
14 
Abstract 
 
 The non-ionic surfactants Cremophor EL (CrEL; polyoxyethyleneglycerol 
triricinoleate 35) and polysorbate 80 (Tween 80; polyoxyethylene-sorbitan-
20-monooleate) are widely used as drug formulation vehicles, including for 
the taxane anticancer agents paclitaxel and docetaxel. A wealth of recent 
experimental data has indicated that both solubilisers are biologically and 
pharmacologically active compounds, and their use as drug formulation 
vehicles has been implicated in clinically important adverse effects, including 
acute hypersensitivity reactions and peripheral neuropathy. CrEL and 
Tween 80 have also been demonstrated to influence the disposition of 
solubilised drugs that are administered intravenously. The overall resulting 
effect is a highly increased systemic drug exposure and a simultaneously 
decreased clearance, leading to alteration in the pharmacodynamic 
characteristics of the solubilised drug. Kinetic experiments revealed that this 
effect is primarily caused by reduced cellular uptake of the drug by large 
spherical micellar-like structures with a highly hydrophobic interior, which 
act as the principal carrier of circulating drug. Within the central blood 
compartment, this results in a profound alteration of drug accumulation in 
erythrocytes, thereby reducing the free drug fraction available for cellular 
partitioning and influencing drug distribution as well as elimination routes. 
The existence of CrEL and Tween 80 in blood as large polar micelles has 
also raised additional complexities in the case of combination chemotherapy 
regimens with taxanes, such that the disposition of several coadministered 
drugs, including anthracyclines and epipodophyllotoxins, is significantly 
altered. In contrast to the enhancing effects of Tween 80, addition of CrEL 
to the formulation of oral drug preparations seems to result in significantly 
diminished drug uptake and reduced circulating concentrations.  
 The drawbacks presented by the presence of CrEL or Tween 80 in drug 
formulations have instigated extensive research to develop alternative 
delivery forms. Currently, several strategies are in progress to develop 
Tween 80- and CrEL-free formulations of docetaxel and paclitaxel, which 
are based on pharmaceutical (e.g. albumin nanoparticles, emulsions and 
liposomes), chemical (e.g. polyglutamates, analogues and prodrugs), or 
biological (e.g. oral drug administration) strategies. These continued 
investigations should eventually lead to more rational and selective 
chemotherapeutic treatment. 
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Table 1. Examples of clinical drug preparations using Cremophor EL or 
Tween 80 
Agent Therapeutic class Amount administered (mL)a 
Cremophor EL 
Kahalalide F 
Diazepam 
Aplidine 
Teniposide 
Didemnin B 
Cyclosporin 
C8KC 
Propofol 
Clanfenur 
BMS-247550 
DHA-paclitaxel 
Paclitaxel  
 
Tween 80 
Carzelesin 
Docetaxel 
Etoposide 
 
Antineoplastic 
Sedative 
Antineoplastic 
Antineoplastic 
Antineoplastic 
Immunosuppressive 
Photosensitiser 
Anaesthetic 
Antineoplastic 
Antineoplastic 
Antineoplastic 
Antineoplastic 
 
 
Antineoplastic 
Antineoplastic 
Antineoplastic 
 
~0.5b 
1.5 
~1.5b 
1.5 
2.0 
3.5 
5.5 
7.0 
10.3 
~10b 
19.9 
25.8 
 
 
0.1 
2.0 
2.0 
 
a For an average patient with a body-surface area of 1.77 m2. 
b Investigational agent for which recommended dose has not yet been established. 
 
 
 Paclitaxel and docetaxel are hydrophobic antineoplastic agents 
demonstrating significant antitumour activity against a broad spectrum of 
human malignancies. After the identification of paclitaxel as the active 
ingredient in crude ethanolic extracts of the bark of the Pacific yew tree, 
Taxus brevifolia L, the development of this drug was suspended for over a 
decade because of problems in drug formulation.(1) After investigation of a 
large variety of excipients to enable parenteral administration of paclitaxel, 
the formulation approach using the polyoxyethylated castor oil derivative, 
Cremophor EL (CrEL; polyoxyethyleneglycerol triricinoleate 35), represented 
the most viable option.(2) Currently, paclitaxel is commercially available as 
vials containing 30 mg of drug dissolved in 5 mL of CrEL/dehydrated 
ethanol USP (1:1 by volume). CrEL is widely used as a vehicle for the 
solubilisation of a number of other hydrophobic drugs, including 
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anaesthetics, vitamins, sedatives, photosensitisers, immunosuppresives, and 
(experimental) anticancer drugs (Table 1). The amount of CrEL per 
administration of paclitaxel is relatively high, and therefore its toxicological 
and pharmacological behaviour in the context of chemotherapeutic 
treatment with paclitaxel is of major importance.(3) 
 The structurally related taxane docetaxel is prepared by chemical 
manipulation of 10-deacetyl-baccatin III, an inactive precursor isolated from 
the needles of the European yew tree, Taxus baccata L.(4) Like paclitaxel, it is 
a potent inhibitor of cell replication by stabilisation of the microtubule 
cytoskeleton. For clinical use, this slightly less hydrophobic agent is 
formulated in another polyoxyethylated surfactant, polysorbate 80 (Tween 
80). The clinically used formulation consists of 80 mg of docetaxel in 2 mL of 
undiluted Tween 80. This non-ionic surfactant is also used to solubilise 
several other anticancer drugs, including etoposide and minor-groove-
binding cyclopropylpyrroloindole analogues such as carzelesin (Table 1). 
 In recent years, substantial evidence has been generated suggesting that 
CrEL and Tween 80 are biologically and pharmacologically active 
compounds. In this report, we will review the physicochemical and biological 
properties of both non-ionic surfactants, with a focus on their effects on the 
disposition characteristics of the carried drugs and that of other agents 
administered concomitantly. 
 
1. Physicochemical properties of surfactants 
 
 CrEL is a white to off-white viscous liquid with an approximate molecular 
weight of 3000 Da and a specific gravity 1.05-1.06. It is produced by the 
reaction of castor oil with ethylene oxide at a molar ratio of 1:35. Castor oil is 
a colourless or pale yellow fixed oil obtained from the seeds of Ricinus 
communis, with an extremely high viscosity, and consists mainly of the 
glycerides of ricinoleic, isoricinoleic, stearic, dihydroxystearic, and oleic 
acids. The non-ionic surfactant produced from castor oil is usually of highly 
variable composition, with the major component (about 87%) identified as 
oxyethylated triglycerides of ricinoleic acid (Figure 1). As a result of the 
heterogeneous nature of castor oil and its variable composition, the 
polyoxyethylated components of CrEL have been poorly characterised. Using 
fractionation by cyclodextrin-modified micellar electrokinetic capillary 
chromatography (CD-MEKC) and UV detection, in combination with delayed 
extraction matrix-assisted laser desorption/ionisation time of flight mass 
spectrometry (DE-MALDITOF-MS), a more detailed structural elucidation 
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and a semiquantitative analysis of CrEL components was achieved 
recently.(5) These investigations indicated that the elimination of water from 
ricinoleic acid during the synthesis of CrEL leads to various previously 
unidentified species, including (glycerol-)polyoxyethylene-∆9,11-
didehydrostearate. It is noteworthy that equipment used for intravenous 
administration of CrEL should be free of polyvinylchloride, since CrEL is 
capable of leaching phtalate-type plasticisers from polyvinylchloride infusion 
bags and polyethylene-lined tubing sets, which can cause severe hepatic 
toxicity.(6,7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of the primary constituents of CrEL 
(polyoxyethyleneglycerol triricinoleate 35; A) and Tween 80 (polyoxyethylene-20-
monooleate; B). 
 
 
 In contrast to CrEL, Tween 80 is a relative homogenous and 
reproducible, amber-coloured, viscous liquid (270-430 centistokes) with a 
molecular weight of 1309.7 Da, and a density of 1.064 g/mL. The base 
(CH2CH2O)zOCO(CH2)7CH=CH(CH2)7CH3
(CH2CH2O)yOH
HO(CH2CH2O)w (CH2CH2O)xOH
O
H2C(CH2CH2O)zOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
HC(CH2CH2O)yOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
H2C(CH2CH2O)xOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
            
A
B
(x + y + z ~ 35)
(w + x + y + z ~ 20)
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chemical name of the major component of Tween 80 is polyoxyethylene-20-
sorbitan monooleate (Figure 1), which is structurally similar to the 
polyethyleneglycols. Like most non-ionic surfactants, CrEL and Tween 80 
are capable of forming micelles in aqueous solution, with critical micellar 
concentrations of 0.009% (weight/volume) and 0.01% (weight/volume), 
respectively, in protein-free aqueous solution.(8) 
 
2. Biological properties of surfactants 
 
2.1 Acute hypersensitivity reactions 
 The most extensively described biological effect of drugs formulated with 
CrEL is an acute hypersensitivity reaction characterised by dyspnoea, 
flushing, rash, chest pain, tachycardia, hypotension, angioedema and 
generalised urticaria, and this reaction has been attributed to CrEL.(9-12) 
Nevertheless, allergic reactions to taxanes formulated without CrEL have 
been reported as well,(13) suggesting that some functionality of the taxane 
molecule contributes, in part, to the observed effect. Already in the 1970s it 
was demonstrated that CrEL-containing drug preparations (e.g. rectal 
diazepam) can cause complement activation.(14,15) The mechanistic basis for 
this effect has not been fully elucidated, but a number of seminal studies 
indicate that CrEL-mediated complement activation plays a significant role. 
It has been postulated that due to binding of naturally occurring 
anticholesterol antibodies to the hydroxyl-rich surface of CrEL micelles, 
complement C3 is activated, leading to the clinical signs of hypersensitivity 
reactions.(16) The CrEL-induced complement activation is clearly 
concentration dependent, with a minimum CrEL concentration of 
approximately 2 µL/mL being required, a concentration readily achieved in 
plasma of cancer patients following standard doses of paclitaxel.(17) This 
explains why slowing down the infusion rate of paclitaxel formulated with 
CrEL can alleviate hypersensitivity symptoms, and also explains the need for 
proper dissolution of CrEL-containing drugs to prevent large variations in 
CrEL infusion rate leading to unpredictable reactions.(18) A recent 
investigation into the structure-activity relationships of surfactant-mediated 
complement activation has shown that several analogues of CrEL have 
reduced ability to induce complement activation as measured by a decrease 
in serum concentrations of the SC5b-9 marker (Figure 2). Additional clinical 
studies will be required to evaluate the clinical utility of some of these 
substitute vehicles for CrEL-containing drugs. 
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Figure 2. Vehicle-mediated complement activation in human serum by CrEL, Tween 
80 and some structurally related analogues. Experiments were based on 50 µL 
human serum incubations (45 minutes at 37°C) in the presence of each respective 
vehicle at a concentration of 10 µL/mL. The complement activation marker SC5b-9 
was measured by enzyme-linked immunoassay. Data are presented as mean values 
(bars) ± SD (error bars) of triplicate observations and were obtained from Loos et al.(19) 
 
 
 In studies with dogs it was demonstrated that CrEL, mainly its minor 
free-fatty acid constituents such as oleic acid, can cause histamine 
release.(20) Despite premedication with corticosteroids, and histamine H1 and 
H2 blockers, minor reactions (e.g. flushing and rash) still occur in 
approximately 40% of all patients,(21-24) with major potentially life-threatening 
reactions observed in 1.5 to 3% of treated patients.(9) 
 Oleic acid is also present in Tween 80, and thus may be a cause of 
hypersensitivity reactions to docetaxel therapy or other therapies using 
drugs with Tween 80 as a solvent. Patients allergic to intravenously 
administered etoposide tolerated the oral formulation, which is devoid of 
Tween 80, very well.(25-28) The early clinical studies with docetaxel revealed 
an incidence of hypersensitivity reactions ranging from 5-40%, with only a 
minority of more than grade 2 on the 4-point scale of the National Cancer 
Institute common toxicity criteria.(29-31) Hypersensitivity reactions to 
docetaxel therapy can be effectively ameliorated by premedication with 
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corticosteroids and antihistamines,(32) consistent with a role of histamine in 
its aetiology. A comparative evaluation of paclitaxel- and docetaxel-mediated 
non-haematological toxicities, with the drugs given in an every 21-day 
schedule, is provided in Table 2. 
 
2.2 Peripheral neurotoxicity 
 A well-known adverse effect of agents formulated in CrEL is peripheral 
neurotoxicity,(35) but it is less well acknowledged that CrEL may play an 
important causative role. In a study performed with radiolabelled paclitaxel 
in rats, no detectable paclitaxel could be demonstrated in the peripheral 
nerve fibers,(36) but electrophysiological studies in patients with neuropathy 
after treatment with paclitaxel have shown evidence of both axonal 
degeneration and demyelinisation.(37) In approximately 25% of patients 
treated with cyclosporin, neurotoxicity is noted.(38) This adverse effect is 
never induced by oral formulations of cyclosporin, which is consistent with 
observations that CrEL is not absorbed intact when given orally. Moreover, 
CrEL plasma concentrations achieved with therapeutic doses of intravenous 
paclitaxel or cyclosporin have been shown to produce axonal swelling, 
vesicular degeneration and demyelinisation in rat dorsal root ganglion 
neurons.(39,40) The precise mechanism of this CrEL-induced neurotoxicity 
remains unclear, but recent work has indicated that unsaturated fatty acids 
may cause neurotoxicity, possibly due to the appearance of peroxidation 
products(39,40). This suggests that the ethoxylated derivatives of castor oil 
probably account for most of the neuronal damage in addition to the 
presence of residual ethylene oxide residues.(41) 
 A detailed investigation into neurological adverse effects associated with 
docetaxel chemotherapy was recently performed in a group of 186 
patients.(42) Twenty-one patients developed mild to moderate sensory 
neuropathy on treatment at a wide range of cumulative doses (50-750 
mg/m2) and dose levels (10-115 mg/m2). Ten of these patients also 
developed weakness in proximal and distal extremities of varying degree.  
 Nine of the 21 patients had received neurotoxic chemotherapy before, 
and 16 were treated with docetaxel at a dose level of 100-115 mg/m2. This 
suggests that docetaxel produces a mild and predominantly sensory 
neuropathy in a high proportion of treated patients. This adverse effect 
appears to be dose-dependent and may be severe and disabling at higher 
dose levels.(42-44) Corticosteroid co-medication does not prevent docetaxel-
induced neuropathy.(45) 
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Table 2. Comparative nonhaematological toxicity of paclitaxel and docetaxela 
Adverse effect Incidence (%)  
 paclitaxel 
(n=812) 
docetaxel 
(n=2045) 
Hypersensitivity reactionsb 
All 
Severe (at least grade 3) 
 
Fluid retentionb,c 
All 
Severe 
 
Nail changesd 
All 
Severe (at least grade 3) 
 
Peripheral neuropathye 
All 
Severe (at least grade 3) 
 
Skin toxicityf 
All 
Severe (at least grade 3) 
 
41 
2 
 
 
0 
0 
 
 
2 
0 
 
 
60 
3 
 
 
2 
0 
 
15 
2 
 
 
64 
6.5 
 
 
31 
2.5 
 
 
49 
4 
 
 
48 
5 
 
a Data represent overall incidence as percentage of patients with solid tumours 
treated with single-agent regimens containing either paclitaxel formulated in a 
mixture of Cremophor EL and ethanol at doses of 135–300 mg/m2 or docetaxel 
formulated in Tween 80 at a dose of 100 mg/m2, given every 21-days.(33,34)  
b All patients received a 3-day dexamethasone premedication (docetaxel, n = 92).  
c Characterised by one or more of the following events: poorly tolerated peripheral 
oedema, generalised oedema, pleural effusion requiring urgent drainage, 
dyspnoea at rest, cardiac tamponade, or pronounced abdominal distension (due 
to ascites).  
d Mostly changes in pigmentation or discoloration of the nail bed.  
e Mostly peripheral sensory (numbness, paraesthesias, loss of proprioception), 
axonal degeneration and secondary demyelination. 
f Primarily involves pressure or trauma sites (e.g. hands, feet, and elbows). 
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Tween 80 is capable of producing vesicular degeneration. This property 
depends on the polyethylene substitutions produced by reaction of the polyol 
compound with ethylene oxide. However, the incidence of neurotoxicity 
during treatment with docetaxel is much lower as compared to that of 
paclitaxel (Table 2).(46,47) Furthermore, the Tween 80-containing 
epipodophyllotoxin etoposide is not known to be neurotoxic. This suggests 
that the aetiology of taxane-induced neuropathy is different for paclitaxel 
and docetaxel, with formulation vehicles contributing to the overall picture 
to a different extent. 
 
2.3 Dyslipidaemia 
 In the mid-1970s, lipoprotein alterations caused by CrEL were 
mentioned for the first time.(48) Later, CrEL was found to alter the buoyant 
density of high-density lipoprotein (HDL) and shift the electrophoretic and 
density gradient HDL to low-density lipoprotein (LDL).(49-52) These authors 
demonstrated the strong affinity of paclitaxel for serum lipoprotein 
degradation products, potentially affecting the pharmacokinetics of the drug 
by altering protein binding characteristics. High concentrations of CrEL may 
also cause dyslipidaemia, possibly resulting in rouleaux formation of 
erythrocytes.(53) Although cyclosporin is known for its atherosclerosis-
inducing capacities, it remains unclear if the observed hyperlipidaemia after 
CrEL administration is contributing to this risk for vascular accidents. In 
vivo studies of the effects of cyclosporin on the de-endothelialised carotid 
artery of New Zealand White rabbits treated with therapeutic doses of 
cyclosporin (15 mg/kg/day) or with a vehicle control (CrEL) revealed intimal 
proliferation in both groups.(54) Mean plasma cholesterol levels were 
moderately increased in both groups. Although this may have contributed to 
foam cell formation in the cyclosporin-treated animals, it was not the sole 
determinant, as foam-cell-rich lesions were not observed in animals receiving 
only CrEL. In contrast, Tatou et al observed significant adverse effects of 
CrEL on endothelial function and vascular muscle on isolated and perfused 
rat hearts, leading to a reduction of coronary flow and aortic output.(55) The 
potential clinical implications with respect to these CrEL-related phenomena 
remain unknown. 
 
2.4 Inhibition of P-glycoprotein activity 
 P-glycoprotein is a drug transporting membrane protein, and its 
expression is increased in tumour cells having a multidrug resistance 
phenotype.(56,57) Several in vitro studies in the early 1990s observed 
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modulation of the activity of P-glycoprotein by CrEL.(58-60) Later, similar 
phenomena were observed for various other non-ionic surfactants, including 
Tween 80,(61,62) Solutol HS 15,(63) and Triton X-100.(64) However, in vivo 
studies never demonstrated reversal of multidrug resistance by any non-
ionic surfactant, including CrEL and Tween 80.(65-67) The extremely low 
volume of distribution of CrEL and the rapid degradation of Tween 80 in 
vivo are the likely explanations for this lack of in vivo efficacy (see section 
3.2). Indeed, the volume of distribution of CrEL is approximately equal to the 
volume of the blood compartment, suggesting that concentrations necessary 
to affect reversal of multidrug resistance in vitro are not reached in vivo in 
solid tumours.(68) However, it should be noted that the pharmacokinetic 
selectivity of CrEL for the central blood and bone marrow compartment can 
provide an advantage to treatment of haematological malignancies with 
resistance to chemotherapy caused by elevated P-glycoprotein expression.(69) 
 
2.5 Intrinsic antitumor effects 
 Cell-growth inhibitory properties of CrEL were first observed by Fjällskog 
et al in doxorubicin-resistant human breast-cancer cell lines,(70,71) and were 
later confirmed in other malignant cell types.(72,73) The formation of free 
radicals by peroxidation of polyunsaturated fatty acids and/or a direct 
pertubing effect on the cell membrane are possible mechanisms responsible 
for this type of cell growth inhibition.(74-76) Using in vitro clonogenic assays, 
however, it has been demonstrated that CrEL, at clinically-achievable 
concentrations, can antagonise the cytotoxicity of paclitaxel by a cell-cycle 
block.(77) Several reports also suggest that Tween 80 has intrinsic 
antitumour activity in animal models,(78-80) which might be linked to the 
release of oleic acid, a fatty acid known to interfere with malignant cell 
proliferation due to formation of peroxides(81) and inhibition of 
angiogenesis.(82) The exact contribution of Tween 80 to antitumour activity 
observed in patients treated with chemotherapeutic drugs formulated in this 
vehicle substance has not been clarified. 
 
3. Pharmacological properties of surfactants 
 
3.1 Analytical methods 
 At present, a large variety of analytical procedures are available for 
clinical pharmacokinetic studies with CrEL and Tween 80. The first assay 
developed for measurement of CrEL concentrations in patient material was 
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based on the ability of this vehicle to modulate daunorubicin efflux in 
multidrug resistant T-cell leukaemia VLB100 cells.(83) Alternatively, a more 
sensitive and reliable method was developed that required sample volumes of 
only 20 µL.(84) This method is based on measurement of ricinoleic acid after 
base-induced hydrolysis (saponification) of CrEL followed by an acylchloride 
formation, precolumn derivatisation with naphthylamine, and reversed-
phase high-performance liquid chromatography (HPLC) to detect N-
ricinoleoyl-1-naphthylamine at 280 nm. Because of the high costs and the 
time-consuming nature of both assays, a new method, based on a selective 
binding of CrEL to the Coomassie Brilliant Blue G-250 dye in protein-free 
extracts was developed for human plasma samples.(85,86) This method has 
also been used to measure Tween 80 concentrations in murine and human 
plasma.(87) More recently, a potentiometric titration method for CrEL was 
developed for quantitative analysis in urine and plasma based on coated wire 
electrode as an end-point indicator with sodium tetraphenylborate at 20oC 
and pH 10.(88) Each of these methods has its drawbacks and limitations, and 
the methodological differences between them probably contribute to the 
variations in measured CrEL concentrations. 
 In addition to the Coomassie Brilliant Blue G-250 colourimetric dye-
binding assay, various other analytical procedures are available for Tween 
80. Initially measurement of the polyoxyethylated portion of the molecule 
was used for quantification of Tween 80 concentrations. The so-called 
polyol moiety is detectable by a wide variety of methods, including a 
resorcinol-glucose precipitation, a colourimetric method using ammonium 
cobaltothiocyanate, turbidimetric or gravimetric procedures, and complex 
formation with barium phosphomolybdic reagent.(89,90) The ammonium 
cobaltothiocyanate complexation has also been used in combination with 
HPLC and UV detection for analysis of Tween 80 in urine and ascites fluid, 
using either post-column or on-line complexation.(91-94) A less complex 
procedure that does not require complexation involves a one-step hydrolysis 
with sulphuric acid followed by HPLC with UV detection at 210 nm.(95) Most 
recently, Tween 80 concentration in human plasma samples have been 
analysed by a liquid chromatographic assay with tandem mass-
spectrometric detection, with a 60-fold increased sensitivity as compared 
with previous published assays.(96) 
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3.2 Pharmacokinetics 
 The various analytical methods described above have been used in 
different pharmacokinetic studies of CrEL, sometimes leading to conflicting 
results and conclusions. There have been no studies thus far comparing the 
different analytical methods. Initial pharmacokinetic analyses have indicated 
that CrEL shows linear pharmacokinetic behaviour.(97) However, with 
prolongation of infusion duration from 1-3 and 24 hours, CrEL clearance 
increased from about 160 to 300 and 400 mL/h/m2, respectively (Figure 
3).(17) A recently developed population pharmacokinetic model revealed that 
the plasma concentration-time data of CrEL were best fitted to a three 
compartment model with Michaelis-Menten elimination (Table 3).(98,99)  
 It thus appears that CrEL shows schedule-dependent pharmacokinetics, 
possibly related to saturated elimination due to capacity-limited CrEL 
metabolism within the systemic circulation. This schedule dependency leads 
to an increase in systemic exposure, and thus an increase in CrEL related 
biological effects, with shortening of the infusion duration. An example of 
this phenomenon is the apparent increase of allergic reactions in 1-hour 
versus 3- or 24-hour infusions of paclitaxel,(9,100) as well as increased 
incidence of peripheral neuropathy with shorter paclitaxel infusions.(101,102) 
The observed changes in adverse effects as a function of paclitaxel infusion 
duration will need to be confirmed in larger comparative trials in order to 
provide recommendations for treating clinicians. 
 The terminal half-life of CrEL amounts to approximately 80 hours with 
reported values ranging between 10 and 140 hours, depending on the 
sampling time period and the method used for CrEL analysis. Therefore, 
studies using sparse-sampling strategies with application of the bioassay 
method may lead to underestimation of the terminal half-life.(103) With the 
more sensitive colourimetric assay, detectable concentrations of CrEL were 
demonstrated even 1 week after initial treatment.(68) Despite this relatively 
long terminal disposition phase of CrEL, long-term weekly administration of 
paclitaxel does not cause significant accumulation of CrEL although the 
vehicle is always detectable in pre-dose samples.(104) In all studies, the 
observed volume of distribution of CrEL was extremely small and almost 
equal to the volume of the central blood compartment. As outlined, this 
implies that tissue and tumour delivery of CrEL is insignificant.(68) 
 Little is known about elimination routes of CrEL. Pharmacokinetic 
studies in patients with hepatic dysfunction treated with paclitaxel 
suggested that hepatobiliary elimination of CrEL is not of major 
importance.(105) 
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Figure 3. Effect of infusion duration on the clearance of CrEL. Data are expressed as 
mean values (bars) ± SD (error bars) and were obtained from patients treated with 
paclitaxel formulated in CrEL at dose levels of 135 mg/m2 (white bars; CrEL dose, 
11.3 mL/m2), 175 mg/m2 (black bars; CrEL dose, 14.6 mL/m2), or 225 mg/m2 
(hatched bars; CrEL dose, 18.8 mL/m2).(17) 
 
 
Despite its highly hydrophilic nature, the renal elimination of CrEL accounts 
for less than 0.1% of the administered dose and CrEL pharmacokinetics in a 
patient with severely impaired renal function was not different from those in 
historic controls.(10) It is possible that elimination pathways for CrEL are 
mainly dictated by serum carboxylesterase-induced degradation, leading to 
the release of free fatty acids such as ricinoleic acid. This metabolic route 
occurs apparently at a low rate and the involved enzymes may be easily 
saturated, which explains the peculiar time-dependent non-linear 
pharmacokinetics of this vehicle. 
 The pharmacokinetic behaviour of Tween 80 is very different from that 
of CrEL. In animal studies a rapid decline of the concentration was shown 
after injection (Figure 4). Plasma concentration were below 0.05 µL/mL (i.e. 
the lower limit of quantification of the analytical method) within 15 minutes 
after the drug administration.(87) Observations in 5 patients treated with 
docetaxel as a 1-hour infusion at a dose of 100 mg/m2 showed peak plasma 
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concentrations of Tween 80 of 0.16 ± 0.05 µL/mL, consistent with more 
recent observations.(96,107) In vitro experiments have shown that this rapid 
elimination is caused by a rapid carboxylesterase-mediated hydrolysis in the 
systemic circulation, cleaving the oleic acid side chain from the molecule.(87)   
 
 
Table 3. Population pharmacokinetic parameters of Cremophor EL following 
paclitaxel administrationa  
Parameter Estimate RSE (%) 
V1 (L)  
Q2 (L/h) 
V2 (L) 
Q3 (L/h) 
V3 (L) 
Km (mL/L) 
Vmax (mL/h) 
 
Residual error 
Additional (mL/L) 
Proportional (%) 
2.59 
1.44 
1.81 
0.155 
1.61 
0.122 
0.193 
 
 
0.0951 
6.94 
7 
24 
9 
22 
7 
61 
9 
 
 
34 
8 
 
a Data are from patients treated with paclitaxel formulated in a mixture of 
Cremophor EL and ethanol, and were from Van den Bongard et al.(99) 
Determination of Cremophor EL in plasma samples was performed by pre-column 
derivatisation and reversed-phase high-performance liquid chromatography, as 
described elsewhere.(84) 
Km = plasma concentration at half Vmax; Q2 and Q3 = intercompartmental 
clearances from the central to the first or second peripheral compartments; RSE = 
relative standard error; Vmax = maximum elimination rate; V1, V2 and V3 = volumes 
of the central, first peripheral and second peripheral compartments.  
 
 
 Earlier studies performed in rats and humans with the structurally 
related surfactants polysorbate 20 and polysorbate 40 have shown similar 
metabolic pathways, with ester bond cleavage and subsequent oxidation of 
the fatty acid moiety (reviewed in Van Zuylen et al(108)). 
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Figure 4. Comparative plasma concentration-time profiles of CrEL (closed symbols) 
and Tween 80 (open symbols) in mice receiving 0.83 mL/kg of each vehicle by bolus 
injection. Data show mean values of 4 observations per time point and were obtained 
from Van Tellingen et al.(87) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of CrEL on the plasma concentration-time profiles of paclitaxel in mice 
treated at a paclitaxel dose of 10 mg/kg formulated with CrEL (closed symbols) or 
with Tween 80 (open symbols). Data were obtained from Sparreboom et al.(122) 
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Table 4. Pharmakinetic effects of Cremophor EL and Tween 80 on 
intravenously administered drugs 
Agent Species Pharmacokinetic effect(s) Reference 
Cremophor EL 
Cyclosporin 
Doxorubicin  
 
 
 
Epirubicin 
Etoposide 
SN-38 
C8KC  
Oxaliplatin 
Paclitaxel 
 
 
Tween 80 
Doxorubicin 
 
Etoposide 
Methotrexate 
Vigabatrin 
 
baboon 
mouse 
mouse 
mouse 
human 
mouse 
rat 
mouse 
mouse 
rat 
mouse 
rat 
human 
 
mouse 
human 
rat 
mouse 
rat 
 
4.2-fold increased AUC 
2-fold increased AUC 
increased concentrations in plasma, liver 
increased concentrations in heart, liver  
1.2-fold increase in AUC 
increased levels in spleen 
4.6-fold increased AUC 
2-fold increased AUC 
increased Cmax and T1/2β 
1.6-fold increased AUC 
7-fold increased AUC 
9-fold increased AUC 
2-fold increased AUC 
 
increased levels in plasma, spleen 
2-fold reduced AUC 
1.2-fold increased AUC 
increased uptake in brain 
increased GABA in brain 
 
113 
114 
115 
116 
117 
118 
111 
119 
120 
121 
122 
109 
123 
 
116,124,125
126 
118 
127 
128 
 
AUC = area under the plasma concentration-time curve; Cmax = peak plasma 
concentration; GABA = γ-aminobutyric acid; T1/2β = half-life of the terminal 
disposition phase. 
 
 
4. Modulation of drug disposition patterns 
 
4.1 Intravenous administration 
 Various studies have shown that CrEL alters the pharmacokinetic 
behaviour of many drugs administered intravenously, including cyclosporin, 
anthracyclines, etoposide, the irinotecan metabolite SN38, the 
photosensitiser C8KC, and paclitaxel (Table 4). The most common effect is a 
substantial increase in the systemic exposure to the studied agent with a 
concomitantly reduced systemic clearance, as was first described for 
paclitaxel in a mouse model (Figure 5). Various proposed causes of the CrEL-
drug interactions have been put forward in recent years, including altered 
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protein binding characteristics,(52) altered hepatobiliary secretion,(109) and 
inhibition of endogenous P-glycoprotein mediated biliary secretion, thereby 
reducing elimination of drugs.(110) In the isolated perfused rat liver, CrEL 
inhibited the hepatic elimination of paclitaxel, preventing the drug from 
reaching the sites of metabolism and excretion,(109) and the same effect was 
noted for Tween 80.(111) However, recent studies indicate that drug-
transporting P-glycoproteins are not essential for normal hepatobiliary 
secretion of paclitaxel,(112) suggesting that this protein does not play a major 
role.(8) 
 In view of the very small volume of distribution of CrEL, it is likely that 
the pharmacokinetic interaction observed with some drugs takes place 
within the central blood compartment. This was recently confirmed by in 
vitro experiments demonstrating that encapsulation of the model drug 
paclitaxel within the hydrophobic interior of CrEL micelles takes place in a 
concentration-dependent manner, causing changes in cellular partitioning 
and blood:plasma concentration ratios of paclitaxel (Table 5).(8,19) It was 
shown that the affinity of paclitaxel was (in decreasing order) CrEL > plasma 
> human serum albumin, with CrEL present above the critical micellar 
concentration (i.e., ~0.01%). Since the effect was also observed in the 
absence of plasma proteins, it could not have been caused by altered protein 
binding or by an increased affinity of paclitaxel for protein dissociation 
products that are produced by the action of CrEL on native lipoproteins.(51,52) 
These findings are consistent with the hypothesis that paclitaxel can be 
entrapped within micelles, and that these micelles act as the principal 
carrier of paclitaxel in the systemic circulation. 
 An intriguing feature of paclitaxel pharmacokinetics is a distinct dose-
dependent pharmacokinetic behaviour, with clearance values decreasing 
substantially with an increase in drug dose. This effect is particularly evident 
with 3-hour infusion regimens, and CrEL has been linked to this 
phenomenon. It has been shown that the percentage of total paclitaxel 
trapped in micelles increases disproportionally with higher doses of CrEL 
administered,(8) thereby influencing the unbound drug concentration and 
making it less available for distribution to tissues, metabolism, and biliary 
and intestinal secretion. Indeed, the free fraction of paclitaxel is inversely 
related to CrEL concentrations in vitro,(129) and CrEL has also been shown to 
alter the blood : plasma concentration ratios in vivo by reducing drug uptake 
in red blood cells.(130) Interestingly, when paclitaxel dissolved in another 
vehicle was administered to mice, no pharmacokinetic nonlinearity in 
plasma concentration profiles was evident.(122) The concentrations in tissues 
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also increased linearly with increasing dose even when dissolved in CrEL, 
suggesting linear kinetics for the unbound drug.  
 
Table 5. Effect of Cremophor EL (CrEL) and derivatives on the blood:plasma 
concentration ratio of paclitaxela 
Compound added (µg/mL) Blood : plasma ratio Change (%) pb 
None 
CrEL (0.1) 
CrEL (0.5) 
CrEL (1) 
CrEL (5) 
CrEL (10) 
Castor oil (5) 
CrEL fraction 1 (5)c 
CrEL fraction 2 (5) 
CrEL fraction 3 (5) 
CrEL fraction 4 (5) 
CrEL fraction 5 (5) 
1.07 ± 0.004  
1.09 ± 0.009 
0.990 ± 0.015 
0.901 ± 0.017 
0.690 ± 0.005 
0.625 ± 0.008 
1.23 ± 0.171 
1.06 ± 0.008 
0.926 ± 0.018 
0.763 ± 0.055 
0.645 ± 0.051 
0.943 ± 0.039 
 
+1.83 
-9.35 
-15.8 
-35.5 
-41.6 
+13.0 
-0.94 
-13.5 
-28.7 
-39.7 
-11.9 
 
0.387 
0.012 
0.003 
<0.0001 
<0.0001 
0.061 
0.520 
0.043 
0.010 
0.003 
0.103 
 
a Paclitaxel was used at an initial concentration of 1 µg/mL and incubated in whole 
blood for 15 min at 37°C before fractionation and analysis by high-performance 
liquid chromatography. Ratio data are presented as mean values ± SD of (at least) 
triplicate measurements and were obtained from Sparreboom et al.(8) 
b Probability of significant difference versus control (unpaired two-sided Student’s t 
test).  
c Five CrEL fractions, each with progressively increased hydrophobicity, were isolated 
as chromatographic peaks, as described elsewhere.(8) The fractionation process was 
based on reversed-phase high-performance liquid chromatography of crude CrEL. 
The first fractions mainly contain polyoxyethyleneglycerol and oxyethylated glycerol, 
and the pharmacologically active fraction 4 contains the micelle-forming 
component, polyoxyethyleneglycerol triricinoleate along with fatty acid esters of 
polyethyleneglycerol. 
 
 Earlier, the nonlinearity in paclitaxel pharmacokinetics had been 
described by empirical models using both saturable elimination and 
saturable distribution, where the saturable distribution has been described 
as saturable transport,(131) or saturable binding.(132) A recent study 
demonstrated that a mechanistic model could be used to describe the 
nonlinear kinetics of the drug using simultaneous description of total and 
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unbound plasma concentrations, whole blood concentrations, and 
concomitant CrEL concentrations.(133) This pharmacokinetic model has a 
foundation in the known properties of paclitaxel as determined with micellar 
trapping of paclitaxel, distribution to red blood cells and binding to serum 
albumin, α1-acid glycoprotein and platelets. The results of that study showed 
that the nonlinear pharmacokinetics are predominantly explained by 
nonlinear binding to CrEL and that the unbound drug displayed linear 
pharmacokinetics when administered over a 3-hour period. 
 The drug fraction not bound to serum proteins or CrEL is a rather small 
fraction of the total under normal physiological conditions, and at high 
concentrations, paclitaxel is mainly bound to CrEL. From simulated 
concentration components in patients treated with 24-hour infusions, it was 
demonstrated that because CrEL concentrations are rather low, the linear 
binding to serum proteins and binding to blood cells are of greater 
importance than the CrEL binding.(133) Because of the schedule-dependent 
clearance of CrEL, this has serious clinical ramifications in that the systemic 
exposure to unbound paclitaxel will be a function of infusion duration. This 
was recently confirmed in a randomised comparative clinical trial evaluating 
drug disposition characteristics following 1- versus 3-hour infusions.(102) The 
area under the plasma concentration-time curve (AUC) of unbound 
paclitaxel was 24% (P = 0.009) reduced as compared with the 3-hour 
infusion group (Figure 6), despite significantly higher peak concentrations 
(0.26 ± 0.007 µM vs 0.15 ± 0.07 µM; P = 0.0002). Most importantly, this 
effect translated into more severe haematological toxicity with the 3-hour 
schedule of drug administration,(102) suggesting that the various infusion 
schedules currently employed for paclitaxel dosing are not interchangeable 
nor pharmacologically equivalent. 
 The existence of CrEL in blood as large polar micelles with a highly 
hydrophobic interior also raises the possibility of interactions occurring with 
other (poorly water-soluble) drugs. For example, the combination of 
paclitaxel with anthracycline drugs may result in altered cellular distribution 
and a concomitantly increased plasma concentration, because of 
incorporation of the anthracycline drug into CrEL micelles.(134) In this 
respect, several studies have demonstrated significant pharmacokinetic 
interactions between paclitaxel and/or CrEL and doxorubicin. 
(110,114,117,135,136) Although not tested explicitly, it is likely that the presence of 
CrEL in the clinical formulation of certain drugs contributes, at least in part, 
to various pharmacokinetic interactions described with other agents (Table 
6). 
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Figure 6. Effect of infusion duration of the systemic exposure (AUC) to unbound 
paclitaxel. Data were obtained from 29 cancer patients receiving a 1-hour [n = 15; 
mean AUC (± SD), 0.50 ± 0.10 µM•h] or a 3-hour infusion [n = 14; mean AUC (± SD), 
0.62 ± 0.12 µM•h] and were obtained from Gelderblom et al.(102) Each symbol 
represents the AUC of an individual patient and the horizontal lines indicate mean 
values for each group. AUC=area under the concentration-time curve. 
 
 
Table 6. Clinically relevant drug interactions attributable (partially) to 
Cremophor EL.  
Agents Pharmacokinet effect(s) Reference 
Paclitaxela 
Doxorubicin 
Epirubicin 
Gemcitabine/epirubicin 
Irinotecan 
Cyclosporina 
Etoposide 
Etoposide/mitoxantrone 
Doxorubicin 
Vinblastine 
Valspodara 
Etoposide 
Doxorubicin 
 
1.4-fold increased AUC 
1.7-fold increased AUC 
1.7-fold increased epirubicin AUC 
1.4-fold increased SN-38 AUC  
 
1.8-fold increased AUC 
1.5-fold increased etoposide AUC 
1.5-fold increased AUC 
increased myelosuppression 
 
1.9-fold increased AUC 
2.0-fold increased AUC 
 
137 
138 
139 
140 
 
141 
142 
143 
144 
 
145 
146 
a Formulated for clinical use in a Cremophor EL-containing vehicle, and administered 
intravenously. AUC = area under the plasma concentration-time curve. 
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 There are conflicting reports in the literature on the effects of Tween 80 
on the distribution and elimination of drugs administered intravenously 
(Table 4). In mice it was demonstrated that Tween 80 caused an increase of 
doxorubicin plasma concentrations by decreasing the plasma volume as a 
result of the osmotic effect of Tween 80 on total blood volume.(124,125) 
However, in patients receiving the same relative amount of Tween 80 
(administered concomitantly with etoposide at a dose of 100 mg/m2), both 
the volume of distribution and the clearance of doxorubicin were increased, 
due to reduced plasma concentrations of doxorubicin in the early phase of 
the concentration-time profile.(126) In the isolated perfused rat liver, Tween 
80 decreased the clearance and the volume of distribution of etoposide,(111) 
but it increased the renal and biliary excretion of methotrexate.(127) The 
majority of clinical investigations have shown minimal alteration in the 
pharmacokinetic profiles of agents when used in combination with drugs 
formulated in Tween 80.(135,147,148) This is most likely the result of the rapid 
degradation of Tween 80 in plasma by esterases, such that it can not 
interfere to any significant extent with the pharmacokinetic behaviour of 
other agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Extent of docetaxel binding to human plasma in vitro expressed as the 
unbound drug fraction as a function of Tween 80 concentration. Data are expressed 
as mean values (bars) ± SD (error bars) of triplicate observations and were obtained 
from Loos et al.(149) 
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 However, recent observations indicate that Tween 80, at concentrations 
observed in patients treated with docetaxel, causes a profound and 
significant alteration of the fraction unbound docetaxel, which increased by 
50% (Figure 7).(149) The mechanistic basis for the decreased binding of 
docetaxel in the presence of Tween 80, contrary to that observed with CrEL 
and paclitaxel, is as yet unclear. It is possible, however, that with time 
Tween 80 is able to form micellar complexes with proteins, including serum 
albumin and α1-acid glyoprotein, so that the binding of docetaxel becomes 
saturable on single sites.(150) Similar observations have been reported for the 
binding of several other drugs that bind with high affinity but low capacity to 
α1-acid glycoprotein in the presence of structurally-related mixed-micellar 
systems.(151) Alternatively, the phenomenon might be the result of Tween 80 
metabolism by serum esterases and subsequent oleic acid-mediated protein-
binding displacement of docetaxel, causing increases in unbound drug.(152) 
Regardless of the mechanism underlying this effect, it is consistent with 
recent observations that, similar to paclitaxel, also in the case of docetaxel 
nonlinear distribution pathways exist that may be related to the presence of 
non-ionic surfactants in the clinical formulated product.(153) 
 
4.2 Extravascular routes of administration 
 There have been many reports highlighting the ability of Tween 80 to 
increase the absorption in in vitro systems, animals and humans of 
numerous agents involving various classes of drug. Typical examples of this 
phenomenon are provided in Table 7. The main overall conclusion from 
these studies is that Tween 80 acts as an enhancer of the systemic 
exposure to orally administered agents by increasing biomembrane 
permeability,(154,155) as has also been described for intravesical instillation of 
thiotepa in the presence of Tween 80 in cancer patients.(156) It has also been 
proposed that agents like Tween 80 and CrEL not only support 
solubilisation, but also may inhibit the activity of P-glycoprotein with oral 
administration.(157,158) This protein is a membrane-bound drug efflux pump, 
which is abundantly present in the gastrointestinal tract,(159,160) and 
mediates direct secretion of substrate drugs into the intestinal lumen, 
thereby limiting its oral uptake.(112) However, following oral administration, 
polyoxyethylated surfactants are known to be extensively metabolised in the 
intestine by pancreatic lipases into the free fatty acid and the polyol moiety, 
with only less than 3% of the administered dose being excreted into the 
urine.(108) This makes it unlikely that the modulating effects are 
Chapter 2 
36 
predominantly caused by a direct influence on active drug transport by the 
intact vehicles. 
 In contrast to the enhancing effects of Tween 80, addition of CrEL to the 
formulation of oral drug preparations, in general, seems to result in 
significantly diminished drug uptake and reduced circulating concentrations 
(Table 7). One of the best studied examples is the influence of CrEL on the 
oral absorption of paclitaxel. Oral administration of this drug is an attractive 
alternative for the currently used intravenous regimen, because it is 
convenient and practical for patients and it may circumvent systemic 
exposure to CrEL, which is known to be not absorbed intact after oral 
administration.(173,174)  
 
Table 7. Influence of formulation vehicles on oral drug absorption 
characteristics 
Agents Test system Effect(s) Ref 
Cremophor EL 
Acf(N-Mef)NH2 
Digoxin 
Paclitaxel 
   
Saquinavir 
Phytomenadione 
 
Tween 80 
Albendazole 
Cyclosporin  
Danazol 
Digoxin 
Griseovulvin 
Indomethacin 
Itazigrel  
Methotrexate 
Tetracycline 
 
Caco-2 cells 
Human 
Human 
Mouse 
Human 
Human (infant)
 
 
Rat 
Rat 
Dog 
Rat intestine 
Human 
Rat 
Rat 
Mouse 
Rat intestine 
 
2.6-fold reduced permeability 
Decreased lag time  
2.0-fold decreased AUCa 
1.4-fold decreased AUCb 
5.0-fold increased AUC 
Decreased PIVKA-II 
 
 
1.9-fold increased AUC 
33-fold increased bioavailabilityc 
16-fold increased bioavailability 
Increased uptake 
1.5-fold decreased AUC 
1.6-fold increased AUC 
1.5-fold increased absorption  
2.0-fold increased AUC 
2.7-fold increased absorption 
 
157 
161 
162 
163 
164 
165 
 
 
166 
167 
168 
158 
169 
170 
171 
127 
172 
 
a As compared to a Tween 80 formulation; b As compared to a formulation containing 
7-fold less CrEL; c As compared to a nanosphere formulation. 
AUC = area under the plasma concentration-time curve; PIVKA-II = des-gamma-
carboxyprothrombin. 
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A study of paclitaxel formulated in Tween 80 resulted in a significant 
increase in the peak concentration and AUC of paclitaxel in comparison with 
the CrEL formulations.(162,163) Fecal elimination data revealed a decrease in 
excretion of unchanged paclitaxel for the Tween 80 formulation compared 
to the CrEL formulations, suggesting that entrapment of paclitaxel in CrEL 
micelles is an important factor limiting the absorption of orally administered 
paclitaxel from the intestinal lumen. Obviously, this has significant clinical 
ramifications in that oral paclitaxel delineates very distinct apparent 
saturable absorption kinetics with no further increase of the AUC with a 
given increase in dose (Figure 8).(175-178) Similar dose-dependence was not 
observed with oral administration of docetaxel formulated in Tween 80,(179) 
suggesting that the effect is CrEL specific, and that other formulations 
should be developed in order to increase the usefulness of oral paclitaxel 
administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of oral drug dose on the systemic exposure to paclitaxel in cancer 
patients. Data are expressed as mean values (symbols) ± SD (error bars) and were 
obtained from Malingre et al.(175) The broken line indicates the hypothetical dose-
proportional increase in the area under the plasma concentration-time curve (AUC). 
 
 
 Entrapment of drug in CrEL micelles has also been demonstrated for 
several agents delivered intraperitoneally [e.g. O6-benzylguanine in mice(180) 
and paclitaxel in cancer patients(123)] or intravesically [e.g. paclitaxel in 
dogs(181)]. The major goal of intraperitoneal therapeutic strategies is to expose 
Chapter 2 
38 
tumours within the peritoneal cavity to higher concentrations of 
antineoplastic agents for longer periods of time than can be achieved by 
systemic drug administration.(182,183) Treatment with paclitaxel given 
intraperitoneally is attractive in patients with ovarian carcinoma, since 
paclitaxel has proven single-agent activity in this disease.(184) With this route 
of drug administration, the presence of CrEL as an integral component of the 
clinical formulation may actually be advantageous as it prolongs exposure to 
the tumour cells and reduces transport across the peritoneal/blood barrier 
(Table 8).  
 
Table 8. Influence of Cremophor EL (CrEL) on the pharmacokinetics of 
intraperitoneal paclitaxela 
Parameter With CrEL Without CrEL pb 
Cmax (µmol/L) 
AUC (µmol•h/L)  
F (%)  
0.14 ± 0.08 
5.04 ± 1.92 
31.4 ± 5.18 
0.26 ± 0.07 
7.55 ± 3.38 
98.8 ± 16.6 
0.062 
0.044 
0.005 
 
a Data were obtained from 4 cancer patients treated in a randomised cross-over 
setting with paclitaxel administered at a dose of 125 mg/m2 in the presence and 
absence of CrEL and represent mean values ± SD; from Gelderblom et al.(123)  
b Probability of significant difference versus control (two-sided test for matched 
pairs). 
AUC = area under the plasma concentration-time curve; Cmax = peak plasma 
concentration; F = bioavailability. 
 
 
5. Conclusion 
 
 Numerous investigations have studied the role of pharmaceutical 
vehicles such as CrEL and Tween 80 in the pharmacological behaviour of 
the formulated drugs. These investigations have yielded fundamental insight 
into modes of action, pharmacokinetic profiles and considerations of dosage 
and scheduling. Indeed, the administration of CrEL and Tween 80 to 
patients presents a number of serious concerns, including unpredictable 
intrinsic adverse effects such as acute hypersensitivity reaction and 
peripheral neuropathy. Furthermore, these substances modulate the 
disposition profiles of various drugs using them as vehicles, and of other 
compounds administered concomitantly, by alteration of the blood 
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distribution resulting from entrapment of the compound in circulating 
micelles.  
 The drawbacks presented by the presence of CrEL or Tween 80 in drug 
formulations have instigated extensive research to develop alternative 
delivery forms, and currently, several strategies are in progress to develop 
formulations of the anticancer agents docetaxel and paclitaxel that are free 
from Tween 80 and CrEL, respectively.(185)  
 
Table 9. Examples of alternative approaches to development of taxane drugs 
Strategy Example(s) Stage Reference 
Pharmaceutical 
Co-solvents 
Emulsions 
   
Liposomes 
Cyclodextrins 
Nanoparticles 
Microspheres 
 
Chemical 
Analogues 
 
  
  
Prodrugs 
  
 
Biological 
Oral administration
 
HSA-paclitaxel  
S8184    
LDE-paclitaxel 
LEP  
PTX-CYD 
ABI-007  
Paclimer 
 
 
BMS-184476  
BMS-275183 (oral)  
IDN5109/BAY59-8862 (oral)
RPR 109881A   
DHA-paclitaxelc  
PNU-166945d  
CT-2103e   
 
paclitaxel + cyclosporin  
 
Preclinical (in vivo) 
Clinical (phase I) 
Preclinical (in vivo)  
Clinical (phase I) 
Preclinical (in vivo) 
Clinical (phase II) 
Preclinical (in vivo) 
 
 
Clinical (phase II) 
Clinical (phase I) 
Clinical (phase I) 
Clinical (phase II) 
Clinical (phase II) 
Discontinued 
Clinical (phase I) 
 
Clinical (phase II) 
 
188 
189 
190 
191 
192 
187,193 
194 
 
 
195 
196 
197 
198 
199,200 
201 
202 
 
203 
 
a Poly(ethylene glycol)-human serum albumin-paclitaxel conjugate. 
b Cholesterol-rich emulsion that binds to low-density lipoprotein receptors. 
c Docosohexaenoic acid-paclitaxel. 
d Water-soluble polymeric conjugate of paclitaxel. 
e Polyglutamated paclitaxel. 
 
A recent dose-finding study with a new submicronic Tween 80-free 
dispersion formulation of docetaxel suggested a lower incidence and severity 
of haematological and non-haematological toxicity (fluid retention) at 
equimolar doses compared to the current formulation of docetaxel with 
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Tween 80.(186) Likewise, the absence of CrEL in a novel formulation of 
paclitaxel (ABI-007) permitted drug administration without premedication 
routinely used for the prevention of hypersensitivity reactions, as well as 
increases in the maximum tolerable dose as compared with paclitaxel 
formulated in CrEL.(187) A summary of various approaches currently pursued 
to eliminate non-ionic surfactants from taxane formulations is provided in 
Table 9. Continued investigations into the role of pharmaceutical vehicles in 
taxane-related drugs should eventually lead to a more rational and selective 
chemotherapeutic treatment with these agents. 
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Introduction 
 
 Pharmaceutical excipients have a vital role in drug formulations, a role 
that has tended to be neglected as evidenced by the lack of procedures to 
assess excipient safety outside a new drug application process.(1) In contrast 
to earlier views, excipients are not inert vehicles, but can exert a range of 
intrinsic adverse effects and have the potential to cause clinically significant 
drug interactions.(2-4) Polyoxyethylene-20-sorbitan monooleate (polysorbate 
80, Tween 80; ICI Group, London, United Kingdom; Figure 1), and 
polyoxyethylated castor oil (Cremophor EL -CrEL-; BASF, Ludwigshafen, 
Germany, Figure 1) are widely used as drug formulation vehicles, a.o for the 
taxanes paclitaxel and docetaxel.(5) Recent experimental data have indicated 
that that both solubilisers are biologically and pharmacologically active 
compounds with clinically important side effects including hypersensitivity 
reactions (HSR)(6-9) and peripheral neuropathy.(10-16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of Cremophor EL (A) and Tween 80 (B) 
(CH2CH2O)zOCO(CH2)7CH=CH(CH2)7CH3
(CH2CH2O)yOH
HO(CH2CH2O)w (CH2CH2O)xOH
O
H2C(CH2CH2O)zOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
HC(CH2CH2O)yOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
H2C(CH2CH2O)xOCO(CH2)7CH=CHCH2CHOH(CH2)5CH3
            
A
B
(x + y + z ~ 35)
(w + x + y + z ~ 20)
Disposition of polyoxyethylated excipients in humans 
 
55 
 Both vehicles have been demonstrated to influence the disposition of the 
solubilised drugs.(17-19) This effect is possibly caused by entrapment of the 
drug in large spherical micellar structures consisting of the polyoxyethylated 
vehicles.(2,20) In general this mechanism results in a highly increased 
systemic drug exposure and a simultaneously decreased clearance. 
 It was hypothesised that the possibility for excipients to affect drug 
disposition and toxicity patterns is inversely linked to their rate of 
elimination.  
 Here, we performed a comparative pharmacokinetic analysis of these two 
commonly used and structurally-related excipients with validated and 
sensitive analytical methods for the determination of both vehicles in human 
plasma. 
 
Sample Collection and Pharmacokinetic analysis 
 
 For Tween 80, samples were obtained from 32 cancer patients treated 
with a 30-minute or 1-hour infusion of docetaxel (Taxotere; Aventis Pharma, 
Vitry-sur-Seine Cedex, France; 26.0 mg of Tween 80 per mg of drug) at dose 
levels ranging from 25 to 75 mg/m2 (Table 1). For Cremophor EL, samples 
were obtained from 31 cancer patients treated with a 1-hour infusion of 
paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ; 87.8 mg of 
CrEL per mg of drug) at dose levels ranging from 70 to 100 mg/m2 (Table 1). 
Blood sampling for Tween 80 and CrEL analysis was performed on day 1 of 
the first chemotherapy course from a vein in the arm opposite to that used 
for docetaxel or paclitaxel infusion. Blood samples were collected in vials 
containing lithium heparin up to 48 h after infusion. Immediately after 
sampling the plasma was separated by centrifugation for 5 min at 3000g, 
transferred to a clean polypropylene tube, and then stored frozen at T<-70°C 
until the time of analysis.  
 Tween 80 and CrEL concentrations in plasma were determined by 
validated assays based on liquid chromatography-tandem mass 
spectrometry21 and Coomassie brilliant blue staining,(22) respectively.  
 In brief, for CrEL aliquots of 25 µL plasma were extracted by addition of 
subsequently 500 µL acetonitrile and 2 mL n-butylchloride, followed vigorous 
vortex-mixing. After centrifugation, the organic layer was evaporated to 
dryness and the residue was redissolved in 50 µL water, from which an 
aliquot of 25 µL was transferred into a 96-well plate. After addition of 250 µL 
of 5-fold water diluted-diluted Coomassie Briliant Blue G-250, detection of  
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the complex formation between CrEL and Coomassie Briliant Blue G-250 
was performed by UV measuring the ratio of absorbances at 595 nm over 
450 nm. The lower limit of quantitation was established at 0.05% (v/v; ~525 
µg/mL).  
 Since a lower limit of quantitation for Tween 80 in the same range was 
insufficient for pharmacokinetic analysis, a new analytical method was 
developed based on liquid chromatography coupled to mass spectrometry. 
Aliquots of 1 mL plasma were extracted, after the addition of the internal 
standard paclitaxel, with 7 ml of a mixture of acetonitril-n-butylchloride (1:4, 
v/v). After vigorous vortex-mixing and centrifugation, the organic layer was 
evaporated to dryness. The residue was subsequently redissolved in 100 µL 
of a mixture of methanol-water (1:1, v/v), from which an aliquot of 10 µL 
were injected into the HPLC system. The analytes were separated on a 
Waters X-Terra MS column packed with ODS material, and eluted with 
methanol-water (9:1, v/v) containing 0.1% formic acid. 
The column effluent was monitored using a triple-quadruple mass 
spectrometric detector, equipped with an electrospray probe, resulting in a 
lower limit of quantitation of 1 µg/mL. 
 Data were evaluated by standard non-compartmental analysis using 
WinNonLin 4.0 using 1/y weighing (Mountain View, CA, USA). 
 
Statistical Considerations 
 
 The correlation between peak plasma concentrations of Tween 80 and 
CrEL and the administered dose level or the corresponding AUC values were 
analysed by means of Pearson’s correlation coefficient, and linear regression 
analysis. Interpatient differences in PK parameters were assessed by the 
coefficient of variation, expressed as the ratio of the SD and the observed 
mean. Variability in PK parameters between the various dose levels was 
evaluated by the Wilcoxon signed-rank test and the Kruskal-Wallis statistic 
followed by Dunn’s multiple comparison test, respectively. 
 
Results 
 
 Pharmacokinetic studies were completed in 32 patients treated with 
docetaxel, and 31 patients treated with paclitaxel in several pharmacokinetic 
trials. Both taxanes were administered as single agent. All patients had a 
histologically confirmed solid malignancy suitable for single agent treatment 
with docetaxel or paclitaxel, or for whom no other treatment options existed. 
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Figure 2. Pharmacokinetic profiles of CrEL (A) and Tween 80 (B) after dose 
adjustments to 1000 mg absolute dosing. 
 
 
 Measures of exposure to Tween 80 and Cremophor EL increased in 
near proportion with an increase in dose (Table 1), and clearance was 
independent of infusion duration (Tween 80, P = .298) and administered 
dose in the range studied (Tween 80, P = .355; Cremophor EL, P = .797). The 
plasma concentration versus time profiles of both Tween 80 and CrEL after 
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taxane infusion were similar for all patients in the separate groups. The 
disappearance of Tween 80 from the central compartment was characterised 
by a short terminal half-life with a mean (± standard deviation) value of 
0.607 ± 0.245 hours and a total plasma clearance of 7.70 ± 2.90 L/h (Figure 
2). In contrast, elimination of Cremophor EL was significantly slower, with 
values for half-life and clearance of 34.2 ± 17.9 hours and 0.211 ± 0.072 
L/h, respectively (P < .00001) (Figure 2). The volume of distribution at 
steady-state was similar for Tween 80 and Cremophor EL (4.78 ± 2.76 L 
versus 9.02 ± 2.46 L, respectively), indicating limited distribution of both 
excipients outside the central compartment, as was suggested previously23. 
 
Discussion 
 
 Despite the widespread and long-term use of Tween 80 as a formulation 
vehicle for several IV drugs, such as etoposide and docetaxel, 
pharmacokinetic data on this vehicle are sparse.(16,24,25) Recently a new 
simple method for the quantitative determination of Tween 80 in human 
plasma by using liquid chromatography-tandem mass spectrometry was 
developed.(21) This novel technique permitted us to compare the 
pharmacokinetics of Tween 80 to CrEL to gain insights in the toxicity 
patterns of both vehicles. 
 Overall, the results from this study suggest that the relative systemic 
exposure to Tween 80 in humans is much lower as compared to Cremophor 
EL, as a result of different rates of elimination. In vitro experiments have 
shown that the rapid elimination of Tween 80 is caused by a rapid 
carboxylesterase-mediated hydrolysis in the systemic circulation, cleaving 
the oleic acid side chain from the molecule.(24) Little is know about 
elimination routes of CrEL. Possibly, the elimination pathways for CrEL are 
also determined by serum carboxylesterase-induced degradation. This route 
apparently is involved at a low rate, most likely caused by a lower affinity of 
CrEL for carboxylesterases compared to Tween 80 and the rapid forming of 
micellar complexes, which explains the typical time-dependent non-linear 
pharmacokinetics of CrEL.  
 This difference in elimination rate is consistent with studies reporting 
that the use of Cremophor EL as a formulation vehicle is more likely to 
result in excipient-related toxic side effects than Tween 80,(26) including 
hypersensitivity reactions(9) and neuropathy.(16) The recognition of the slow 
clearance of CrEL compared to Tween 80 also has implications for the 
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clinical use of CrEL containing drugs with respect to combination 
chemotherapeutic regimens. Several studies demonstrated the influence of 
CrEL on the pharmacokinetic and –dynamic profile of co-administered 
drugs, such as doxorubicin19,27,28 and cisplatin.(29-31) It is proposed that 
proper pharmacokinetic evaluation is needed as an integral component of 
the preclinical screening package for new excipients, and to enable a more 
rational approach in the development of formulations for poorly water-
soluble agents. 
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Summary 
 
 The aim of this multicenter study was to determine whether valspodar 
(Amdray; code designation, SDZ PSC 833), a potent P-glycoprotein (P-gp) 
inhibitor, affects the pharmacokinetics of unbound paclitaxel (Cu). Data were 
obtained from 31 patients with advanced breast cancer. Thirteen patients 
were treated with paclitaxel alone (3-h infusion at 175 mg/m2) and another 
18 received paclitaxel (3-h infusion at 70 mg/m2) in combination with a 21-
day cycle of oral valspodar (5 mg/kg given four times a day) starting 1 day 
before administration of paclitaxel. Serial blood samples were taken in the 
first course and Cu in plasma determined using equilibrium dialysis with a 
[G-3H]paclitaxel tracer. The apparent clearance of Cu was not significantly 
different between the two groups, with mean ± standard deviation (± SD) 
values of 230 ± 56.0 and 202 ± 49.9 L/h/m2 in the absence and presence of 
valspodar, respectively (P = 0.17). The volume of Cu distribution was slightly 
larger in the presence of valspodar (1160 ± 474 vs 1620 ± 552 L/m2; P = 
0.025), which contributed to a minor difference in the terminal disposition 
half-life (6.12 ± 3.42 vs 8.50 ± 2.06 h; P = 0.028). These data indicate that (i) 
valspodar lacks the significant interaction with paclitaxel observed 
previously with other P-gp modulators, (ii) the majority of the increased 
toxicity of the combination does not appear to be attributable to increased 
levels of Cu, and (iii) provide further evidence of the conjecture that the 
plasma concentration of paclitaxel may not be an appropriate measure to 
monitor the impact of P-gp inhibition. 
 
Introduction 
 
 Resistance of malignant cells to various classes of anticancer drugs has 
been linked to the mechanism of multidrug resistance (MDR). This MDR 
phenotype is associated with the overexpression of a drug-transporting P-
glycoprotein (ABCB1; P-gp), a member of the family of adenosine 
triphosphate (ATP) binding cassette transporters, which also includes 
multidrug resistance associated protein [MRP1 (ABCC1)], its homologues 
[MRP2 (ABCC2) to MRP9 (ABCC12)], and the breast-cancer resistance 
protein [BCRP (ABCG2)]. These proteins act as a cellular drug-efflux pump 
transporting many naturally-occurring cytotoxic agents, including 
paclitaxel.(1) Studies performed over the last several years have shown that 
intrinsic and acquired expression of P-gp might play an important role in 
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clinical drug resistance in specific solid tumors and hematological 
malignancies.(2) Consequently, numerous clinical studies have been 
performed to develop inhibitors of P-gp with the aim to overcome resistance 
to the anticancer agents. Unfortunately, the majority of the studied P-gp 
inhibitors have shown substantial pharmacokinetic interactions with the 
coadministered anticancer agent, characterized by a considerable decrease 
in systemic clearance, which resulted in a need to reduce the dose of the 
anticancer agent because of exacerbated toxicity.(3) This dose reduction not 
only complicated the interpretation of toxicity and response data, but also 
presented a serious obstacle in the development and rational use of P-gp 
inhibitors. It is now evident that the pharmacokinetic interference between 
anticancer drugs and P-gp inhibitors is due primarily to competition for drug 
metabolizing enzymes. Indeed, a wealth of recent experimental data shows 
that many of the previously tested P-gp inhibitors, including verapamil,(4) 
cyclosporin A,(5) and valspodar (Amdray; code designation, SDZ PSC 833),(6) 
are prototypical substrates and/or potent inhibitors of CYP3A4. Previous 
work has shown that valspodar, a nonimmunosuppressive and 
nonnephrotoxic cyclosporin D analogue, is approximately 10-fold more 
potent as a P-gp inhibitor than cyclosporin A.(7) It has also been documented 
that valspodar significantly alters the clinical pharmacokinetics of various 
agents including etoposide(8) and doxorubicin.(9) Here, we studied the 
comparative pharmacokinetics of unbound paclitaxel, a known partial 
substrate of cytochrome P450 isozyme 3A4 (CYP3A4),(10) given as a 3-h 
intravenous (i.v.) infusion to two separate conhorts of patients receiving 
paclitaxel alone or in the presence of oral valspodar. 
 
Patients and methods 
 
Eligibility 
 Patients with a histological confirmed diagnosis of breast cancer with 
proven metastasis for whom paclitaxel monotherapy was a viable therapeutic 
option or for whom other treatment options were not available could enter 
this study. Additional eligibility criteria included (i) age >18 years; (ii) World 
Health Organization performance status <3; (iii) life expectancy of at least 3 
months; (iv) off previous anticancer therapy for at least 4 weeks; (v) no 
previous treatment with taxanes or intensified chemotherapy with stem cell 
support; (vi) adequate bone marrow function (absolute neutrophil count >1.5 
× 109/L, and platelet count >100 × 109/L), renal function (serum creatinine 
<2 × upper limit of normal), and liver function (normal bilirubin; aspartate 
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and alanine aminotransferases, and alkaline phosphatase <2.5 × upper limit 
of normal); (vii) symptomatic peripheral neuropathy graded ≤2 (according to 
the National Cancer Institute common toxicity criteria); and (viii) off any 
medication known to interfere with paclitaxel pharmacokinetics. Written 
informed consent was obtained from all patients, and the study was 
approved by the Ethics Board of the participating institutions. Clinical and 
toxicological profiles have been reported elsewhere.(11) 
 
Drug administration 
 Paclitaxel (Bristol Myers Squibb, Wallingford, CT) was supplied as a 
concentrated sterile solution in a mixture of Cremophor EL (CrEL)-ethanol 
(1:1, v/v) at 6 mg/ml (Taxol). The drug was administered intravenously over 
3 h at a dose of 175 mg/m2 to one cohort of patients or at 70 mg/m2 when 
administered in combination with oral valspodar in another cohort of 
patients. The latter patients were concomitantly treated with valspodar 
tablets (Novartis Pharmaceutical Corporation, East Hanover, NJ) at a daily 
dose of 5 mg/kg given four times a day for 21 days, starting 1 day prior to 
the administration of paclitaxel. All patients received pre-medication with 
dexamethasone (8 mg twice daily), starting 12 h prior to infusion of 
paclitaxel and continuing 3 days thereafter. Diphenhydramine (50 mg) and 
ranitidine (50 mg) were routinely administered intravenously 1 h before 
paclitaxel infusion. Patients were eligible to continue treatment until there 
was evidence of progressive disease. 
 
Sample collection and processing 
 Blood specimens were obtained from all patients only during the first 
treatment cycle. Sample volumes of 6 ml were drawn directly from a 
peripheral venous access device into tubes containing lyophilized sodium 
heparin as anticoagulant. The samples were collected directly before 
infusion, and at 0.5, 1, 2, 3, 3.25, 3.5, 4, 5, 6, 9, 15, and 27 h after start of 
infusion. All samples were centrifuged immediately for 10 min at 1000g to 
separate plasma, which was stored at –20°C in polypropylene vials until 
analysis. 
 
Drug analysis 
 The unbound fraction of paclitaxel (fu) was measured by equilibrium 
dialysis as described earlier.(12) The concentrations of total paclitaxel in 
plasma (Cp) were determined by isocratic reverse-phase high-performance 
liquid chromatography with ultraviolet detection (230 nm), as described.(13) 
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Unbound paclitaxel (Cu) was estimated from the product of Cp and fu in each 
individual pharmacokinetic sample, including the blank sample. The 
analytical procedure for CrEL in plasma samples was based on a 
colorimetric dye-binding micro assay using Coomassie Brilliant Blue G-
250,(14) with modifications as described.(15) 
 
Pharmacokinetic analysis 
 Paclitaxel concentration-time profiles of unbound and total drug in 
plasma were analyzed using the Siphar V4.0 package (Innaphase, 
Philadelphia, PA) by determination of slopes and intercepts of the plotted 
curves with multi exponential functions. The program determined initial 
parameter estimates, and these were improved using an iterative numerical 
algorithm based on Powell’s method. Model discrimination was assessed by a 
variety of considerations including visual inspection of the predicted curves, 
dispersion of residuals, minimization of the sum of weighted squares 
residuals, and the Akaike information criterion. Final values of the iterated 
parameters of the best-fit equation were used to calculate pharmacokinetic 
parameters, including the disposition half-lives, area under the plasma 
concentration-time curve (AUC) from time zero and extrapolated to infinity 
using the terminal rate constant, and clearance (defined as dose divided by 
AUC). The peak concentration was put on par with the observed drug level at 
the end of infusion. Threshold concentrations for paclitaxel total and 
unbound drug, that is, the time that plasma concentrations remain higher 
than 0.05 and 0.0167 µM, respectively, were determined as described 
previously.(16) Noncompartmental analysis of CrEL plasma concentration 
data was performed as described previously.(17) 
 
Statistical considerations 
 Pharmacokinetic parameters of paclitaxel and CrEL are reported as mean 
values ± standard deviation (±SD), unless stated otherwise. An unpaired 
(two-sided) Student’s t-test was used to evaluate statistical significance 
between the two treatment groups using the NCSS V5.X package (J.L. Hinze, 
East Kaysville, UT; 1992). Probability values of <0.05 were regarded as 
statistically significant. 
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Results 
 
Patient characteristics 
 A total of 31 patients with measurable or evaluable metastatic breast 
cancer was studied, and all patients were pharmacokinetically evaluable. 
Paclitaxel was administered as single agent (175 mg/m2) to 13 patients, and 
another 18 patients received the combination treatment of paclitaxel (70 
mg/m2) with oral valspodar. Patient characteristics and baseline clinical 
chemistry values were similar between the two patient groups (Table 1). 
 
 
Table 1. Patient demographics 
Characteristics PAC PAC/valspodar 
No. of patients 
Age (years) 
Weight (kg) 
BSA (m2) 
Paclitaxel dose (mg) 
Performance score 
Serum creatinine (mg/dl) 
Total bilirubin (mg/dl) 
ASAT (units/L) 
ALAT (units/L) 
Total protein (g/dl) 
Serum albumin (g/dl) 
13 
42 
65 
1.69 
295 
0 
0.7 
0.5 
23.5 
26.5 
7.5 
4.1 
 
(29-63) 
(40-84) 
(1.28-1.86) 
(224-326) 
(0-2) 
(0.6-0.9) 
(0.3-1.2) 
(17-47) 
(11-58) 
(6.5-8.9) 
(3.2-4.6) 
18 
51 
68 
1.71 
118 
0 
0.7 
0.5 
22.5 
30.0 
7.3 
4.0 
 
(36-68) 
(48-117) 
(1.42-2.17) 
(99-152) 
(0-1) 
(0.2-1) 
(0.3-0.8) 
(13-75) 
(10-59) 
(6.9-9.0) 
(3.3-4.6) 
 
Abbreviations: PAC: paclitaxel; BSA: body-surface area; ASAT: aspartate amino-
transferase; ALAT: alanine aminotransferase. 
 
 
Paclitaxel disposition 
 A summary of model-independent parameter estimates for paclitaxel 
pharmacokinetics is shown in Table 2. This analysis revealed that the times 
that paclitaxel concentrations remained greater than the toxicity thresholds 
of 0.016 µM (unbound drug) and 0.05 µM (total drug) were similar in the 
presence and absence of valspodar in spite of the reduced dose of paclitaxel 
in the former group (Table 2).  
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Table 2. Noncompartmental pharmacokinetics of paclitaxel (mean ± SD with 
range) 
Parameter PAC PAC/valspodar 
No. of patients 
Dose (mg/m2) 
Unbound paclitaxel 
Cmax (µM) 
AUC0-∞ (µM h) 
T>0.0164 (h) 
Total paclitaxel 
AUC0-∞ (µM h) 
T>0.05 (h) 
13 
175 
 
0.230 ± 0.116 (0.057-0.543) 
0.836 ± 0.321 (0.257-1.58) 
7.89 ± 2.56 (5.56-14.61) 
 
15.9 ± 7.01 (2.95-31.4) 
25.4 ± 6.37 (7.30-35.5) 
16 
70 
 
0.105 ± 0.072 (0.048-0.357) 
0.427 ± 0.113 (0.257-0.672) 
5.11 ± 1.32 (3.43-8.08) 
 
4.79 ± 0.84 (3.35-6.72) 
21.7 ± 5.49 (11.8-28.6) 
 
Abbreviations: PAC: paclitaxel; Cmax: peak plasma concentration; AUC: area under 
the plasma concentration versus time curve; T>0.0167: time above the unbound 
paclitaxel concentration thresholf of 0.0164 µM; T>0.05: time above the total 
paclitaxel concentration threshold of 0.05 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Observed plasma concentrations of unbound paclitaxel in patients receiving 
paclitaxel alone (175 mg/m2; triangles) or paclitaxel (70 mg/m2; circles) in 
combination with valspodar. 
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 The plasma concentration-time profiles of unbound paclitaxel given alone or 
in combination with valspodar could be best described with a linear three-
compartment model, in agreement with previous findings.(18,19) The observed 
unbound drug concentrations in both groups are shown in Figure 1. The 
apparent clearance of unbound paclitaxel was not significantly different 
between the two groups, with values of 230 ± 56.0 vs 202 ± 49.9 L/h/m2 in 
the absence and presence of valspodar, respectively (P = 0.17) (Table 3). The 
volume of distribution of unbound paclitaxel was larger in the presence of 
valspodar (1160 ± 474 vs 1620 ± 552 L/m2; P = 0.001), which contributed to 
a significant difference in the terminal disposition half-life (6.12 ± 3.42 vs 
8.50 ± 2.06 h; P = 0.028). 
 
 
Table 3. Compartmental parameter estimates of unbound paclitaxel (mean ± 
SD with range) 
Parameter PAC PAC/valspodar P* Diff (± SE)** 95% CL 
CL (L/h/m2) 
 
MRT (h) 
 
Vd (L/m2) 
 
T1/2,z (h) 
230 ± 56.0 
(122-301) 
  5.03 ± 1.34 
(3.56-8.74) 
1160 ± 474 
(531-2510) 
6.12 ± 3.42 
(2.84-17.0) 
202 ± 49.9 
(126-305) 
8.15 ± 2.07 
(2.50-12.3) 
1620 ± 552 
(266-2470) 
8.50 ± 2.06 
(2.94-11.6) 
0.17 
 
0.001 
 
0.025 
 
0.028 
-28.0 ± 19.7 
 
3.12 ± 0.67 
 
461 ± 194 
 
2.38 ± 1.03 
-68.4 | 12.4
 
 1.75 | 4.49
 
63.3 | 858 
 
 0.28 | 4.49
 
Abbreviations: PAC: paclitaxel; CL: apparent plasma clearance; MRT: mean 
residence time; Vd: steady-state volume of distribution; T1/2,z: terminal disposition 
half-life. 
* Unpaired (two-tailed) Student’s t-test; ** mean difference ± standard error with the 
95% confidence limits for the mean difference. 
 
 
CrEL concentrations 
 Substantial interindividual variability in apparent clearance of CrEL was 
observed, with overall mean values of 267 ± 107 vs 294 ± 165 ml/h/m2 
(Table 4 and Figure 2), consistent with previous findings.(20) 
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Table 4. Plasma levels of CrEL (mean ± SD with range) 
Parameter PAC PAC/valspodar 
No. of patients 
Dose (ml/m2) 
Cmax (µM) 
AUC0-t (µL.h/mL) 
CL (ml/h/m2) 
13 
14.6 
4.15 ± 1.42 (1.51-7.31) 
59.9 ± 21.3 (11.2-85.9) 
267 ± 107 (170-520) 
18 
5.83 
2.22 ± 1.85 (1.08-7.58) 
17.4 ± 7.11 (8.17-31.6) 
294 ± 165 (185-714) 
 
Abbreviations: PAC: paclitaxel; Cmax: peak plasma concentration; AUC: area under 
the plasma concentration versus time curve; CL: apparent plasma clearance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Observed plasma concentrations of CrEL in patients receiving paclitaxel 
alone (175 mg/m2; triangles) or in combination with valspodar (70 mg/m2; circles). 
 
 
Discussion 
 
 In the current study, we obtained clinical pharmacokinetic data that 
increase our insight into the role of P-gp in paclitaxel disposition as well as 
the effects of a potent P-gp inhibitor and CYP3A4 substrate on the 
pharmacokinetics of paclitaxel. Overall, our data indicate that the clearance 
of unbound paclitaxel, following administration as a 3-h i.v. infusion, is not 
significantly altered by oral valspodar. Previously, a phase I trial combining 
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oral valspodar with paclitaxel demonstrated a maximum-tolerated dose of 
the anticancer agent of 70 mg/m2 when given as a 3-h i.v. infusion.(21) 
Interestingly, this ~60% reduced dose for equivalent degrees of 
myelosuppression was not accompanied by any significant alteration in total 
paclitaxel plasma clearance.(22) Unfortunately, a clear-cut interpretation of 
the magnitude of the pharmacological interaction between paclitaxel and 
valspodar has been hampered by a number of important issues, including (i) 
the concomitant administration of other cytotoxic agents, including 
carboplatin(23) and doxorubicin,(24) (ii) the lack of a control group of patients 
treated without valspodar,(23) (iii) and/or variability and unpredictability of 
kinetic profiles associated with 96-h continuous paclitaxel-infusion 
regimens.(25) In addition, the data generated in these trials have without 
exception been based on comparison of two different dose groups in patients 
treated either with or without valspodar administration. This latter issue is 
of particular importance for paclitaxel in view of the profound nonlinear drug 
disposition in plasma,(26,27) which suggests that the pharmacological 
consequences of the combination treatment can not be predicted based on 
total plasma levels alone when different dose groups are compared. Since the 
AUC of unbound paclitaxel (i.e. not bound to serum proteins, its formulation 
vehicle CrEL or other macromolecules in the systemic circulation) is a linear 
function of the paclitaxel dose administered,(12,16) we focused here on 
comparing the fraction-unbound paclitaxel between the two treatment 
groups. This was made possible by the recent development of a novel robust 
and validated technique to measure unbound drug levels,(12) allowing for a 
better understanding of the clinical pharmacology of paclitaxel.(28) 
 Indeed, the nonlinear pharmacokinetic behavior of total plasma 
concentrations of paclitaxel in cancer patients has been demonstrated in a 
number of studies. Although the exact mechanism underlying this nonlinear 
disposition has not yet been fully elucidated, the presence of CrEL, used as 
formulation vehicle of the clinical paclitaxel preparation, is thought to play a 
principal role in this process.(29) This phenomenon is most likely associated 
with micellar entrapment of paclitaxel in the systemic circulation, thereby 
reducing the cellular accumulation of paclitaxel in blood cells, and thereby 
potentially altering drug distribution, metabolism and excretion pathways.(30) 
Similar to data obtained in clinical trials, it has also been shown previously 
that CrEL has a remarkable influence on the disposition of paclitaxel in 
mice.(31) An intriguing observation from these murine studies has been that 
the effect of mdr1a P-gp on the plasma pharmacokinetics of paclitaxel was 
not observed with a drug formulation vehicle containing CrEL, whereas its 
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impact on concurrent tissue concentrations, including heart and brain was 
clearly identifiable.(32) Thus, although plasma is usually the only biological 
matrix available from patients, these findings suggest that the total plasma 
concentration of paclitaxel may not be an appropriate measure to monitor 
the impact of P-gp inhibition by the use of modulating agents. This is also in 
keeping with previous knowledge from data generated in clinical trials of 
combined treatment with the related agent docetaxel and the P-gp inhibitor 
R101933 indicating unaltered drug clearance of the taxane with either 
oral(33) or i.v. dosing of the modulator,(34) whereas fecal elimination pathways 
were significantly altered. Despite these observations, recent work on the 
combination of paclitaxel with valspodar still applied the total plasma 
concentration of paclitaxel to study the potential for pharmacokinetic 
interactions. 
 Consistent with previous observations,(22) this study demonstrated that 
the systemic exposure (AUC) to unbound paclitaxel was unaffected when 
combined with valspodar. The difference in AUC between the two treatment 
groups in Table 2 are explained by the different dosage of paclitaxel. In 
contrast, valspodar had a pronounced effect on the duration of time that the 
total plasma concentrations of paclitaxel remained greater than the toxicity 
threshold level of 0.05 µM, which was not significantly different in spite of 
the 60% dose reduction in the presence of valspodar. As paclitaxel 
elimination is almost entirely caused by metabolic breakdown through 
CYP3A4 and CYP2C8 isoforms,(35) this may relate to interference by 
valspodar of CYP3A4-mediated paclitaxel metabolism causing changes in the 
terminal disposition phase. Indeed, Kang et al.(36) have shown that inhibition 
of CYP3A4 by valspodar increases the plasma concentrations of 6α-
hydroxypaclitaxel, the formation of which is dependent on CYP2C8 
activity.(37) Although the mechanistic explanation for this effect has not been 
conclusively elucidated, it is plausible that inhibition of one of two principal 
metabolic routes results in shunting of parent drug to alternative 
metabolites. However, other possible mechanisms, including altered 
enterohepatic recirculation through inhibition of intestinal P-gp or by 
promoting valspodar-induced cholestasis, cannot be excluded.(36) 
 It is likely that the observed differences in the terminal phase in 
unbound concentrations between treatment with or without valspodar are 
likewise related to changes in drug metabolism. As an alternative 
explanation for the altered terminal disposition phase, we considered a 
possible influence of valspodar on CrEL pharmacokinetics. However, the 
apparent clearance of CrEL was not significantly altered by valspodar, ruling 
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out this possibility as a potential contributing source. In this context, it is 
worth mentioning that since the apparent clearance of CrEL increases 
significantly with prolonged duration of the paclitaxel infusion, the systemic 
exposure to unbound paclitaxel is also schedule dependent.(18) For example, 
the AUC of unbound paclitaxel was substantially reduced following doses of 
100 mg/m2 administered as a 1-h i.v. infusion as compared to a 3-h i.v. 
infusion (0.50 ± 0.10 vs 0.62 ± 0.12 µM.h; P = 0.009). This suggests that the 
effect of valspodar on paclitaxel elimination may depend on the duration of 
drug infusion. In addition, it provides, at least in part, an explanation for the 
extensive effects of valspodar on circulating concentrations of 6α-paclitaxel 
with 96-h i.v. infusions,(36) when concomitant levels of CrEL are expected to 
be very low, as compared to those observed after 1-h i.v. infusions.(24) 
 As outlined, the exposure-toxicity relationships of paclitaxel in cancer 
patients have been most commonly described with a threshold model, 
although other models have been proposed, including those using a general 
model for the time-dissociated effects.(38,39) According to the threshold 
models, the severity of neutropenia is related to the duration of exposure 
above a certain threshold concentration, such that a duration of 17.4 h 
above 0.05 µM (total paclitaxel)(26) or 11.3 h above 0.0164 µM (unbound 
paclitaxel)(16) were predicted to yield a 50% decrease in absolute neutrophil 
count. Based on this kind of modeling exercise, it has been proposed by 
various investigators that the reduction in paclitaxel dose required when 
administered in combination with valspodar is directly attributable to the 
altered values for the threshold duration.(22-25) More recent work, however, 
has shed light on some important mechanistic aspects of paclitaxel-induced 
myelosuppression, and has clearly indicated the importance of unbound 
paclitaxel AUC as a pharmacokinetic parameter to delineate exposure-
toxicity relationships, both with 1-h(28) and 3-h infusion regimens.(16) Since 
our data indicate unchanged clearance of unbound paclitaxel by valspodar, 
alternative mechanisms, in addition to changes in pharmacokinetics, 
contributing to the exacerbated toxicity cannot be excluded. More 
specifically, a direct pharmacodynamic effect of valspodar, by interacting 
with P-gp, might increase the cellular uptake and retention of paclitaxel in 
subpopulations of normal peripheral blood and bone marrow cells.(40) For 
example, recent work from Tidefelt et al.(41) has provided very compelling 
evidence that only patients with P-gp positive leukemia showed a 
significantly increased ratio of daunorubicin AUC in the hematopoietic cells 
to the exposure in plasma after the start of valspodar administration. This 
strongly supports the hypothesis that valspodar can cause an increased 
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intracellular accumulation of P-gp substrate drugs, not only by its effect on 
plasma pharmacokinetics, but also by interacting directly with P-gp 
expressing cells. Furthermore, pharmacodynamic modeling studies with data 
obtained from patients treated with high dose cyclosporin A and etoposide 
suggest that a certain degree of the enhanced myelotoxicity observed in this 
regimen is attributable to inhibition of P-gp in bone marrow precursor 
cells.(42) Clearly, this would be consistent with the in vitro observations where 
valspodar was shown to enhance the toxicity to and modulates cellular 
accumulation of paclitaxel in normal (human) cellular systems expressing P-
gp.(43) Hence, it is hypothesized that due to P-gp inhibition by valspodar, the 
intracellular accumulation and retention of paclitaxel in bone marrow 
precursor cells is prolonged, thus leading to extensive myelosuppression 
when the two drugs are given concomitantly. This increase in toxicity 
requires dose reductions of the concomitantly administered paclitaxel and 
other chemotherapeutic agents, possibly leading to a less effective cytotoxic 
treatment.  
 Collectively, our study demonstrates that a linear three-compartment 
model best described the unbound paclitaxel concentration-time profiles, 
and that the apparent clearance of unbound paclitaxel is not significantly 
different in the absence and presence of valspodar. This indicates that 
valspodar lacks the profound interaction with paclitaxel observed previously 
with other modulators, including cyclosporin A and verapamil.(3) The 
increased toxicity of the combination regimen appears to be, at least 
partially, attributable to inhibition of P-gp function in bone marrow 
precursor cells and not solely to pharmacokinetic interactions resulting in 
increased levels of (unbound) paclitaxel, as suggested previously. In view of 
our current findings, it is concluded that the total plasma concentration of 
paclitaxel is not an appropriate measure to monitor the impact of P-gp 
inhibition. 
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Abstract 
 
 Purpose: To investigate the cerebrospinal fluid (CSF) penetration of 
docetaxel in cancer patients.  
 Methods: Docetaxel was administered as a 1-h infusion at a dose of 75 
mg/m2 to 2 patients with metastatic breast cancer and leptomeningeal 
carcinomatosis. CSF samples were obtained using a lumbar puncture up to 
a 72-h time period. Total and unbound docetaxel concentrations in plasma 
and CSF were determined by liquid chromatography (lower limit of 
quantitation, 0.5 nM for plasma and 0.050 nM for CSF) and equilibrium 
dialysis, respectively. Results: The pharmacokinetics of docetaxel in plasma 
are in line with data of previous studies. The concentrations of docetaxel in 
CSF did not follow the general pattern in plasma, with relatively stable 
concentrations over the 72-h time period. The fraction unbound docetaxel in 
plasma ranged from 6 to 13%, while those in CSF ranged from 67 to 103%. 
For total and unbound docetaxel, the CSF to plasma concentration ratio 
progressively increased in 72 h from 0.01% to 0.6%, and from 0.1% to 9%, 
respectively.  
 Conclusions: These data suggest that measurement of unbound docetaxel 
is required to accurately assess the extent of drug penetration into CSF, and 
that the drug can produce distribution to CSF at levels associated with 
significant antitumor activity in experimental models. 
 
Introduction 
 
 Knowledge on the penetration of anticancer drugs into the central 
nervous system is essential for tumor targets localized within the brain. The 
pharmacodynamics of the drug in the central nervous system depends 
largely on the concentration-time profile at the site of action. This 
concentration-time profile is determined by several factors, including 
transport across the blood-brain barrier and the blood-cerebrospinal fluid 
barrier.(5) For obvious reasons, direct measurement of drug concentrations in 
the brain tissue of cancer patients is highly restricted. Hence, in the clinical 
setting, drug concentrations in cerebrospinal fluid (CSF) are commonly used 
as a surrogate for drug concentrations in the brain.(5) However, the brain 
consists of multiple compartments and many factors, such as the presence 
of drug-transporting proteins and disruption of the blood-brain barrier by 
tumor cells, are involved in the process of altering the transport of drugs to 
these compartments. In the current study, CSF concentrations of docetaxel 
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were used to evaluate the extent of drug delivery to the brain and in 
particular the meninges in 2 patients with metastatic breast cancer, because 
docetaxel is a commonly used drug in this malignancy,(8) which is frequently 
associated with leptomeningeal carcinomatosis.(4) 
 
Patients and methods 
 
Patients and treatment 
 Pharmacokinetic studies were performed on 2 patients treated for 
metastatic breast cancer with single-agent docetaxel. The patients received 
docetaxel (Taxotere; Aventis, Hoevelaken, the Netherlands) as a 1-h infusion 
at a dose of 75 mg/m2 (absolute dose, 120 and 125 mg, respectively). Both 
patients had a World Health Organization performance score < 2; normal 
kidney function (serum creatinine < 130 µmol/l); adequate hepatic function 
[total serum bilirubin < 1.5 x upper limit of institutional normal (ULN); 
transaminases < 2 times ULN; and alkaline phosphatase < 2 times ULN]; and 
adequate bone marrow function (absolute neutrophil count > 1.5 × 109/liter, 
and platelet count > 100 × 109/liter). Both patients gave written informed 
consent, and the Ethics Board of the Erasmus MC (Rotterdam, the 
Netherlands) approved the study. 
 
Sample collection 
 Blood and CSF samples in the 2 patients were collected up to 25 and 72 
h, respectively. Blood samples were drawn from a venous access site into 
heparinized tubes, separate from the site of the docetaxel infusion, while 
CSF samples were obtained by lumbar puncture. Blood samples were 
centrifuged immediately for 5 minutes at 2,500 × g to separate plasma, and 
CSF samples and plasma were stored at a temperature lower than -70°C in 
propylene vials, until analysis. Prior to analysis, it was confirmed that the 
CSF samples were not contaminated with blood (i.e., less than 1 × 106 
erythrocytes), except for one sample, which was not taken into consideration 
in the final analysis. 
 
Docetaxel analysis 
 Analytical measurement of total docetaxel concentrations in plasma was 
performed using a validated assay based on liquid chromatography with 
tandem mass-spectrometric detection [lower limit of quantitation, 0.5 nM (~ 
0.4 ng/mL)], as described previously.(1) For determination of total docetaxel 
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in CSF, the method was slightly modified. In brief, aliquots of 1 mL were 
extracted using a mixture of acetonitrile and n-butyl chloride (1:4, v/v) 
following the addition of the internal standard, paclitaxel. Chromatographic 
separations were achieved on a Waters X-Terra MS column (20 × 2.1 mm 
internal diameter) packed with a 3.5-µm octadecyl stationary phase (Waters), 
and a mobile phase composed of acetonitrile and 0.1% aqueous formic acid 
(80:20, v/v) that was delivered at a flow rate of 0.15 ml/min. Sample 
extracts were analyzed using a Micromass Quattro LC triple-quadrupole 
mass-spectrometry detector (Beverly, MA, USA) with an electrospray probe in 
the positive ionization mode. The spectrometer was programmed to detect 
the protonated molecular ion / product ion pairs of docetaxel (m/z 808.5, 
m/z 527.2) and paclitaxel (m/z 854.5, m/z 509.4). Calibration curves were 
constructed in Elliott’s B solution over the range 0.050 to 1.0 nM, and 
computed using the peak area ratio of paclitaxel and docetaxel by weighted 
(1/x) linear-regression analysis. The lower limit of quantitation of the assay 
for docetaxel in CSF is 0.050 nM (~ 40 pg/mL). 
 For the determination of the fraction unbound docetaxel in plasma and 
CSF a validated equilibrium dialysis method was used.(9) In brief, aliquots of 
260-µL plasma or CSF were dialyzed against an equal volume of phosphate-
buffered saline containing a [G-3H]docetaxel tracer over a membrane with a 
12,000-14,000 Da molecular weight cut-off (Spectrum Medical, Houston, TX, 
USA). Dialysis experiments were performed using 2-mL polypropylene Safe-
Lock vials (Eppendorf, Hamburg, Germany) as dialysis chamber in a 
humidified atmosphere at 37°C. After the end of the 48-h dialysis period, the 
radioactivity was measured by liquid-scintillation counting for 20 minutes 
using a Wallac Oy 1409 counter (Turku, Finland). The fraction unbound 
docetaxel was expressed as a percentage, while the unbound docetaxel 
concentration was calculated as the product of the fraction unbound 
docetaxel and the concentration of total docetaxel. 
 
Pharmacokinetic analysis  
 Pharmacokinetic parameters estimates of docetaxel were derived from 
weighted (1/y) non-compartmental analysis using WinNonlin version 4.0 
(Pharsight Corp., Mountain View, CA, USA). The CSF to plasma 
concentration ratios for docetaxel were calculated using the concurrent 
plasma concentrations at the time point of CSF sampling. 
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Results 
 
 A summary of the pharmacokinetics of total and unbound docetaxel in 
plasma and CSF is presented in Table 1. The values for total docetaxel 
parameters showed wide variability with 2.5-fold variation in clearance 
between the 2 patients, but are in line with data from several previous 
studies on docetaxel pharmacokinetics.(3) Using the applied analytical 
method, docetaxel concentrations in CSF could not be quantified in the 
patient in which the drug was cleared fast (i.e., levels were below 40 pg/mL).  
 
Table 1. Summary of docetaxel pharmacokinetics 
Parameter Patient 11 Patient 22 
Plasma 
Cmax (µg/mL) 
AUC (µg·h/mL) 
CL (L/h) 
T1/2,z (h) 
 
CSF 
C1.35 h (pg/mL) 
C2.62 h (pg/mL) 
 
C1.53 h (pg/mL) 
C25.1 h (pg/mL) 
C72.0 h (pg/mL) 
total 
1.18 
1.34 
89.6 
12.4 
 
total 
NQ 
NQ 
unbound 
0.119 
0.112 
1067 
13.3 
 
unbound 
total 
3.21 
3.47 
36.0 
33.9 
 
total 
 
 
 
71.6 
56.5 
63.1 
unbound 
0.169 
0.201 
620 
23.6 
 
unbound 
 
 
 
47.7 
42.9 
46.5 
 
1 Plasma samples taken up to 26 h; 2 Plasma samples taken up to 72 h. 
Abbreviations: Cmax, peak concentration; AUC, area under the plasma 
concentration-time curve extrapolated to infinity; CL, total clearance; T1/2,z (h), half-
life of the terminal disposition phase; CSF, cerebrospinal fluid; C i h, concentration 
of docetaxel at i h after the start of infusion; NQ, not quantifiable (i.e., total CSF 
concentration below 40 pg/mL). 
 
 
The fraction unbound docetaxel in plasma ranged from 6 to 13% in samples 
from the two patients, while those in CSF ranged from 67 to 103%, 
presumably because of lower concentration of binding proteins in CSF 
compared to plasma. The concentration time curves of total and unbound 
docetaxel in plasma and CSF are presented in Figure 1.  
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Figure 1. Plasma concentration time curves of total (closed circles) and unbound (open 
circles) docetaxel in patient 2. The triangles indicate the observed total (closed 
triangles) and unbound (open triangles) docetaxel concentrations in cerebrospinal 
fluid samples. 
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Figure 2. Cerebrospinal fluid (CSF) to plasma concentration ratios of total docetaxel 
(closed symbols) and unbound docetaxel (open symbols) in patient 2. 
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The concentrations of docetaxel in CSF did not follow the general 
pattern of docetaxel in the plasma compartment, with relatively stable levels 
being observed over the entire sampling-time period. As shown in Figure 2, 
the CSF to plasma concentration ratio of docetaxel varied in time with values 
for the total drug ratio increasing from 0.01% to 0.6%, and the unbound 
drug ratio increasing from 0.1% to 9%. 
 
 
Discussion 
 Despite numerous studies describing the clinical pharmacokinetics and 
pharmacodynamics of docetaxel (reviewed in [3]), the CSF pharmacokinetics 
and penetration for this agent have only been described previously in a 
single case report.(6) This current investigation adds to that knowledge 
because it is the first to take into account the vascular binding of docetaxel 
by measuring unbound concentrations. In addition, it reports on the 
application of a recently developed, highly sensitive assay based on liquid 
chromatography coupled with tandem mass-spectrometric detection.(1) 
 In both patients with metastatic breast cancer and leptomeningeal 
carcinomatosis studied here, only very low concentrations of docetaxel were 
measured in CSF, despite plasma levels of total docetaxel being within the 
therapeutic range associated with this regimen.(2) Interestingly, the docetaxel 
concentrations in CSF remained relatively constant over time, suggesting a 
very slow clearance from the CSF compartment relative to that in the 
systemic circulation. As a result, apparent equilibrium for docetaxel could 
not be determined within the time-frame in which CSF samples were drawn. 
The limited surface area for docetaxel diffusion and the hydrophobic nature 
of the drug, combined with extensive vascular binding to serum proteins like 
alpha 1-acid glycoprotein(10) likely contributed to the slow equilibrium 
kinetics. For this reason, CSF represented only a relatively small additional 
compartment for docetaxel distribution, particularly in view of the large 
volume of distribution of docetaxel. It is of particular note that, because the 
CSF to plasma unbound concentration ratios are time-dependent, single-
point data are clearly inappropriate to directly assess the extent of CSF 
penetration by docetaxel. Furthermore, analysis based on total drug levels in 
plasma as done previously,(6) potentially results in an estimated 10 to 20-fold 
underestimation of the extent of drug penetration in CSF.   
 Although the concentrations of docetaxel measured in CSF are relatively 
low, results of in vitro tests with several cell lines continuously exposed to 
docetaxel for 96 h previously suggested more than 50% inhibition of cell 
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growth (IC50) at a mean concentration of 0.4 ng/mL (5,1 x 10-10 M).(7) 
Assuming a protein-bound fraction of approximately 90% for docetaxel in 
cell culture due to the presence of binding proteins in fetal calf serum, the 
IC50 for unbound docetaxel is around 40 pg/mL, which is comparable to 
values observed in the patient’s CSF. Although the current data are limited 
to only two patients, the results suggest that docetaxel administered 
intravenously at doses commonly used in 3-weekly treatment regimens (i.e., 
≥ 75 mg/m2) produces unbound drug levels in CSF for prolonged time 
periods that are associated with significant antitumor activity in 
experimental models. 
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Abstract 
 
 Objective: In vitro studies indicate that the anticancer drug docetaxel is 
primarily eliminated by CYP3A4-mediated metabolism. Co-administration of 
drugs that modulate the activity of CYP3A4 is therefore likely to have 
undesirable clinical consequences. Here, we investigated the effects of the 
potent CYP3A4 inhibitor, ketoconazole, on the pharmacokinetics of docetaxel 
in cancer patients. 
 Methods: Seven patients were treated in a randomized crossover design 
with docetaxel (100 mg/m2) followed 3 weeks later by docetaxel (10 mg/m2) 
given in combination with orally administered ketoconazole (200 mg once 
daily for 3 days), or the reverse sequence. Plasma concentration-time data 
were analyzed using non-compartmental analysis. 
 Results: Ketoconazole co-administration resulted in a 49% decrease in 
clearance of docetaxel (P = .018). The mean (± SD) clearance values were 
35.0 ± 11.8 L/h (95% confidence interval, 24.1 – 45.9 L/h) for docetaxel 
alone and 18.2 L/h (95% confidence interval, 9.22 – 27.1 L/h) in the 
presence of ketoconazole, respectively. The docetaxel clearance ratio in the 
presence and absence of ketoconazole was weakly related to the area under 
the curve of ketoconazole (R-squared, 0.529; P = .064). 
 Conclusion: Inhibition of CYP3A4 by ketoconazole in vivo results in 
docetaxel clearance values that were previously shown to be associated with 
a several-fold increase in the odds for febrile neutropenia at standard doses. 
Caution should be taken and substantial dose reductions are required if 
docetaxel has to be administered together with potent inhibitors of CYP3A4.  
 
Introduction 
 
 Drug interactions are a major cause of morbidity and mortality in 
modern clinical practice.(1) Many anticancer drugs have a narrow therapeutic 
index and are administered to cancer patients who are also taking numerous 
concomitant medications.(2) An understanding of the implications of 
interactions is therefore particularly important in anticancer therapy. The 
human cytochrome P450 3A (CYP3A) subfamily, which is involved in the 
metabolism of more than 50% of currently prescribed drugs, plays a 
dominant role in many clinically-relevant drug interactions.(3) In adults, 
CYP3A activity represents the combined activities of the isoforms CYP3A4, 
CYP3A5, and CYP3A7.(4) In the majority of humans, however, CYP3A activity 
in the intestine and liver is predominately reflected by CYP3A4 activity. 
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Significant interindividual variability in the pharmacokinetics of CYP3A 
substrates has been observed both in vitro and in vivo. These differences are 
thought to be related to variations in both basal content and catalytic 
activity of total CYP3A.(4) Disease-related differences, drugs inducing or 
repressing transcription, and possibly inherited and ethnic differences are 
also factors contributing to CYP3A phenotype.(5) 
 The anticancer drug docetaxel is extensively metabolized by CYP3A.(6,7) 
The major metabolites and less than 10% of the parent drug are excreted 
into the feces, whereas total urinary excretion is also less than 10%.(8) The 
metabolites demonstrate substantially reduced cytotoxic activity as 
compared to the parent drug, making biotransformation by CYP3A a major 
route of inactivation.(9) Furthermore, total CYP3A activity has been identified 
as a strong predictor of docetaxel clearance and most likely accounts to a 
large extent for the observed interindividual variability in drug clearance and 
area under the plasma concentration-time curve (AUC).(10-12) Although the 
fact that docetaxel is predominately metabolized by CYP3A makes the agent 
subject to a host of enzyme-mediated drug interactions, data on potential 
interactions are lacking in humans. The aim of the current trial was to 
assess the effect of CYP3A inhibition on the pharmacokinetics of docetaxel in 
cancer patients, using the model inhibitor, ketoconazole.(13) 
 
Methods 
 
Patients selection 
 Eligible patients had a histologically or cytologically confirmed diagnosis 
of cancer for which docetaxel has proven efficacy, or for which no other 
treatment option was available. Additional eligibility criteria included: (i) a 
life expectancy of ≥12 weeks; (ii) a World Health Organization performance 
status ≤1; (iii) no chemotherapy, hormonal therapy, radiotherapy, or major 
surgery within four weeks prior to treatment; (iv) age above 18 years; (v) 
adequate contraception for women of child-bearing potential; and (vi) 
adequate bone marrow function (absolute neutrophil count, >1.5 × 109/L; 
platelets, platelet count, >100 × 109/L), renal function [serum creatinine, 
≤1.5 × the upper limit of normal (ULN)], and hepatic function (serum 
bilirubin, ≤1 × ULN; alanine aminotransferase and aspartate 
aminotransferase, <2.5 × ULN; and alkaline phosphatase, ≤5 × ULN in the 
presence of only bone metastases and in the absence of any liver disorders). 
Simultaneous use of any medication, dietary supplements, or other 
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compounds known to inhibit or induce CYP3A was not allowed. The study 
protocol was approved by the Erasmus Medical Center ethical review board, 
and all patients provided written informed consent before study entry. 
 
Study design 
 Treatment consisted of two courses of docetaxel (Taxotere; Aventis 
Pharma BV, Hoevelaken, the Netherlands), administered three weeks apart. 
Docetaxel was diluted in 250 mL of 0.9% (wt/vol) sodium chloride solution, 
and delivered as a 1-hour intravenous infusion. One course was given at a 
docetaxel dose of 100 mg/m2, and the other at a dose of 10 mg/m2 in 
combination with three 200-mg doses of orally administered ketoconazole 
(Nizoral; Janssen Pharmaceutical, Beerse, Belgium). Previously, it was 
shown that the AUC of docetaxel is dose-proportional over a large dose range 
(5 to 145 mg/m2) in the tested 3-week regimen with the drug administered 
as a 1-hour intravenous infusion, indicating a linear pharmacokinetic 
behavior (reviewed by Clarke and Rivory).(8) Therefore, values for clearance of 
docetaxel between the treatment courses with and without ketoconazole co-
administration were compared directly without any correction. 
 The first ketoconazole dose was administered 1 hour before start of the 
docetaxel infusion, and the second and third doses were given 24 and 48 
hours later. The ketoconazole dose and schedule were based on previously 
published data.(14) We hypothesized that CYP3A inhibition would prolong the 
exposure to docetaxel, and that a significant dose reduction was required to 
prevent unacceptable toxicity in the combination cycle. The decision to 
administer docetaxel at a dose of 10 mg/m2 (in combination with 
ketoconazole) was based on the mild toxicity profile seen at this dose level in 
a previous Phase I study with single agent docetaxel,(15) and the hypothesis 
that transient inhibition of CYP3A-mediated metabolism of docetaxel would 
result in associated exposure levels not exceeding those observed at the 
recommended single-agent dose for docetaxel in this regimen, while 
maintaining above the therapeutic threshold level. The allocation sequence 
of the courses for each patient was determined at study entry using a 
restricted-block randomization procedure. Premedication consisted of 
dexamethasone (dose, 8 mg orally) given twice daily for three consecutive 
days, starting on the evening before docetaxel infusion. Side effects were 
scored according to the National Cancer Institute common toxicity criteria 
(version 2.0; available at http://ctep.info.nih.gov). Patients benefiting from 
docetaxel treatment were offered continuation of treatment beyond cycle 2 at 
standard doses outside of the study protocol. 
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Sample size calculation 
 The mean clearance for docetaxel used in the sample size calculation was 
23.99 L/h/m2, estimated from a group of 56 cancer patients that had 
sampling for pharmacokinetics on at least 2 occasions (unpublished data). 
In this group of patients, the SD of the expected differences of the two 
measurements was estimated to be 4.89 L/h/m2. It was assumed that the 
interval between treatments was an adequate washout period, with no 
carryover or period effect. The trial was designed to detect an effect size of 
6.00/4.89, where 6.00 is 25% of the mean docetaxel clearance. Based on a 
pair-wise (two-sided) analysis, this results in a sample size of (at least) 6 for 
the prospective evaluation, with a significance level of 0.05 (5%) and power of 
0.7 (70%). The statistical analysis was performed in the SISA-Binomial 
program (D. G. Uitenbroek, Hilversum, the Netherlands, 1997; available at 
http://home.clara.net/sisa/samsize.htm). 
 
Pharmacokinetic analysis   
 Blood samples were collected in glass tubes containing lithium heparin 
as anticoagulant and immediately centrifuged (4000 g at 4ºC for 10 minutes) 
to separate plasma, which was stored at –80ºC until analysis. Samples were 
taken at the following time points: immediately prior to infusion, at 30 
minutes after the start of infusion, immediately before the end of infusion, 
and at 10, 20, 30 minutes, and 1, 1.5, 2, 4, 8.5, 24, 32, 56, 64, and 72 
hours after the end of infusion. Determination of docetaxel and ketoconazole 
concentrations in plasma was performed by high-performance liquid 
chromatography with tandem mass-spectrometric and UV detection, 
respectively, according to published procedures.(16,17) These assay for 
docetaxel has a lower limit of quantitation of 0.0004 µg/mL (0.5 nM), which 
is sufficiently sensitive to allow quantitation of docetaxel in samples (within 
the tested collection time period) obtained from patients treated with low 
drug doses. Determination of the fraction of unbound docetaxel was 
performed using equilibrium-dialysis with a tritiated-docetaxel tracer 
(Moravek Biochemicals, Brea, CA).(18) 
 Pharmacokinetic parameters for docetaxel and ketoconazole were 
calculated using non-compartmental analysis as implemented in the 
software package WinNonlin version 4.0 (Pharsight Corp., Mountain View, 
CA). For docetaxel, the parameters of interest included the peak plasma 
concentration (Cmax), the area under the plasma concentration-time curve 
extrapolated to infinity (AUC), clearance (CL, defined as dose divided by 
AUC), and volume of distribution at steady-state (Vss), and the half-life of 
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the terminal phase (t1/2). The latter parameter was calculated as ln(2)/k, 
where k is the rate constant of the terminal phase estimated from log-linear 
regression analysis of the final 3 to 5 sampling time points. For 
ketoconazole, the parameters of interest included Cmax, the time to Cmax, and 
AUC over the first dosing interval. 
 
Statistical considerations 
 Pharmacokinetic data are presented as mean values ± SD with 95% 
confidence intervals (CI), unless stated otherwise. The effect of ketoconazole 
co-administration on the pharmacokinetic parameters of docetaxel was 
evaluated statistically using a non-parametric, two-sided, Wilcoxon signed 
rank test for paired observations. The relationship between the exposure to 
ketoconazole and reduction of docetaxel clearance was evaluated using a 
least-squares linear regression analysis. The cut-off for statistical 
significance was set at P < .05. All statistical calculations were performed 
using NCSS 2001 (Number Cruncher Statistical System, Kaysville, UT). 
 
Results 
 
Patients and toxicity profiles 
 To determine the influence of ketoconazole co-administration on the 
pharmacokinetics of docetaxel, a total of seven patients entered the study 
(Table 1). All patients completed the study within the scheduled time. In 
three patients, uncomplicated grade 4 neutropenia was observed, and grade 
3 leukocytopenia in another two patients during the single-agent cycle with 
docetaxel. During the combination course with ketoconazole administration, 
only minimal toxicity was noted. 
 
Ketoconazole analysis 
 The median peak concentration and AUC for ketoconazole over the first 
dosing interval were 1.90 µg/ml (range, 0.886 – 7.37 µg/ml) and 7.80 
µg·h/ml (range, 2.73 – 44.8 µg·h/ml), respectively, similar to previous 
findings.(13) The mean time to peak concentration on day one was observed 
at 2.24 hours (range, 1.50 – 3.47 hours), suggesting that high 
concentrations of ketoconazole were present during and immediately after 
the administration of docetaxel. Although ketoconazole is generally well 
absorbed, large inter- and intraindividual pharmacokinetic variation after 
the same oral dose has been reported.(13) This is partly due to differences in 
gastric acidity, as an increased pH in the stomach decreases the extent of 
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ketoconazole absorption. A large interindividual variation in peak 
concentration and AUC was also observed in the current population; for one 
patient this could be explained by administered co-medication (see below).  
 
Table 1. Baseline patient characteristics* 
Demographic 
variable 
No.of patients Median value Range 
Age, years 
Sex 
Male 
Female 
BSA, m2 
WHO performance  
0 
1 
Tumor type 
Head and neck 
Cervix 
Sarcoma 
Melanoma 
ACUP 
Rectum 
 
 
4 
3 
 
 
3 
4 
 
2 
1 
1 
1 
1 
1 
40 
 
 
 
1.8 
1 
 
 
 
36 – 59 
 
 
 
1.6 – 2.1 
0 – 1 
 
 
 
 
AST, U/L 
ALT, U/L 
Alk Phos, U/L 
Total bilirubin, µM 
WBC, × 10-9/L 
ANC, × 10-9/L 
 24 
18 
73 
6 
8.4 
7.1 
17 – 79 
6 – 30 
62 – 241 
4 – 11 
6.7 – 12.9 
2.6 – 15.1 
 
Abbreviations used: BSA, body surface area; WHO, World Health Organization; 
ACUP, adenocarcinoma of unknown primary; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; Alk Phos, alkaline phosphatase; WBC, white blood 
cell counts; ANC, absolute neutrophil count. 
* The upper limits of institutional normal for the pretherapy clinical chemistry 
parameters are: AST, < 93 U/L for males and < 78 U/L for females; ALT, < 103 U/L 
for males and < 78 U/L for females; Alk Phos, ≤ 600 U/L; total bilirubin < 
17µmol/L. 
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Figure 1. Observed plasma concentrations of docetaxel in the absence (closed circles, 
solid lines; dose, 100 mg/m2) and presence of ketoconazole co-administration (open 
circles, dashed lines; dose, 10 mg/m2; data normalized to 100 mg/m2). 
 
 
Docetaxel analysis 
 The observed plasma concentrations of docetaxel for both treatments are 
shown in Figure 1. When ketoconazole was co-administered, the fractional 
change for clearance was 0.51 (95% CI, 0.36 – 0.65; range, 0.26 – 0.68), 
indicating that, overall, clearance was reduced by 49% (P = .018) (Table 2). 
However, large interindividual variability was seen in the reduction in 
clearance, which reached a maximum value of 74%. The fractional change in 
docetaxel clearance was weakly correlated to the corresponding AUC of 
ketoconazole (Figure 2), as determined by a linear regression analysis (R-
squared, 0.529; P = .064). A similar relationship was not observed with the 
time to peak concentration of ketoconazole (R-squared, 0.047; P = .639), 
suggesting that the rate of absorption was unrelated to variability in effect. 
For one patient, the fractional change was only 0.68, which was attributable 
to a very low exposure to ketoconazole due to concomitant administration of 
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ranitidine, which is known to alter the gastrointestinal absorption of 
ketoconazole.(19)  
 It may seem paradoxical that, although docetaxel clearance is inhibited 
by ketoconazole, the terminal half-life for docetaxel was found to be slightly 
shorter in the presence of ketoconazole (Table 2). However, the elimination 
half-life also depends on intercompartmental rate constants. When these 
processes take place at a higher rate, the elimination half-life, which 
characterizes the decline in plasma concentration from the site of 
measurement, will decrease. 
 Docetaxel in plasma was approximately 94% bound in all patients (mean, 
94.2 ± 1.45%; range, 88.8 – 96.7%), consistent with previous estimates.(18) 
The fraction unbound docetaxel was not significantly different in courses 
with and without ketoconazole (5.74 ± 1.96% versus 5.81 ± 1.45%; P = .74), 
indicating that protein binding of docetaxel is not significantly affected by 
ketoconazole. 
 
 
Figure 2. Relationship between ketoconazole area under the curve (AUC, µg·h/ml) and 
the fractional change in docetaxel clearance (CL), defined as the ratio of CL in the 
presence and absence of ketoconazola co-administration. The change is described by 
the following equation: (0.623 ± 0.0660) – (0.0077 ± 0.0033) × (ketoconazole AUC in 
µg·h/mL); R-squared = 0.529; P = .064). 
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Discussion 
 
 This study shows that the clearance of docetaxel is significantly reduced 
by 49% upon co-administration with ketoconazole, albeit at large 
interindividual variability. This degree of variability was shown to be related 
to interindividual differences in the systemic exposure to ketoconazole, with 
low AUC values leading to only minimal inhibitory effects.  
 The main toxic side effect associated with docetaxel treatment is a short-
lasting neutropenia that reaches grade 3-4 in approximately 90% of patients 
(see: http://www.taxotere.com). Bruno et al have reported previously that 
the AUC of docetaxel is a significant predictor of severe neutropenia; a 50% 
decrease in clearance corresponds to a 4.3-fold increase in the odds for 
grade 4 neutropenia and in a 3.0-fold increase in the odds for febrile 
neutropenia.20 In the present study, the maximum decrease in clearance 
observed was 74%, which translates into a 6.5-fold increase in the odds for 
grade 4 neutropenia, and in a 4.5-fold increase in the odds for febrile 
neutropenia. This could have had clinical consequences had docetaxel been 
administered in combination with ketoconazole at the full recommended 
dose. Calculation of the predicted AUC in combination with ketoconazole (ie, 
the AUC normalized to a 100 mg/m2 dose) for this same patient resulted in a 
relative increase in exposure of approximately 290%, further supporting the 
potential for a substantially increased risk of severe toxicity. The current 
findings are inconsistent with previously published data that suggest that 
ketoconazole does not consistently affect docetaxel pharmacokinetics,(21) 
even though much higher doses of ketoconazole were administered. In that 
study, however, plasma concentrations of ketoconazole were not reported, 
making a direct comparison impossible. 
 As mentioned previously, human adult CYP3A activity reflects the 
heterogeneous expression of CYP3A4, CYP3A5, and CYP3A7, although the 
level of hepatic CYP3A4 seems to be the major determinant in the 
metabolism of docetaxel.(22) However, the polymorphic distribution of 
CYP3A5 indicates that metabolically active CYP3A5 is expressed in 
approximately 30% of Caucasians and in 50-73% of African Americans.(23,24) 
In these individuals, CYP3A5 expression accounts for at least 50% of the 
total CYP3A content, and likely contributes substantially to the metabolic 
clearance of many CYP3A substrates. However, CYP3A5 is less susceptible to 
inhibition by ketoconazole as demonstrated by increased Ki values.(25) 
Furthermore, the percentage of inhibition by ketoconazole is inversely 
related to the fractional percentage of CYP3A5 in total CYP3A.(25) The 
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presence of variable expression ratios of CYP3A4/CYP3A5 in other ethnic 
populations may therefore result in a different drug interaction between 
docetaxel and ketoconazole. 
 In conclusion, co-administration of the potent CYP3A4 inhibitor 
ketoconazole leads to a 49% decrease in docetaxel clearance and, as such, to 
an increased risk for severe neutropenia. The extent to which docetaxel 
clearance was reduced depends on the exposure to ketoconazole, as 
expressed by AUC. Further research is required to ascertain whether this 
measurement of ketoconazole exposure can be used a priori to identify 
patients potentially at risk for a clinically relevant interaction when being 
treated with ketoconazole and docetaxel, a strategy that is currently being 
pursued in the treatment of androgen-independent prostate cancer.(26,27) 
Most importantly, with concomitant use of docetaxel and ketoconazole, or 
other potent CYP3A4 substrates or inhibitors, potentially dangerous 
interactions are likely. Hence, caution should be taken and substantial dose 
reductions are necessary if these drugs need to be administered together. 
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Abstract 
 
 The pharmacokinetic behaviour of anticancer drugs may be altered with 
aging due to (for example) differences in body composition and decreased 
hepatic and renal function. To address this issue for paclitaxel, we studied 
the pharmacokinetics of the drug in eight elderly women (≥70 years) with 
metastatic breast cancer [median age (range), 77 years (70 – 84)] and a 
control group of 15 patients aged <70 years [median age (range), 54 years 
(22 – 69)]. Paclitaxel was administered as a 1-h intravenous (i.v.) infusion at 
a dose of 80 (elderly) or 100 mg/m2 (<70 years), and serial blood samples 
were obtained at baseline, and up to 24 h after the end of infusion. Paclitaxel 
concentration-time profiles were fitted to a linear three-compartment model 
without any demonstration of saturable behaviour. The clearance of 
unbound paclitaxel was 124 ± 35.0 (elderly) versus 247 ± 55.4 l/h/m2 (<70 
years) (P = 0.002), and was inversely related to patient’s age (R2 = 0.857; P 
<0.00001). Total plasma clearance of the formulation vehicle Cremophor EL 
(CrEL) was 150 ± 60.7 (elderly) versus 115 ± 39.2 ml/h/m2 (< 70 years) (P = 
0.04). These data indicate an approximately 50% change in total body 
clearance of unbound paclitaxel and a concomitant significant increase in 
systemic exposure with age, most likely as a result of altered CrEL 
disposition. The clinical relevance of these observations with respect to 
toxicity profiles and antitumour efficacy requires further evaluation. 
 
Introduction 
 
 As the incidence of breast cancer rises with advancing age, and 
populations in Western countries are aging, the total number of women with 
breast cancer will increase substantially.(1) Unfortunately, elderly patients 
are still underrepresented in trials on cancer therapies, especially on breast 
cancer treatment.(2) This holds true even after the exclusion of trials 
restricted to patients younger than 65 years.(2) Moreover, as elderly patients 
frequently suffer from impaired organ functions and/or comorbidity, 
extrapolating standard recommendations for chemotherapy in metastatic 
breast cancer patients to the elderly might result in excessive toxicity.(3) 
Notwithstanding the large number of elderly patients, and the known impact 
of impaired renal and hepatic functions on the absorption, distribution, 
metabolism and excretion of various anticancer agents, including taxanes, 
there have been only a few pharmacological studies conducted in this 
subgroup of patients.(4)  
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 The cytotoxic agent paclitaxel (Taxol) is registered for the treatment of 
advanced breast cancer, for which it is usually administered in second-line 
therapy as a single agent every 3 weeks at a dose of 175–225 mg/m2. 
Frequently encountered side-effects are neutropenia, neuropathy, asthenia 
and alopecia. Weekly administration of paclitaxel has demonstrated 
sustained efficacy together with a more favourable toxicity profile lacking 
severe myelotoxicity.(5) While the related agent docetaxel, despite a dose 
reduction of 75% of the standard dose of 100 mg/m2 every 3 weeks, 
appeared to be too toxic in non-pretreated patients aged >70 years with 
metastatic breast cancer, a weekly schedule at a dose of 36 mg/m2 in heavily 
pretreated elderly patients indeed appeared effective and well tolerated.(6-8) 
Recently published data suggest similar efficacy for weekly paclitaxel.(9,10) 
This way of administering paclitaxel therefore seems an attractive 
chemotherapeutic alternative for elderly women with metastatic breast 
cancer, although no pharmacological data are yet available. Here, we studied 
the pharmacokinetics of paclitaxel and its formulation vehicle Cremophor EL 
(CrEL) in patients with breast cancer aged ≥70 years treated in a weekly 
schedule, and compared the results with a control group of patients aged 
<70 years treated in a similar way. 
 
Patients and methods 
 
Eligibility criteria 
 Two groups of patients were studied based on age; patients aged ≥70 
years were eligible if they had histologically or cytologically confirmed breast 
cancer, unresponsive to hormonal therapy, while patients aged between 18 
and 70 years were eligible if they had any histologically or cytologically 
confirmed metastatic solid tumour for which treatment with paclitaxel was a 
viable option. Prior to recruiting male patients in the control group, it was 
confirmed that there are no sex-related differences in unbound paclitaxel 
clearance. This was investigated in unpublished data from a historical 
patient population treated at the Erasmus MC – Daniel den Hoed Cancer 
Center (Rotterdam, the Netherlands) with single agent paclitaxel given as a 
1-h intravenous (i.v.) infusion at dose levels ranging between 70 and 200 
mg/m2. The group consisted of 10 males (median age, 58 years; range, 46–
70 years) and 30 females (median age, 57 years; range, 29 – 71 years). The 
mean (± SD) values for clearance of unbound paclitaxel in male and female 
patients were 200 ± 35.6 and 195 ± 48.3 l/h/m2, respectively, which is a not 
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statistically significant difference [P = 0.75; mean difference (± SE), 5.26 ± 
16.3 l/h/m2; 95% confidence limits for the mean difference, -27.8 and 38.3; 
unpaired two-tailed Student’s t-test]. 
 Other criteria for patient enrollment were (i) acceptable performance 
status according to the World Health Organization criteria (WHO) (0-2), (ii) 
an adequate bone marrow function (defined by pretherapy values of 
haemoglobin ≥ 6.0 mM, absolute neutrophil count (ANC) >1.5 × 109/l, and 
platelet count >160 × 109/l), (iii) adequate renal function (creatinine levels 
<175 µM) and (iv) adequate hepatic function (bilirubin levels < 25 µM). 
Patients with other malignancies during the past 5 years, neuropathy graded 
≥2, symptomatic cardiac disease, and/or signs of central nervous system 
involvement were excluded. All patients gave written informed consent, and 
the study protocol was reviewed and approved by the Erasmus MC – Daniel 
den Hoed Cancer Center review board (Rotterdam, the Netherlands). 
 
Treatment schedule and patient evaluation 
 Paclitaxel was administered as a 1-h i.v. infusion at a dose of 80 mg/m2 
(elderly patients) or 100 mg/m2 (< 70 years) on days 1, 8 and 15 with 
treatment cycles repeated every 4 weeks until progressive disease or the 
occurrence of serious treatment-related side-effects. All premedication, 
consisting of dexamethasone (10 mg), clemastine (2 mg) and ranitidine (50 
mg), was administered by the i.v. route at 30 minutes prior to paclitaxel 
infusion. Pretreatment evaluation consisted of a complete history and 
physical examination, complete blood cell counts, serum chemistry analysis, 
electrocardiogram, chest X-ray. Complete blood cell counts were measured 
on a weekly basis, while other tests were repeated before the next full cycle. 
Toxicity in each patient following paclitaxel administration was evaluated 
using the National Cancer Institute common toxicity criteria (NCI CTC) 
version 2.0. 
 
Pharmacokinetic and pharmacodynamic analysis 
 Blood samples for pharmacokinetic analysis were collected from all 
patients only on day 1 of the first administration from a vein in the arm 
opposite to the one used for drug infusion. Blood samples of 5 ml were 
obtained at the following time points: before infusion, at 0.5 h after the start 
of infusion, 5 min before the end of infusion, and at 5, 15, 30 min and 1, 2, 
4, 8, 12 and 24 h after the end of infusion. Samples were collected in tubes 
containing lithium heparin as anticoagulant and were subsequently 
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centrifuged at 3000g for 10 min at 4ºC to separate plasma and cells. Plasma 
samples were stored frozen at –80ºC until analysis. 
 In view of the profound non-linear disposition of paclitaxel in patients,(11) 
the pharmacological consequences of the treatment in patients with 
increasing age can not be predicted based on total plasma levels alone when 
different dose groups are compared. Since the area under the plasma 
concentration-time curve (AUC) of unbound paclitaxel is a linear function of 
the dose administered,(12,13) we focused here on comparing the fraction 
unbound paclitaxel between the two groups. Concentrations of total 
paclitaxel in plasma samples were determined by a validated reversed-phase 
high-performance liquid chromatography with ultraviolet detection as 
described earlier.(14) The free drug fraction of paclitaxel was measured by 
using a reproducible equilibrium dialysis method using a tritiated-paclitaxel 
tracer.(12) Coinciding levels of CrEL were measured by a colorimetric dye-
binding microassay, as published.(15) The kinetics of paclitaxel and CrEL 
were evaluated for each patient separately by a linear three-compartment 
model and by model-independent methods, respectively, using the Siphar 
version 4.0 software package (InnaPhase, Philadelphia, PA, USA). This 
program determines the slopes and intercepts of the logarithmically plotted 
curves of multiexponential functions using non-linear least-squares, iterative 
steps. Initial parameter estimates were determined by an automated curve-
stripping procedure. The mathematical equations describing the drug 
concentration C(t) at any time t during (eq. 1) and after i.v. administration 
(eq. 2) are given by: 
 
  C(t) = Σ {Ci / (λi × Tinf) × (1 – e(-λi × t))} (eq. 1) 
 C(t) = Σ {Ci / (λi × Tinf) × (e(-λi × [t – Tinf]) – e(-λi × t))} (eq. 2) 
 
 In these equations, λi is the component of the I-th exponential term, Ci is 
the initial concentration of the i-th component of the curve, and Tinf is the 
infusion duration. In all cases, paclitaxel-concentration-time curves were 
best described with a tri-exponential model, which gave the lowest Akaike 
information criterion, without any demonstration of saturable behaviour (R2 
= 0.996 ± 0.002, root mean square error = 13.5 ± 3.53%). The curve fitting 
procedure with this model yields the parameters C1, C2, C3, λ1, λ2, and λ3. 
The AUC values were determined on the basis of the parameters of equations 
1 and 2 with extrapolation to infinity using the terminal disposition rate 
constant. The clearance was defined as dose (expressed in µmol/m2) divided 
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by AUC. The volume of distribution at steady-state was calculated as the 
product of clearance and the mean residence time, also estimated from 
equations 1 and 2. Peak plasma concentrations were put on par with 
observed (experimental) drug levels immediately following the end of 
infusion. The fraction unbound paclitaxel was defined as the ratio of 
unbound paclitaxel AUC and total paclitaxel AUC. Pharmacodynamics was 
assessed by calculation of the relative haematological toxicity of white blood 
cell count (WBC) and absolute neutrophil count (ANC), defined as: 
 
%decrease = [(pretherapy value – nadir value) / (pre-therapy value)] × 100% (eq. 3) 
 
Statistical evaluation 
 All pharmacological parameters are expressed as mean values ± SD. 
Differences in any of the studied pharmacokinetic and pharmacodynamic 
parameters between the two age groups or within the control group between 
male and female patients were evaluated statistically using an unpaired two-
tailed Student’s t-test after testing for normality. The relationship between 
clearance of unbound paclitaxel and age was evaluated using least-squares 
linear regression analysis and adjusted R2 values to compensate for the 
expected chance prediction when the null hypothesis is true. The level of 
significance was set at P<0.05. All statistical calculations were performed 
using Number Cruncher Statistical System v5.X (Jerry Hintze, Kaysville, UT, 
USA). 
 
Results 
 
Patient characteristics 
 A total of 8 elderly patients and 15 patients aged < 70 years was studied 
(Table 1), and all were evaluable for paclitaxel pharmacokinetics and toxicity. 
The median age in the groups was 77 years (range 70 – 84) and 54 years 
(range 22 – 69), respectively. Other patient characteristics and baseline 
clinical chemistry values were similar between the two groups (Table 1). In 
the elderly group, 7 of 8 patients had received prior hormonal therapy for 
metastatic disease, and a median number of four cycles (range, 1 to 6 cycles) 
was administered per patient.  
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Table 1. Patient characteristics and baseline clinical chemistry values 
(median with range) 
Characteristic patients ≥70 years patients <70 years 
No. studied 
Age (years) 
BSA (m2) 
Weight (kg) 
Height (cm) 
Sex (M/F) 
Serum albumin (g/L) 
Total serum protein(g/L) 
Hematocrit (l/l) 
8 
77 (70-84) 
1.75 (1.45-1.91) 
71.6 (54.0-84.3) 
160 (150-167)  
0/8 
42 (38-47) 
74 (69-80) 
0.35 (0.27-0.40) 
15 
54 (22-69) 
1.76 (1.31-2.37) 
68.1 (36.6-116) 
165 (157-185) 
7/8 
38 (24-47) 
69 (49-79) 
0.35 (0.29-0.44) 
 
BSA, body-surface area; M, male; F, female. 
 
 
Pharmacokinetics 
 Unbound paclitaxel concentration-time curves for both groups are shown 
in Figure 1. Overall, the interpatient variability in unbound paclitaxel 
clearance was moderate (coefficient of variation, 30.8%). A summary of 
pharmacokinetic data of unbound paclitaxel, total paclitaxel and CrEL is 
shown in Table 2. In the control group, there were no significant sex-related 
differences in unbound paclitaxel clearance (males vs females, 251 ± 74.3 vs 
237 ± 43.0 l/h/m2; P = 0.67), total paclitaxel clearance (18.4 ± 5.63 vs 16.6 ± 
2.69 l/h/m2; P = 0.43), the fraction unbound paclitaxel (0.084 ± 0.007 vs 
0.085 ± 0.005; P = 0.76), and the clearance of CrEL (115 ± 41.7 vs 114 ± 
39.2 ml/h/m2; P = 0.94). Therefore, pharmacokinetic data were directly 
compared between the groups despite the distribution of males and females 
being unequally represented in the elderly and younger patient groups. 
 The clearances of unbound paclitaxel and total paclitaxel were 
significantly different between the two age groups, with mean values (elderly 
vs younger) of 124 ± 35.0 vs 247 ± 55.4 l/h/m2 (P = 0.002) and 13.9 ± 2.31 
vs 17.4 ± 4.52 l/h/m2 (P = 0.04), respectively (Table 2). The difference in 
unbound paclitaxel clearance remained significant when the eight females in 
the elderly group were compared with the eight females in the control group 
(124 ± 35.0 vs 237 ± 43.0 l/h/m2; P = 0.002). In the entire patient 
population, a significant negative correlation was observed between age and 
unbound paclitaxel clearance [Figure 2; clearance (in l/h/m2) = (-4.127 × 
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age) + 457.5; adjusted R2 = 0.847; P < 0.00001]. The unbound paclitaxel 
volume of distribution at steady state was also significantly smaller in the 
elderly patients (1105 ± 300 vs 2546 ± 754 l/m2; P < 0.001), whereas the 
terminal disposition half-life was similar (18.0 ± 7.40 vs 21.7 ± 4.33 h; P = 
0.14). The clearance of CrEL was significantly faster in the elderly patients 
compared with the control group (150 ± 60.7 vs 115 ± 39.2 ml/h/m2; P = 
0.04).  
 
 
 
 
 
Figure 1. Plasma concentration-time profiles of unbound paclitaxel in elderly (≥ 70 
years) patients (n = 8; closed symbols and dotted line) and patients < 70 years (n = 
15; open symbols and solid line) receiving a 1-h i.v. infusion of paclitaxel at dose 
levels of 80 and 100 mg/m2, respectively. Data from the elderly group were 
normalized to a paclitaxel dose of 100 mg/m2, by multiplying unbound paclitaxel 
concentrations (Cu) by the dose difference [Cu × (100/80)]. The mathematical 
equations describing the drug concentration (C(t)) at any time (t) during (eq. 1) and 
after i.v. administration (eq. 2) are given by: C(t) = Σ {Ci / (λI × Tinf) × (1 – e(-λI × t))} 
(eq. 1) and (t) = Σ {Ci / (λI × Tinf) × (e(-λI × [t – Tinf]) – e(-λI × t))} (eq. 2). The model 
parameters were C1 = 1.19 µM, C2 = 0.076 µM, C3 = 0.013 µM, λ1 = 2.96 h-1, λ2 = 
0.444 h-1, and λ3 = 0.033 h-1 for elderly patients, and C1 = 0.976 µM, C2 = 0.033 
µM, C3 = 0.005 µM, λ1 = 4.26 h-1, λ2 = 0.350 h-1, and λ3 = 0.029 h-1 for younger 
patients. 
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Table 2. Summary of paclitaxel and CrEL pharmacokinetics (mean ± SD) 
Parameter patients ≥70 years patients <70 years 
No. of patients 
Paclitaxel dose 
(mg/m2) 
(mg)a 
Infusion duration (h)a 
 
Unbound paclitaxel 
Cmax (µM) 
AUC (µM•h) 5 
CL (l/h/m2) 
Vss (l/m2) 
T1/2 (h) 
fu 
 
Total paclitaxel 
Cmax (µM) 
AUC (µM•h) 
CL (1/h/m2) 
 
CrEL 
Cmax (µl/ml) 
AUC (µl•h/ml) 
CL (ml/h/m2) 
8 
 
80 
140 (105 - 170) 
1.00 (0.90 - 1.21) 
 
 
0.366 ± 0.155 
0.749 ± 0.231 
124 ± 35.0 
1105 ± 300 
18.0 ± 7.40 
0.095 ± 0.014 
 
 
3.22 ± 1.30 
6.92 ± 1.25 
13.9 ± 2.31 
 
2.51 ± 0.34 
51.8 ± 22.0 
150 ± 60.7 
15 
 
100 
170 (130 - 226) 
1.00 (0.98 - 1.19) 
 
 
0.262 ± 0.079 
0.503 ± 0.095 
247 ± 55.4b 
2546 ± 754C 
21.7 ± 4.33 
0.085 ± 0.006 
 
 
3.37 ± 0.730 
5.99 ± 1.12 
17.4 ± 4.52d 
 
2.82 ± 0.76 
80.2 ± 27.3 
115 ± 39.2e 
 
Cmax, peak plasma concentration; AUC, area under the plasma concentration-time 
curve; CL, plasma clearance; T1/2, half-life of the terminal disposition phase; fu, 
unbound drug fraction (AUC unbound drug / AUC total drug). 
a Median with range; b P = 0.002; c P < 0.001; d P = 0.04; e P = 0.04. 
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Figure 2. Relationship between patient age and unbound paclitaxel clearance (CL). 
The solid line indicates the fit of a least-squares linear regression analysis [CL = 
(-4.127 × age) + 457.5; adjusted R2 = 0.847; P < 0.00001]. 
 
 
Toxicity profiles 
 Only four administrations (5%) were delayed, of which one was due to 
erysipelas and three were due to non-therapy-related morbidity. Dose 
reductions were not required in any patient from both groups, and no 
cumulative toxicity of any kind was seen. In the elderly group grade 2 fatigue 
was common, in line with previous findings,(16) and resulted in the 
discontinuation of treatment in 2 patients. One patient experienced a grade 
3 toxicity (neutropenia and skin toxicity with generalized erythroderma), 
while no grade 3 or 4 toxicities were noted in any of the other patients. In 
spite of the difference in the paclitaxel dose administered, no significant 
difference was observed in haematological pharmacodynamics between the 
two groups as defined by the percent decrease in white blood cells (WBC) 
(40.7 ± 7.96 vs 45.9 ± 15.5%; P = 0.39) and the percent decrease in ANC 
(50.8 ± 14.6 vs 56.3 ± 14.8%; P = 0.40). This is consistent with the increased 
exposure to paclitaxel in the group of elderly patients. 
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Discussion 
 
 In the present study, we have described for the first time the 
pharmacokinetics of unbound paclitaxel in cancer patients as a function of 
age. Overall, our data indicate that the clearance of unbound paclitaxel, 
following weekly administration as a 1-h i.v. infusion, is approximately 50% 
reduced in elderly patients (≥ 70 years) compared with younger patients, and 
that age is a significant predictor of paclitaxel disposition in the population 
studied. These data complement previous knowledge on the clinical 
pharmacology of paclitaxel, and may have important practical implications 
for its optimal use. Indeed, while some studies examined the efficacy and 
feasibility of chemotherapy in elderly patients with metastatic breast cancer, 
little is known about the pharmacokinetic behaviour of the anticancer agents 
involved, with the notable exception of some anthracyclines and Vinca 
alkaloids.(4) For doxorubicin, a trend for delayed clearance in elderly cancer 
patients has been documented, while the AUC of daunorubicinol, an active 
metabolite of daunorubicin, was significantly increased in 13 elderly patients 
with acute leukaemia.(17,18) In patients aged ≥ 70 years, the clearance of 
vinorelbine was reduced by 30-40%, compared with adult patients.(19) To 
adjust for decreasing renal function with age, a study investigating 
combination chemotherapy with cyclophosphamide, methotrexate and 5-
fluorouracil in women aged ≥ 65 years used creatinine clearance for 
calculation of appropriate doses of cyclophosphamide and methotrexate.(20) 
While indeed less toxicity resulted, unfortunately no pharmacokinetic 
analysis was performed. 
 For paclitaxel, only scarce data are available on the effect of aging on the 
agent’s pharmacokinetic behaviour. Nakamura and colleagues performed a 
retrospective analysis investigating total paclitaxel pharmacokinetics in 120 
lung cancer patients, of whom 28 were elderly, treated at a dose of 210 
mg/m2 given over 3 h in a 3-weekly regimen.(21) These authors could not 
detect any differences in AUC, peak concentration, terminal disposition half-
life, and time above the threshold of 0.1 µM between patients aged <70 years 
and those >70 years.(21) Likewise, Fidias and colleagues recently reported 
that the clearance of total paclitaxel in a group of 8 patients with non-small 
cell lung cancer (age ≥ 70 years) treated with a dose of 90 mg/m2 as a 1-h 
i.v. infusion was comparable to values that have been reported for studies 
involving younger patients.(22) However, these apparent inconsistencies with 
our current findings need to be interpreted with great caution as, in the 
study performed by Fidias and colleagues, no control group involving 
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younger patients was studied, and a host of confounding factors might 
influence their overall conclusions, including differences in the paclitaxel 
dose administered between the comparative trials, variability in analytical 
methods employed, and parameter calculation procedure used. In contrast 
to conclusions drawn in the above studies,(21,22) Lichtman and colleagues 
recently reported in abstract form a significant difference in AUC and 
clearance of total paclitaxel with advancing age in 113 patients treated with 
paclitaxel at a dose of 175 mg/m2 administered as a 3-h infusion.(23) The 
total paclitaxel clearances in patients aged 55-64 years and in 28 patients 
>75 years were 10.9 and 8.21 l/h/m2, respectively, which was significant at 
P = 0.012. Unfortunately, these investigators used a strategy for AUC 
calculation based on the use of only a few timed samples early (i.e. a limited-
sampling strategy) up to 7 h after dosing, which may have caused a serious 
flaw in that any alteration in drug elimination as a result of aging (e.g. 
metabolic and excretory routes) may remain undetected by such 
methodology. Moreover, as it cannot be excluded that any alteration in 
paclitaxel disposition is (partially) associated with changes in CrEL 
pharmacokinetics as a function of age (see below), the use of total plasma 
concentrations and subsequent calculation of total plasma clearance, as was 
done in the mentioned studies,(21-23) may be essentially less meaningful. The 
results of the various investigations performed to date further emphasise the 
need to simultaneously study paclitaxel pharmacokinetics in a control group 
of younger patients when evaluating the role of patient age in drug 
disposition. 
 Previous investigations have demonstrated the importance of unbound 
paclitaxel AUC as a pharmacokinetic parameter to delineate exposure-
toxicity relationships, both with 1- and 3-h infusion schedules.(13,24) 
Although intuitively the unbound fraction of paclitaxel accounts for the 
(cyto)toxic actions of the treatment, its concentration has never been 
investigated in elderly patients. We have recently shown that CrEL, the 
vehicle used for i.v. paclitaxel administration, has a substantial impact on 
the fraction unbound paclitaxel.(25,26) Although the exact mechanism 
underlying this interaction has not yet been fully elucidated, the presence of 
CrEL in the circulation as large polar micelles is thought to entrap 
paclitaxel, thereby reducing cellular accumulation of paclitaxel in blood cells 
(e.g. erythrocytes) and altering the fraction of unbound paclitaxel in whole 
blood. Since CrEL clearance increases with prolonged duration of infusion 
from 1- to 3- and 24-h, the systemic exposure to unbound paclitaxel and 
CrEL significantly depends on the duration of drug infusion.(27) Our current 
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data on unbound paclitaxel levels in elderly patients should therefore not be 
compared with studies using other infusion schedules. In any event, the 
demonstration that CrEL clearance is significantly increased by 30% in 
elderly patients, combined with the notion that CrEL micelles act as the 
principal carrier of paclitaxel in the systemic circulation,(28) suggests that 
this phenomenon likely contributes substantially to the changes in unbound 
paclitaxel clearance. 
 The mechanisms underlying the age-dependent pharmacokinetics of 
CrEL are not clear. In fact, the faster clearance of CrEL in the group of 
elderly patients is rather unusual, because for most xenobiotics that exhibit 
age-dependent pharmacokinetics, clearance tends to decrease with 
advancing age.(29) It has been previously shown that elimination routes of 
polyoxyethylated surfactants like CrEL are associated with esterase-
mediated metabolic breakdown within the systemic circulation.(26) One 
possibility to explain the age-dependent pharmacokinetics of CrEL would be 
that CrEL biotransformation takes place at an accelerated rate as a result of 
elevated enzyme levels in the systemic circulation in elderly patients. This 
would be consistent with the observation that the clearance of CrEL is 
significantly higher (approximately 3 to 4 fold) in adult patients with 
moderate to severe hepatic dysfunction compared with patients with normal 
hepatic function.(30) This and several other possibilities, including diminished 
liver volume and blood flow,(31) are currently under investigation. 
 As paclitaxel elimination is almost entirely caused by metabolic 
breakdown through cytochrome P450 (CYP) isoforms 3A4 and 2C8,(32) an 
alternative explanation for the altered paclitaxel clearance is an impaired 
hepatic function with advancing age. Although eligibility criteria excluded 
patients with an elevated bilirubin and all patients entered had normal 
values of aspartate and alanine aminotransferases, these laboratory values 
do not represent the actual capacity of hepatic metabolism.(33) A previous 
investigation in a group of 226 patients with equal histopathological 
conditions has shown a significant decline in total CYP content with age and 
a concomitant approximately 30% reduction of drug metabolism in patients 
after 70 years of age.(34) Thus, one possibility to investigate the role of altered 
liver function in relation to the current findings would be to determine 
pretreatment CYP3A4 and CYP2C8 activity in each patient using a functional 
surrogate such as the erythromycin breath test.(35) Additional clinical and 
pharmacological information is currently being collected by implementation 
of such assays in ongoing trials with paclitaxel as well as docetaxel to 
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further explore the role of enzyme capacity in taxane disposition in elderly 
patients. 
 Collectively, our study demonstrates that CrEL and unbound paclitaxel 
clearance are subject to considerable changes depending on age. In our 
patient population, haematological toxicity was relatively mild and not 
clinically relevant due to the low paclitaxel doses, precluding detection of 
statistically significant differences between both age groups. More insight 
will be provided by the ongoing Cancer Leukaemia Group B (CALGB) 9762 
study, evaluating paclitaxel pharmacology in relation to patient age with 
drug administration over 3-h in a 3-weekly schedule at higher doses.(23) As 
the unbound fraction of paclitaxel is responsible for its cellular actions and 
its clearance is remarkably reduced in the elderly, this observation warrants 
further studies on the efficacy and feasibility of paclitaxel in aged patients 
using dose-dense regimens. 
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Abstract 
 
 Purpose: To prospectively study the pharmacokinetics and toxicity profile 
of docetaxel as well as cytochrome P450 3A (CYP3A) phenotype in elderly 
patients with cancer  
 Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 
once every 3 weeks to 20 elderly cancer patients aged ≥ 65 years and 20 
cancer patients aged < 65 years. CYP3A was phenotyped using the 
erythromycin breath test (ERMBT) prior to drug administration. 
Pharmacokinetic studies were performed during the first cycle of therapy. 
 Results: Of 51 patients treated, 20 aged ≥ 65 years (median [range], 71 
years [65-80]) and 20 aged < 65 years (53 years [26-64]) were evaluable for 
pharmacokinetic and CYP3A studies, and 39 were evaluable for toxicity. 
Patient characteristics were similar (P ≥ .15) between the 2 cohorts. The 
ERMBT parameter, percentage 14C-exhaled/h, was not altered in elderly 
patients (mean, 2.38% vs 2.74%; P = .23), suggesting similar CYP3A4 
activity. Mean (SD) docetaxel clearance was also similar between the 2 
cohorts: 30.1 (18.3) L/h versus 30.0 (14.8) L/h (P = .98). The development of 
febrile neutropenia was associated with higher AUC values (P = .02). The 
percentage of patients with grade 4/febrile neutropenia was 63%/16% 
versus 30%/0% (P ≥ .06) in the older and younger cohort, respectively; 
febrile neutropenia in the elderly cohort may be related to drug exposure and 
not age. 
 Conclusion: CYP3A activity and docetaxel pharmacokinetics are unaltered 
in elderly patients. It is concluded that docetaxel 75 mg/m2 in a 3-weekly 
regimen is feasible in the elderly.    
 
Introduction 
 
 Docetaxel is a semi-synthetic taxane derived from an extract of the 
needles of the European yew tree (Taxus baccata), and acts by disrupting the 
microtubule network.(1) The drug has significant antitumor activity against 
numerous tumors and is approved for treatment of locally advanced or 
metastatic breast and non-small cell lung cancers. In patients with advanced 
breast cancer receiving docetaxel 100 mg/m2 as a 1 hour infusion every 3 
weeks (3-weekly), grade 4 and febrile neutropenia occur in 84% and 11.8% of 
patients, respectively (see: http://www.taxotere.com/- last accessed 
February 12, 2004); in patients with non-small cell lung cancer receiving 75 
mg/m2, grade 3/4 and febrile neutropenia occur in 65% and 6.3% of 
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patients, respectively. Other side effects include alopecia, asthenia, 
dermatologic reactions, fluid retention, hypersensitivity reactions, and 
stomatitis. Drug exposure-toxicity relationships have been extensively 
studied for docetaxel monotherapy administered 3-weekly and indicate that 
the area under the curve (AUC) of total plasma concentrations during the 
first cycle of treatment is related to incidence of grade 4 neutropenia and 
febrile neutropenia.(2) 
 As the population in Western countries ages and life expectancy 
increases,(3) there is an increasing number of cancer patients 65 years of age 
or older that might benefit from chemotherapeutic treatment. There is often 
hesitation to treat elderly patients with chemotherapy due, in part, to the 
older patient being more susceptible to therapy-related toxicity.(4-6) However, 
studies have demonstrated that elderly patients with good performance 
status and lacking comorbidities are not at increased risk for treatment-
related toxicities.(4-7) Studies also indicate that undertreatment is associated 
with inferior outcome in older patients.(8-10) Little is known about the clinical 
pharmacokinetics and pharmacodynamics of anticancer agents, including 
docetaxel, and their relation to drug tolerance and outcome in the elderly.(4-6) 
Docetaxel administered in weekly schedules at lower doses has been found 
to be both efficacious and generally well tolerated in elderly patients,(11-13) 
and a study evaluating the population pharmacokinetics of weekly docetaxel 
showed no effect of age on drug clearance.(14) There is general reluctance to 
administer docetaxel 3-weekly to elderly patients due to the prevalence of 
neutropenia with docetaxel therapy,(15) although this has not been 
adequately evaluated in a clinical trial. 
 The objective of the present study was to prospectively characterize the 
pharmacokinetic and toxicity profile of docetaxel during one cycle of 
treatment when administered at a dose of 75 mg/m2 once every 3 weeks to 
patients aged less or older than 65 years. Because docetaxel undergoes 
extensive metabolism by cytochrome P450 3A (CYP3A),(16) CYP3A activity was 
assessed prior to treatment to determine if the function and/or expression of 
enzyme is altered with increasing age. 
 
Patients and methods 
 
Patient Eligibility  
 Patients were eligible when they had histologically or cytologically 
confirmed solid tumor malignancies, for which docetaxel was a viable 
treatment option. Other criteria for patient enrollment were: 1) age ≥ 18 
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years; 2) performance score (PS) < 3 according to the Eastern Cooperative 
Oncology Group criteria; 3) adequate bone marrow function as defined by 
pre-therapy values of hemoglobin ≥ 8.0 g/dL, ANC ≥1,500/µL, and platelet 
count ≥ 100,000/µL; 4) creatinine ≤ 2.0 × the institutional upper limit of 
normal (ULN); 5) total bilirubin < 1.5 x ULN; 6) if alkaline phosphatase was ≤ 
ULN, any elevations in AST/ALT; or if AST/ALT were ≤ ULN, any elevation in 
alkaline phosphatase; patients with ALT and/or AST  1.5 × ULN with 
concomitant alkaline phosphate  2.5 × ULN were not eligible for treatment; 
7) peripheral neuropathy ≤ grade 1 and no symptomatic brain metastasis; 8) 
no previous treatment with docetaxel; and 9) no concomitant use of 
phenytoin, carbamazepene, barbiturates, rifampicin, phenobarbital, St. 
John’s wort, and ketoconazole. All concomitant drugs and the use of herbal 
medicines were recorded. The clinical protocols were approved by the local 
institutional review boards (Baltimore, MD, Rotterdam, the Netherlands, and 
Washington, DC), and all patients provided written informed consent before 
enrollment. Before treatment, a complete registration form was received by 
the coordinating center (Baltimore, MD), and a study number was assigned. 
Patients who did not have complete pharmacokinetic and CYP3A 
phenotyping studies during cycle 1 were replaced. 
 
Drug Treatment 
 Two groups of patients were studied based on age. The control group 
consisted of patients aged 18 to 64 years, and the elderly group consisted of 
patients aged 65 years or older. The clinical docetaxel preparation (Taxotere; 
Aventis Pharmaceuticals) containing 20 or 80 mg of the drug formulated in 
0.5 mL and 2.0 mL of polysorbate 80, respectively, was diluted with a 
solution of 13% ethanol in water to a 10 mg docetaxel/mL concentration. 
This solution was diluted further in a 250-mL infusion bag or bottle of either 
0.9% sodium chloride solution or 5% dextrose solution to produce a final 
concentration of 0.30 – 0.74 mg/mL. Individual drug doses were normalized 
to body-surface area and administered intravenously over 1 h at a dose of 75 
mg/m2 every 3 weeks in both treatment groups. Dexamethasone, 8 mg orally 
every 12 hours for 5 doses (3 days), was administered starting 24 h before 
drug treatment. Patients did not routinely receive anti-emetic prophylaxis. 
After 1 cycle of therapy, treatment continued at the discretion of the treating 
physician until tumor progression, development of unacceptable toxicity, or 
patient withdrawal. 
 
Prospective evaluation of docetaxel in the elderly 
 
123 
 
Patient Evaluation  
 The extent of prior treatment was assessed two-fold: 1) the number of 
prior treatment regimens; and 2) patients were considered heavily pretreated 
if they received ≥ 2 cycles of mitomycin C, ≥ 4 cycles of carboplatin, ≥ 6 
cycles with cisplatin or an alkylating cytostatic drug. Pretreatment 
evaluations included assessment of PS, height, weight, toxicity assessment, 
a complete blood count with differential (CBC), and the following serum 
chemistries: creatinine, alkaline phosphatase, AST, ALT, total bilirubin, α1-
acid glycoprotein (AAG), and albumin. 
 Toxicity assessment and a CBC with differential were performed weekly 
for a total of 3 weeks (1 cycle). Toxicity assessments were performed 
according the National Cancer Institute Common Toxicity Criteria version 
2.0. Management of toxicity was at the discretion of the treating physician 
per institutional guidelines. 
 
Erythromycin Breath Test (ERMBT) 
 Within one week prior to docetaxel administration during cycle 1, CYP3A 
activity was determined using the ERMBT. The ERMBT dose consisted of 
0.04 mg [14C-N-methyl]-erythromycin, containing 3 µCi of radioactivity, 
dissolved in 4.5 mL of 5% dextrose solution. The dose was administered as 
an intravenous bolus injection over approximately 1 min. Breath samples 
were collected in balloons post-injection at 5, 10, 15, 20, 25, 30 and 40 
minutes. Samples were shipped to Metabolic Solutions (Nashua, NH) for 
measurement of breath carbon dioxide. The data was reported as percentage 
14C metabolized per min (% 14C exhaled/min) at each time point. The 
conventional ERMBT parameter, percentage 14C metabolized per hour (% 14C 
exhaled/h), was calculated using the equation y = -65.988·x2 + 54.645·x + 
0.0377, where x is the value for % 14C exhaled/min at the 20 min time point 
[17]. The area under the % 14C exhaled/min-time curve from time zero to 40 
min (AUC0-40) was determined using the linear trapezoidal method. The 
ERMBT parameter, 1/Tmax, was determined as described previously.(18) A 
mono-exponential equation was also fitted to the % 14C exhaled/min-time 
data and the time of the maximum % 14C/min (Tmax) was the estimated 
value. 
 
Pharmacokinetic Sampling and Assay 
 Blood samples were collected for docetaxel pharmacokinetic studies 
during the first cycle of treatment cycle at the following time points: pre-
treatment, 30 min during the infusion, 59 min (immediately before the end 
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of the infusion), and post-infusion at 10 and 30 min, 1, 3, 7, 24, and 48 h, 
and on day 8. Samples were collected in a 10 mL heparinized tube and 
placed on ice until further processing within 30 minutes of collection. 
Plasma was isolated by centrifugation at 4 oC, at 1000 g for 10 minutes and 
frozen at or below –20 °C until the time of analysis. 
 Docetaxel was quantitated in plasma over the range of 0.50 nM to 100 
nM using a validated liquid chromatographic method with tandem mass-
spectrometric detection, as previously described.(19) The bias and precision of 
quality control (QC) samples, which included docetaxel concentrations of 
2.0, 20.0, 80.0 nM, and an 80-nM QC that was diluted 100-fold prior to 
processing, were < 15%. At the assay lower limit of quantitation of 0.50 nM 
(~400 pg/mL), bias and precision were < 20%. 
 Individual docetaxel pharmacokinetic parameters were estimated using 
model-dependent methods as implemented in Adapt II release 4 (Biomedical 
Simulations Resource, Los Angeles, CA).(20) Concentration-time data were fit 
with a three-compartment model using weighted least-squares as the 
estimation procedure, and inverse variance of the output error (linear) as the 
weighting option. Calculated secondary pharmacokinetic parameters in-
cluded half-life during the terminal phase of the disposition curve (t1/2,λz) 
and systemic clearance (CL). The AUC was calculated as dose divided by CL. 
Maximum plasma concentration (Cmax) values were the observed values. 
 
Statistical Analysis 
 Group sample sizes of 20 in both age groups (< 65 years and ≥ 65 years) 
were calculated to achieve 88% power to detect a ratio of 1.50 between 
clearance variances in the respective groups, using a two-sided F test with a 
significance level (α) of .05. Sample size calculations were performed using 
the computer program SISA-binomial (Uitenbroek DG, 1997, Available 
http://home.clara.net/sisa/binomial.htm, Accessed January 16, 2004). 
 Docetaxel and ERMBT pharmacokinetic parameters were summarized as 
the mean, standard deviation, and range. For continuous variables, 
nonparametric tests were used to compare mean values between the two age 
groups. The method of Tukey-Kramer was used to adjust for multiple 
comparisons of mean values. Categorical variables were compared using 2-
tailed Fisher’s Exact Test for 2-by-2 tables. Statistical calculations were 
performed using the software package JMP version 3.2.6 (SAS Institute, 
Carey, NC). 
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Table 1. Patient demographics 
Age <65 years (n=20) Age ≥65 years (n=20)  
Median (Range) Median (Range) 
Age (years) 
Body Surface Area (m2) 
Sexa 
Female 
Male 
AAG (mg/dL)a 
Liver Function Tests 
AST (x ULN) 
ALT (x ULN) 
Alkphos (xULN) 
Total bilirubin 
CYP3A activity (% 14C) 
ECOG Performance Statusa,b 
0 
1 
2 
Primary Tumor Typea 
Breast  
Head and Neck 
Lung 
Melanoma 
Prostate 
Angiosarcoma 
Unknown 
Other 
Prior Treatmenta 
None 
1-2 regimens 
≥3 regimens 
Light 
Heavy 
53 
1.93 
 
10 
10 
159 
 
0.95 
0.70 
0.85 
0.50 
2.38 
 
4 
15 
1 
 
5 
3 
5 
3 
0 
0 
1 
3 
 
1 
14 
5 
12 
8 
(26-64) 
(1.49-2.45) 
 
 
 
(86-257) 
 
(0.30-3.9) 
(0.20-6.6) 
(0.50-2.0) 
(0.30-1.1) 
(0.83-4.35) 
71 
1.85 
 
9 
11 
126 
 
0.80 
0.50 
0.80 
0.40 
2.74 
 
4 
12 
3 
 
3 
1 
3 
0 
5 
3 
4 
1 
 
5 
14 
1 
13 
7 
(65-80) 
(1.45-2.45) 
 
 
 
(60-201) 
 
(0.40-4.7) 
(0.10-1.5) 
(0.40-6.2) 
(0.20-0.60) 
(0.78-5.79) 
 
aData are mean (range) values;  
bData is number of patients;  
cBaseline performance status was not performed in one patient aged ≥ 65 years. 
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Results 
 
 Between August 2002 and September 2003, 51 patients (26 were aged 
< 65 and 25 were ≥ 65 years) were enrolled on this study. Of these patients, 
40 (20 in each age group) were evaluable for pharmacokinetic and ERMBT 
studies. Patients were not evaluable for pharmacokinetic studies for the 
following reasons: 1) severe hypersensitivity reaction with discontinuation of 
drug treatment (1 patient); 2) inability to perform pharmacokinetic studies 
due to poor venous access (2 patients); 3) plasma samples became thawed 
during shipment for analytical analysis (7 patients); and 4) erroneous 
administration of a lower docetaxel dose of 50 mg/m2 (1 patient). Patient 
characteristics for the 40 evaluable patients are listed in Table 1. Body 
surface area, liver function, performance status, and prior treatment were 
similar between the 2 cohorts (P ≥ .15), although pre-treatment serum ǂ1-
acid glycoprotein concentrations were 20% lower in the elderly (mean, 126 
mg/dL [ 65 years] vs 159mg/dL [< 65 years]; P = .04). 
 
Table 2. Docetaxel pharmacokinetic parameters 
 < 65 years ≥ 65 years 
Parameter Mean SD Range Mean SD Range 
Cmax (µg/mL) 
AUC (µg/mL*h) 
Cl (L/h) 
Cl (L/h/m2) 
Vc (L) 
Vc (L/m2) 
Vss (L) 
Vss (L/m2) 
t1/2,α (h) 
t1/2,β (h) 
t1/2,γ (h) 
4.06 
5.69 
30.0 
15.4 
5.24 
2.70 
803 
413 
0.078 
1.78 
64.6 
1.38 
2.27 
14.8 
6.94 
2.63 
1.28 
370 
170 
0.031 
1.34 
19.2 
1.65-6.36 
2.47-10.2 
13.7-68.8 
7.30-30.1 
2.16-10.1 
1.29-5.25 
399-1479 
185-788 
0.046-0.15 
0.84-6.91 
45.9-117 
3.44 
6.01 
30.1 
16.6 
6.24 
3.45 
923 
513 
0.087 
1.65 
72.8 
1.58 
3.23 
18.3 
10.0 
3.45 
1.94 
435 
249 
0.024 
0.51 
32.8 
0.88-6.52 
1.54-13.7 
9.5-91.6 
5.20-49.2 
2.76-16.3 
1.44-8.78 
382-2408 
193-1301 
0.051-0.013
0.66-2.60 
32.2-164 
 
 
Plasma Pharmacokinetics 
 Docetaxel pharmacokinetic parameters were similar in the elderly and 
younger patient cohorts (P ≥ .15; Table 2). Mean (SD) docetaxel clearance 
was 30.1 (18.3) L/h in patients aged ≥ 65 years and 30.0 (14.8) L/h in 
patients < 65 years (P = .98). Interpatient variability in clearance was larger 
in the elderly (9.6-fold) versus the younger patients (5.0-fold) (Figure 1B). 
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One patient aged 70 years had the highest clearance of 91.6 L/h. Removal of 
this outlier clearance value (> 3 standard deviations) from the elderly group 
resulted in a mean (range) clearance of 27 (9.5 to 48.3) L/h and interpatient 
variation (5.1-fold) similar to the younger patients. It is possible that the 
patient with an outlier value for clearance was in the elderly group by 
chance, and hence, there appears to be no age-related interpatient variation 
in docetaxel clearance. 
 
CYP3A Phenotyping 
 The ERMBT was performed 24 hours before docetaxel treatment in 82% 
of patients and immediately before the docetaxel infusion in 18% of patients. 
The ERMBT parameter, percentage 14C-exhaled/h, was not altered in elderly 
patients (mean, 2.74 %; range, 0.78 to 5.79) compared to patients < 65 years 
(mean, 2.38%; range, 0.83 to 4.35; P = .23) suggesting similar CYP3A4 
activity between the 2 age groups. The other ERMBT parameters (% 14C 
exhaled/min, AUC0-40, and 1/Tmax) were also similar between the 2 groups (P 
≥ .42). Interpatient variation in CYP3A activity was 7.4-fold and 5.2-fold in 
patients ≥ 65 years and < 65 years, respectively (Figure 1A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. [A] CYP3A activity (% 14C exhaled/h) and [B] docetaxel clearance as a 
function of age group. Lines represent the mean values.  
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Toxicity 
 Twenty patients aged < 65 years and 19 patients aged ≥ 65 years, 
respectively, were evaluable for hematological toxicity. The incidence of grade 
3 and 4 neutropenia and febrile neutropenia, the ANC nadir, and percentage 
decrements in ANC are summarized in Table 3. The absolute neutrophil 
count nadir occurred on day 8 in 85% and 80% of patients in the younger 
and elderly groups, respectively, and no patient had grade 4 neutropenia for 
> 7 days. Grade 4 neutropenia occurred more frequently in the elderly (63% 
versus 30%), but the difference was not statistically significant (P = .06); 
however, because the sample size was not calculated to detect statistical 
differences in docetaxel-mediated neutropenia between the 2 groups, the 
possibility of such a difference cannot be fully excluded. Three elderly 
patients developed febrile neutropenia. One patient had metastatic 
pancreatic cancer with a performance status of 2, and her disease 
progressed rapidly 3 weeks after docetaxel treatment at cycle 1. One patient 
had metastatic prostate cancer, having received prior treatment with 
bicalutamide, and one patient had adenocarcinoma of unkown primary 
without any prior chemotherapy. All three patients were treated with broad 
spectrum antibiotic therapy without administration of growth factors, and 
ANC values returned to pretreatment values on day 15. 
 
 
Table 3. Hematological toxicity 
 Neutropeniaa   
Treatment 
Group 
Grade 3 Grade 4 Febrile ANC Nadir 
(x109/L)b 
%Decrease ANCb
< 65 years 
 
≥ 65 years 
7 (35%) 
 
1 (5%) 
6 (30%) 
 
12 (63%)
0 (0) 
 
3 (16%)
1.1 (0.08-5.5) 
 
0.61 (0.05-1.8)
83 (42-98) 
 
92 (46-99) 
 
aData is number of patients (% of patients) 
bData is mean (range) 
 
 
 The association between docetaxel AUC and neutropenia was assessed 
(Figure 2). Patients with febrile neutropenia had significantly higher AUC 
values (mean, 10.2 µg/mL*h) than patients with grade 0 to 3 (mean AUC, 5.6 
µg/mL*h) or uncomplicated grade 4 neutropenia (mean, 5.6 µg/mL*h; P = 
.02) (Figure 2A). It is likely that development of febrile neutropenia in the 3 
elderly patients versus no patients in the younger cohort was related to 
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higher drug exposure in these individual patients rather than age. 
Percentage decrements in ANC was greater in those patients with AUC 
values in the upper quartile (mean decrement, 93%) compared to those with 
AUC values in the interquartile range (mean, 77%; P = .02) (Figure 2B). 
 Nineteen patients in both age groups were evaluable for non-
hematological toxicity. Non-hematological toxicities that were monitored are 
listed in Table 4. The most frequent toxicities occurring in > 20% of patients 
were grade 1 or 2 alopecia, asthenia, nausea, oral mucositis, cutaneous 
toxicity, and neuropathy. The frequency of non-hematological toxicities 
appeared similar between the 2 age groups, although the small number of 
patients and low incidence precluded statistical evaluation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. [A] Worst grade of neutropenia (grade 0 – 3 versus grade 4 versus febrile 
neutropenia) and [B] percentage decrease in absolute neutrophil count as a function of 
docetaxel AUC. Dotted lines are the 25% quantile and dashed lines are the 75% quantile.  
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Discussion 
 
 Despite the widespread clinical use of docetaxel, only few data are 
available on the effect of aging on the pharmacokinetic and 
pharmacodynamic behavior of this drug. Recent investigations have 
emphasized the disappointingly low participation of elderly patients in 
cancer treatment trials and the barriers associated with patient accrual.(3) 
Several of the factors identified include the lack of information on age-related 
changes in organ function and on the pharmacokinetics and 
pharmacodynamics of anticancer agents. Indeed, while some studies have 
examined the efficacy and feasibility of chemotherapy in elderly patients, 
including several studies with weekly docetaxel in breast and nonsmall cell 
lung cancers,(11-13) little is known about the pharmacokinetic behavior of the 
anticancer agents under evaluation. A few exceptions include studies that 
evaluated the pharmacokinetics of anthracyclines, cisplatin, ifosfamide, 
methotrexate and paclitaxel in elderly patients, although most of these 
studies provide data for a limited number of patients (< 10 patients aged 
greater than 65 years) and did not include a comparative cohort of younger 
patients.(4-21) In an attempt to fill this gap of knowledge, we have 
prospectively evaluated the pharmacokinetics of docetaxel administered once 
every 3 weeks as well as the phenotypic activity of the major enzyme involved 
in its elimination, CYP3A, in elderly cancer patients in comparison to 
younger patients. Overall, the results indicate that there is no statistically 
significant change in the pharmacokinetics of docetaxel or in CYP3A activity, 
as measured by the ERMBT, between the two studied age groups. These data 
complement previous knowledge on the clinical pharmacology of docetaxel, 
and may have important practical implications for its optimal use in the 
elderly.  
 The influence of age on the expression and activity of drug-metabolizing 
enzymes remains controversial with reports describing either a decline in 
activity or no change in activity in elderly patients.(22-24) In the current study, 
docetaxel clearance and the associated interpatient variability 
(approximately 5-fold) were found to be similar in both treatment groups. 
Likewise, CYP3A activity and its interpatient variation was not significantly 
altered with age in this study. Prior in vitro studies have suggested an age 
related decline in CYP3A activity.(25) However, our results are consistent with 
in vivo studies applying the ERMBT as a phenotyping probe of CYP3A-
mediated drug clearance where no decrease in CYP3A activity was observed 
as a function of age.(22-24) 
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 The incidence of grade 3/4 neutropenia in the elderly group (68%) was 
consistent with other studies evaluating docetaxel monotherapy at 75 
mg/m2 once every 3 weeks (65%). Neutropenia resolved within 7 days in all 
patients without administration of growth factors. It is noteworthy that 
incidences of neutropenic fever were observed in 3 patients (16%) in the 
elderly group, which might seem more prevalent than that observed in other 
studies (6.3%). These 3 patients, however, all had docetaxel clearance values 
in the lower quartile, which was shown to be associated with the severity of 
neutropenia. The apparent inconsistencies between unaltered docetaxel 
clearance in both age groups and a slightly increased incidence of 
neutropenic fever in the elderly needs to be interpreted with caution, as our 
trial was not designed to detect statistical differences in variability in 
docetaxel-mediated neutropenia between the tested groups with sufficient 
power. Therefore, the provided information on neutropenia, which was based 
on a sparse set of hematological toxicity data (ie, blood cells measured on a 
once a week basis), should not be taken as evidence for a meaningful clinical 
difference in toxicity between the two age groups and/or as an argument for 
the use of standard reductions in docetaxel dose administered to the elderly. 
In line with this contemplation, previous studies with weekly docetaxel 
schedules in heavily pretreated elderly patients indeed appeared to be both 
effective and very well tolerated.(11-12) 
 The incidence of non-hematological toxicities was also similar between 
both age groups. It is important to note, however, that docetaxel-mediated 
non-hematological toxicity was not assessed over multiple cycles of 
treatment as has been done with weekly docetaxel schedules,(11-13) where the 
development of non-hematological toxicities often occur at later cycles. 
Further investigation is clearly required to shed light on this aspect as well 
as on efficacy of the once every 3 weeks treatment schedule in elderly cancer 
patients. 
 The current pharmacokinetic findings with docetaxel are in contrast with 
recent data obtained for the related drug, paclitaxel, where drug clearance 
was found to be inversely correlated with patient age. In addition, exposure 
to the pharmacologically active fraction unbound paclitaxel was 
approximately 25% increased in the elderly as compared to younger 
patients.(21) The mechanisms underlying the discrepant findings observed 
with paclitaxel and docetaxel are not clear, but may involve age-dependent 
differences in elimination pathways involved with each agent as well as a 
differential influence of pharmacokinetic interference by their respective 
formulation vehicles (ie, polysorbate 80 vs Cremophor EL). Regardless, it 
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further underscores the importance of conducting appropriately-designed 
prospective clinical trials to recognize potential alterations in the 
pharmacokinetic profile of anticancer drugs with advancing age. 
 In conclusion, this study indicates that docetaxel pharmacokinetics are 
not altered in the elderly and that age appears to be an unimportant 
consideration in drug dosing when considering the potential for age-related 
changes in drug clearance. The overall incidence of grade 3/4 neutropenia in 
the elderly cohort was similar to historical data with single-agent docetaxel 
75 mg/m2, and the incidence of febrile neutropenia in the cohort of elderly 
patients studied may likely be related to drug exposure and not to age. 
Therefore, on the basis of these results it is concluded that the 
administration of docetaxel in a 3-weekly regimen at a dose of 75 mg/m2 is 
feasible in the elderly. In view of the wide degree of interindividual variability 
in drug clearance in both age groups, further evaluations of alternative 
dosing strategies for individual patients to decrease this variability and 
improve therapy are still urgently needed. 
 
References 
 
1. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokin 36:99-
114., 1999 
2. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of 
docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-96, 1998 
3. Yee KW, Pater JL, Pho L, et al: Enrollment of older patients in cancer treatment trials 
in Canada: why is age a barrier? J Clin Oncol 21:1618-23, 2003 
4. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. 
Clin Geriatr Med 13:169-83, 1997 
5. Lichtman SM, Skirvin JA: Pharmacology of antineoplastic agents in older cancer 
patients. Oncology (Huntingt) 14:1743-55; discussion 1755, passim, 2000 
6. Wildiers H, Highley MS, de Bruijn EA, et al: Pharmacology of anticancer drugs in the 
elderly population. Clin Pharmacokinet 42:1213-42, 2003 
7. Siu LL, Shepherd FA, Murray N, et al: Influence of age on the treatment of limited-
stage small-cell lung cancer. J Clin Oncol 14:821-8, 1996 
8. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for 
colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-8, 1999 
9. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant 
chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-7, 
2001 
10. Bouchardy C, Rapiti E, Fioretta G, et al: Undertreatment strongly decreases prognosis 
of breast cancer in elderly women. J Clin Oncol 21:3580-7, 2003 
11. Hainsworth JD, Burris HA, 3rd, Litchy S, et al: Weekly docetaxel in the treatment of 
elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer 
Research Network Phase II Trial. Cancer 89:328-33, 2000 
Chapter 8 
 
134 
12. Hainsworth JD, Burris HA, 3rd, Yardley DA, et al: Weekly docetaxel in the treatment 
of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research 
Network phase II trial. J Clin Oncol 19:3500-5, 2001 
13. Hainsworth JD, Erland JB, Barton JH, et al: Combination treatment with weekly 
docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients 
and patients with poor performance status: results of a Minnie Pearl Cancer Research 
Network phase II trial. Clin Lung Cancer 5:33-8, 2003 
14. Slaviero KA, Clarke SJ, McLachlan AJ, et al: Population pharmacokinetics of weekly 
docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44-53, 2004 
15. Wildiers H, Paridaens R: Taxanes in elderly breast cancer patients. Cancer Treat Rev, 
2004 (in press) 
16. Marre F, Sanderink GJ, de Sousa G, et al: Hepatic biotransformation of docetaxel 
(Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Research 
56:1296-302., 1996 
17. Wagner D: CYP3A4 and the erythromycin breath test. Clin Pharmacol Ther 64:129-30, 
1998 
18. Rivory LP, Slaviero KA, Hoskins JM, et al: The erythromycin breath test for the 
prediction of drug clearance. Clin Pharmacokinet 40:151-8, 2001 
19. Baker SD, Zhao M, He P, et al: Simultaneous analysis of docetaxel and the 
formulation vehicle polysorbate 80 in human plasma by liquid 
chromatography/tandem mass spectrometry. Anal Biochem 324:276-84, 2004 
20. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter 
estimation in pharmacokinetics. Computer Programs in Biomedicine 9:115-1134, 
1979 
21. Smorenburg CH, ten Tije AJ, Verweij J, et al: Altered clearance of unbound paclitaxel 
in elderly patients with metastatic breast cancer. Eur J Cancer 39:196-202, 2003 
22. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of 
human hepatic CYP3A. Biochem Pharmacol 44:275-83, 1992 
23. Tanaka E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J 
Clin Pharm Ther 23:247-55, 1998 
24. Schwartz JB: Race but not age affects erythromycin breath test results in older 
hypertensive men. J Clin Pharmacol 41:324-9, 2001 
25. Schmucker DL: Liver function and phase I drug metabolism in the elderly: a paradox. 
Drugs Aging 18:837-51, 2001 
 
  
 
Chapter 9 
Weekly paclitaxel as first-line chemotherapy for elderly 
patients with metastatic breast cancer. A multicenter 
phase II trial 
A.J. ten Tije,1 C.H.Smorenburg,1,2 C. Seynaeve,1 A. Sparreboom,1.3 
K.L.C. Schothorst,1 L.G.M. Kerkhofs,4 A.G.P.M. van Reisen,5 G. Stoter,1 
M. Bontenbal,1 J. Verweij1 
1Department of Medical Oncology, Erasmus MC - Daniel den Hoed 
Cancer Center, Rotterdam, the Netherlands; 2. Present address: Dept 
of Medical Oncology, Vrije Universiteit Medical Center Amsterdam, The 
Netherlands; 3. Present address: Clinical Pharmacology Research Core, 
Medical Oncology Clinical Research Unit, National Cancer Institute, 
Bethesda MD, USA; 4. Dept. of Internal Medicine, Ziekenhuis 
Walcheren, Vlissingen, The Netherlands; 5. Dept of Internal Medicine, 
Ziekenhuis Zeeuwsch-Vlaanderen, Terneuzen, The Netherlands. 
European Journal of Cancer, 40: 352-357, 2004 
Chapter 9 
136 
Abstract 
 
 Paclitaxel is a cytotoxic agent with proven antitumour activity in 
metastatic breast cancer. Weekly administration of paclitaxel has 
demonstrated sustained efficacy together with a more favourable toxicity 
profile (e.g. less myelotoxicity) than the 3-weekly administration. This study 
evaluates the activity and toxicity of weekly paclitaxel (Taxol£) as first-line 
chemotherapy in elderly patients (>70 years of age) with hormone-refractory 
metastatic breast cancer. Patients with metastatic breast cancer received 80 
mg/m2 paclitaxel administered weely on days 1, 8, and 15 of a 28-day cycle. 
Additional cycles were given until disease progression, or unacceptable 
toxicity. A dose increase to 90 mg/m2 was allowed in the absence of toxicity. 
26 Patients received a total of 101 cycles (median 4, range 1 – 11). 22 
patients completed at least two cycles (six administrations). In 23 patients 
who were evaluable for response, there were 10 partial responses (38%), 9 
patients with stable disease (35%), while 4 patients had disease progression 
(15%). The median duration of response was 194 days (>6 months). Overall 
treatment was relatively well tolerated, but 8 patients (32%) had to 
prematurely discontinue treatment because of fatigue. Neuropathy > grade 1 
was noted only after five or more cycles in 4 patients). Weekly paclitaxel at 
this dose and schedule is an effective treatment regimen in the elderly 
patient with metastatic breast cancer, and is feasible but yields relevant 
fatigue in a subset of patients. 
 
Introduction 
 
 The incidence of breast cancer increases with age. Because the 
population is ageing, the number of elderly women with breast cancer is 
expected to rise significantly in the near future. The treatment of cancer in 
elderly patients is increasingly recognised as an important challenge to the 
medical community.(1) Despite the fact that patients older than 70 years of 
age account for >25% of all breast cancer cases, only a small fraction of this 
group is generally entered into clinical studies.(2,3) Consequently, our 
knowledge of the use of chemotherapy in the elderly is based on very sparse 
data. Therefore, there is an urgent need to develop chemotherapy regimens 
that are well tolerated by elderly patients.  
 Taxanes have been used in a large number of trials investigating their 
activity in cancer patients. Studies with docetaxel in these patients were 
limited to patients younger than 75 years of age.(4) Only one trial on weekly 
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docetaxel in elderly breast cancer patients (>65 years) has demonstrated that 
docetaxel at a dose of 36 mg/m2 is feasible in this group of patients, with 
36% of patients achieving an objective response.(5) 
 Paclitaxel is an active drug in first-line therapy of metastatic breast 
cancer, as well as in patients with relapsed or refractory disease.(6-8) 
Response rates of 21–61% in previously untreated patients have been 
reported in phase II and III trials evaluating paclitaxel at doses of 135-250 
mg/m2 in a 3-weekly schedule.(6,8-16) In vitro experiments and clinical studies 
have suggested that prolonged exposure to paclitaxel, through either a 
continuous infusion schedule or a weekly administration, can lead to 
enhanced cytotoxicity, while maintaining a favourable toxicity profile.(17-19) 
The weekly schedule of administrating paclitaxel therefore seems an 
attractive chemotherapeutic regimen for elderly patients. Paclitaxel has been 
used in elderly patients, but specific trials for this population, exploring the 
weekly administration schedule as first-line treatment, were lacking. We 
performed such a study in patients >70 years of age with hormone-refractory 
metastatic breast cancer to assess the activity and toxicity. 
 
Patients and methods 
 
Eligibility 
 Patients who were previously chemotherapy-naïve with respect to their 
metastatic disease and refractory to hormonal treatment were eligible for this 
study. Other eligibility criteria included age of at least 70 years, histologically 
documented and measurable (or evaluable) metastatic breast cancer; a 
baseline World Health Organization (WHO) performance score (PS) of ≤ 2; a 
life expectance of at least 3 months; bilirubin <25 µmol/l; creatinine <175 
µmol/l; white blood cells (WBC) count >1.5 x 109/l; platelet count >100 x 
109/l; haemoglobin >6.0 mmol/l; no signs of central nervous system (CNS) 
involvement; or neuropathy > WHO grade 1. All patients gave their written 
informed consent. The institutional ethical boards of the participating 
hospitals approved the study. 
 Pre-treatment evaluations included a medical history, complete physical 
examination, a complete blood count with differential, and the following 
serum chemistry tests: electrolytes, creatinine, glucose, alkaline 
phosphatase, aspartate-aminotransferase (AST), alanine-aminotransferase 
(ALT), lactate-dehydrogenase (LDH), and total and direct bilirubin. The 
cardiological function was evaluated by electrocardiogram (ECG), and by a 
multiple gated acquisition (MUGA) scan when indicated. All sites of disease 
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were documented by computerised tomography (CT), X-ray, or bone scan, 
depending on the site of disease activity. 
 
Treatment 
 Paclitaxel (Taxol£, Bristol-Myers Squibb, Woerden, The Netherlands) was 
infused intravenously (I.V.) over 1 hour, at a dose of 80 mg/m2, and given on 
day 1, 8 and 15 of a 28 day cycle. Standard intravenous premedication to 
prevent hypersensitivity reactions (HSR) consisted of dexamethasone 8 mg, 
clemastine 2 mg and ranitidine 50 mg administered approximately 30 
minutes before the paclitaxel infusion.(20) During treatment blood cell count 
and toxicity assessment were performed weekly. Toxicity was evaluated 
using the National Cancer Institute common toxicity criteria version 2.0 
(URL:https://webapps.ctep.nci.nih.gov/ ctcv2/plsql/ctc000w$.startup). The 
dose of paclitaxel was modified depending on the haematological and non-
haematological effects observed. The treatment was postponed in case of a 
neutrophil count < 0.5 x 109/l, and/or platelet count < 50 x 109/l, febrile 
neutropenia (temperature > 38oC and neutrophil count < 1.0 x 109/l), any 
grade > 1 non-haematological toxicity, except nausea and vomiting or 
alopecia. When treatment had to be postponed for a second week, the 
patient went off study. In case the administration had to be postponed for 1 
week, the dosage of paclitaxel was reduced with 10 mg/m2 in the next 
course. In case more than two dose reductions were necessary, the patients 
went off study. In patients who tolerated the weekly regimens for 3 
consecutive administrations without delay, a dose escalation to 90 mg/m2 
per administration was allowed at the discretion of the treating physician.  
 
Response evaluation and follow-up 
 Response evaluation criteria in solid tumours (RECIST) criteria were 
used to define measurable and evaluable disease and response.(21) Response 
was evaluated after every two cycles of treatment (i.e. every 8 weeks), and 
every 2 months thereafter for the first year and every 3 months for the 
following years, for all responding and stable patients until progression. 
Paclitaxel treatment was stopped in the case of progressive disease, stable 
disease (SD) after 16 weeks (four cycles), at patient’s preference at any time, 
or at unacceptable toxicity. 
 
Statistical analysis 
 The primary endpoint in this study was the overall response rate of 
weekly administered paclitaxel. 
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 The sample size was calculated based on the assumption that a 40% 
objective response rate would be detected. The accrual consisted of two 
stages. If there were no complete or partial responses in the first 6 enrolled 
patients, the study would be terminated. In the case of one or more 
responses in these 6 patients, 19 additional patients would be enrolled (for a 
total of 25 patients), so that the standard error of response rate would be 
less than or equal to 0.10. This scheme ensured that if the drug is active in 
at least 40% of the patients, the chance of erroneously rejecting the drug 
after the first 6 patients is less than 5%. The advantage of such two-stage 
scheme is that it allows early rejection of an ineffective drug. 
 Time to disease progression (TTP) was estimated from the beginning of 
paclitaxel therapy, while duration of response (DR) was determined from the 
date the response [complete response (CR) or partial response (PR)] was 
initially reported. Patients who discontinued treatment for any reason or 
died from probable disease-related causes were considered, at that time, as 
having disease progression. 
 The Kaplan-Meier analysis method was used to calculate duration of 
response, and TTP curves. 
 
Results 
 
Patient characteristics 
 The demographics of the 26 enrolled patients is depicted in Table 1. All 
but 5 patients presented with a PS of 0-1. The time from first diagnosis of 
breast cancer to study entry was more than 12 months in 19 patients (73%), 
6 – 12 months in 1 patient (4%), and less than 6 months in 6 patients (23%). 
All patients were chemotherapy naïve for their metastatic disease. 
 
Treatment characteristics 
 A total of 101 treatment cycles was administered to 26 patients. Since 
two responses were noted in the first 6 patients, a total of 25 patients had to 
be included according to the protocol. All patients were evaluable for toxicity. 
One patient was replaced due to the development of a severe HSR 
immediately at the start of the first paclitaxel infusion. One other patient 
developed erythema after paclitaxel infusion, but she was evaluable for 
toxicity evaluation after this single course. One patient received only 2 cycles 
due to vomiting (grade 3) and refused further treatment. In 6 out of the 23 
remaining patients (26%), the dose was escalated to 90 mg/m2. In 2 
patients, the dose was lowered to 70 mg/m2. The median delivered dose 
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intensity was 240 mg/m2/4-week-cycle (range 210 – 270). The median 
number of cycles delivered was 4 (range 1 – 11). 22 patients completet at 
least 2 cycles, 15 patients completed 4 or more cycles. Treatment delay was 
uncommon and was most often related to patients’ requests, rather than 
toxicity. Nine patients (35%) continued treatment after 4 cycles.  
 
Table1. Patient and tumour characteristics 
 n (%) 
n 
 
Age in years 
Median 
Range  
Performance status 
0 
1 
2 
ER/PR 
Positive 
Negative 
Unknown 
Previous adjuvant  
Chemotherapy 
HT 
Previous hormonal treatment for metastatic disease
0 
1 line 
2 lines  
≥ 3 
No of metastatic sites 
1 organ 
2 organs 
≥ 3 organs 
Site of metastasis 
Locoregional only 
Distant 
Bone 
Lung 
Liver 
Lymph Node 
Distant only 
Locoregional + distant 
26 
 
 
77 
71-84 
 
4 
17 
5 
 
10 
10 
6 
 
1 
6 
 
7 
2 
9 
8 
 
2 
11 
13 
 
1 
 
19 
6 
10 
11 
18 
7 
(100) 
 
 
 
 
 
(15) 
(65) 
(20) 
 
(39) 
(38) 
(23) 
 
(4) 
(23) 
 
(27) 
(8) 
(35) 
(31) 
 
(8) 
(42) 
(50) 
 
(4) 
 
(73) 
(23) 
(38) 
(42) 
(69) 
(27) 
 
HT = hormonal therapy; ER = oestrogen receptor; PR = progesterone receptor 
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 Table 2. Worst grade toxicity per patient observed (% of patients)a 
NCI toxicity grade 
Toxicity 
1 2 3 4 
Neutropena 
Anaemia 
Thrombocytopenia 
Infection 
Febrile neutropenia 
HSR 
Fatigue 
Alopecia 
Neuropathy 
Myalgia 
Nausea 
Vomiting 
Nail disorders 
Stomatitis 
50 
15 
- 
- 
- 
- 
27 
15 
23 
8 
4 
- 
8 
23 
23 
27 
- 
4 
4 
4 
38 
73 
12 
- 
12 
4 
4 
8 
12 
12 
- 
- 
- 
4 
4 
NA 
4 
- 
- 
4 
- 
- 
- 
- 
- 
- 
- 
- 
- 
NA 
- 
- 
- 
- 
- 
- 
 
a26 patients were evaluable for toxicity, of whom 1 patient received ony a few mg’s of 
paclitaxel 
HSR=hypersensitivity reactions; NCI=National Cancer Institue; NA=not available. 
 
 
Toxicity 
 Toxicity data were evaluated in the 25 patients receiving at least one full 
cycle. Toxicity data are outlined in Table 2. Overall, paclitaxel therapy was 
relatively well tolerated and manageable on an outpatient basis (Table 2). 
Myelosuppression was mild and relatively infrequent. Fatigue constituted an 
important problem and occurred in 67% of patients. In 8 patients (32%), 
fatigue was the reason for treatment discontinuation. Fatigue could not be 
related to anaemia. In many of these elderly patients, the distinction between 
cancer-related and treatment-related fatigue was difficult to determine. 
Neuropathy occurred in 39% of patients and resulted in discontinuation of 
treatment in three patients. Neuropathy grades 2 and 3 were only seen after 
5 or more courses in 4 out of 9 patients. Nausea was observed in 11 
patients, but not during all their paclitaxel administrations. Alopecia grade 1 
developed in 4 patients; grade 2 in 15 patients. Other toxicities consisted of 
oedema and nail changes in less than 10% of patients, and were all easy to 
manage (CTC grades 1 and 2). Two patients were withdrawn from the study 
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due to HSR. One patient developed a grade 3 toxicity (neutropenia and 
generalised erythroderma) after the first administration; the other patient 
suffered a severe allergic reaction with hypotension after the infusion of a 
small amount of paclitaxel and was not evaluable for further toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kaplan-Meier analysis of time to progression (TTP) of patients treated with weekly 
paclitaxel. Median time to progression = 194 days. Data were censored at May 1, 2003; at this 
time, 2 patients were still free of progression. 
 
 
Tumour response and survival 
 In 23 out of 26 patients (88%) enrolled, the response could be assessed. 
A total of 3 patients were not evaluable for response due to early treatment 
discontinuation because of severe HSR in 2 patients, and vomiting grade 3 in 
1 patient. Two patients withdrew informed consent because of side-effects 
after 2 treatment courses. Ten patients achieved PR (38% - intent-to-treat-
analysis), complete responses were not seen. In addition, SD was observed in 
9 patients.  
 Time-to-progression (TTP) analysis (Figure 1) was performed on May 1, 
2003, at which time 15 patients had died, including the 3 non-evaluable 
patients. Two patients were still in remission. The median time-to-
progression was 6.5 months. Median follow-up time for surviving patients 
was 557 days (range 196-1141). 
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Discussion 
 
 Weekly paclitaxel is clearly active as first line treatment in patients with 
metastatic breast cancer, and has several suggested advantages over 3-week 
schedules in terms of both toxicity and probably efficacy.(16,22-24) In the 
current study, we assessed toxicity and efficacy of weekly paclitaxel as first 
line treatment in patients older than 70 years with metastatic breast cancer. 
This is a clearly underrepresented age group in trials for chemotherapeutic 
treatment of metastatic breast cancer, which is probably due to the high 
incidence of co-morbidity, and the reluctance of physicians to treat elderly 
patients with chemotherapy. Nevertheless, in this phase 2 study a sufficient 
number of patients was included, although the accrual was relatively slow. 
 Weekly paclitaxel at this dose and schedule yielded a response rate of 
38%. This response rate seems relatively high compared to the response rate 
of 20% reported by Perez and colleagues,(25) but might be explained by the 
differences in pre-treatment. All of our patients except one were 
chemotherapy-naïve, while 82% of patients in the study of Perez received 
prior chemotherapy. Response rates of 21 to 49% have been reported from 
other multicentre trials of single agent paclitaxel administered at different 
doses and with different infusion schedules every 3 weeks to patients with 
metastatic breast cancer.(6,8-16) Thus, our response results are within the 
range observed in other trials with paclitaxel. In addition, weekly treatment 
with both docetaxel(5) and vinorelbine(26) in elderly patients revealed similar 
response levels. 
 The regimen appears relatively feasible, but the observation of fatigue in 
67% of patients is of concern. In other studies with weekly administrations 
of paclitaxel in elderly patients, a similar incidence of asthenia was 
reported.(25,27) This side-effect following weekly docetaxel treatment in elderly 
appears to be even more severe when compared with paclitaxel treatment, 
since Hainsworth and colleagues reported grade 3 fatigue in 20% of patients, 
and grades 1 and 2 in 73% of patients.(5) Given the relatively short median 
treatment period of 16 weeks, the incidence of neuropathy in this weekly 
paclitaxel regimen is another reason for concern, although neuropathy > 
grade 1 was only noted after 5 or more cycles. By contrast, docetaxel causes 
hardly any neuropathy in the weekly regimen.(5)  
 In agreement with other studies with weekly paclitaxel, only a few 
patients (12%) developed serious haematological side-effects of neutropenia 
of more than grade 2. This is in line with the haematological side-effects 
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reported in the weekly docetaxel regimen.(5) In the weekly regimen with 
vinorelbine, haematological side-effects were the dose-limiting toxicity.(26)  
 The pharmacokinetic study reported by Smorenburg and colleagues 
performed in this group of patients revealed that the clearance of both 
unbound and total paclitaxel are significantly lower in elderly women with 
metastatic breast cancer, as compared with younger females (124 ± 35.0 
versus 237 ± 43.0 l/h/m2 (p=0.002), and 13.9 ± 2.31 versus 17.4 ± 4.52 
l/h/m2 (p=0.004) respectively.(28) In the entire population, a significant 
negative correlation was observed between age and unbound paclitaxel 
clearance. Therefore, we anticipated observing increased toxicity in this 
elderly population, compared with younger patients. Obviously, a formal 
comparison cannot be made. However, the number of treatment 
discontinuations based on fatigue, and to a lesser extent based on 
neuropathy, is of concern. It suggests a decreased tolerance in this elderly 
population. Whether this is related to the decrease in drug clearance 
remains to be elucidated. In addition, the same pharmacokinetic study 
revealed a significant and rather unusual increase in Cremophor EL (CrEL) 
clearance. Since neuropathy(29,30) and HSR(20,30) are partly related to this 
vehicle, a lower incidence of these side-effects could be expected. However, 
this was not the case.  
 In conclusion, the weekly administration of paclitaxel is an effective first 
line regimen for elderly patients with metastatic breast cancer, but yields 
relevant toxicity. Fatigue is the main toxicity, and, overall, is the main 
reason for treatment discontinuation. Weekly paclitaxel can be considered 
for elderly patients with metastatic breast cancer, although will not be 
tolerated in the longer run in an important sub-set of patients.  
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From the early nineties both paclitaxel and docetaxel have obtained a 
prominent position in anticancer treatment. Many publications have since 
discussed their clinical pharmacological properties, although many aspects 
still remain to be elucidated, in particular those related to pharmacokinetic 
interference by other agents administered concomitantly.  
 
Chapter 2 reviews the neglected role of the non-ionic formulation vehicles 
Cremophor EL and Tween 80, that are used to administer the poorly water-
soluble drugs paclitaxel and docetaxel, respectively. In contrast to earlier 
views, these excipients are not inert, but can exert a variety of side effects 
and can cause clinically significant drug interactions. 
 
In chapter 3 the comparative pharmacokinetics of both vehicles is described 
in a group of patients with cancer. The study revealed that the relative 
systemic exposure to Tween 80 in humans is much lower as compared to 
Cremophor EL, as a result of different rates of elimination. The 
disappearance of Tween 80 from the central compartment was characterized 
by a short terminal half-life with a mean (± standard deviation (SD)) value of 
0.607 ± 0.245 hrs and a total plasma clearance of 7.70 ± 2.90 L/h. In 
contrast, elimination of Cremophor EL was much slower, with values for 
half-life and clearance of 35.7 ± 18.9 hours and 0.216 ± 0.075 L/h, 
respectively. The slower clearance of the latter vehicle is consistent with 
Cremophor EL being more likely to be associated with drug interactions and 
excipient-related toxic effects. It is therefore recommended to evaluate the 
pharmacokinetic properties of excipients as an integral component of the 
development of poorly water-soluble agents. 
 
In chapter 4 the interaction of the P-glycoprotein inhibitor valspodar 
(PSC833; Amdray) with the pharmacokinetics of paclitaxel is described in 
order to explain the increased myelotoxicity of paclitaxel when it is given in 
combination with valspodar. In a clinical study, it was shown that valspodar 
lacks the significant interaction with paclitaxel as compared to studies with 
other P-glycoprotein modulators. The apparent clearance of unbound 
paclitaxel was not significantly different with mean (± SD) values of 230 ± 
49.9 and 202 ± 49.9 L/h/m2 in the absence and presence of valspodar, 
respectively. These findings further suggest that the plasma concentrations 
of paclitaxel may not be an appropriate measure to monitor the impact of P-
glycoprotein inhibition. 
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In chapter 5 an interaction study on docetaxel combined with ketoconazole 
is reported. This combination of drugs is currently being developed for the 
treatment of prostate cancer. Ketoconazole is a known potent inhibitor of the 
main enzyme involved in the elimination of docetaxel (i.e., CYP3A4), and 
hence an interaction was suspected. Indeed, the concomitant administration 
of ketoconazole with docetaxel resulted in a significant 32% decrease in 
clearance of the taxane. The mean clearance values of docetaxel were 33 L/h 
(range, 20 – 50 L/h) and 27 L/h (range, 7 – 46 L/h) in the absence and 
presence of ketoconazole, respectively. The interaction with ketoconazole 
resulted in an increase in docetaxel concentrations that were previously 
shown to be associated with an up to 4-fold increase in the odds to develop 
neutropenic fever at the recommended dose of docetaxel. This suggests that 
substantial dose reductions are required when docetaxel is combined with 
agents interfering with CYP3A4 activity. 
 
The penetration of cytostatic agents into the central nervous system remains 
a controversial issue. In chapter 6 the penetration of docetaxel in the 
cerebrospinal fluid (CSF) in 2 breast cancer patients with leptomeningeal 
metastasis is reported. Although the concentration of docetaxel in CSF 
remains well below those measured in plasma, the pharmacologically-
relevant fraction unbound docetaxel in plasma samples ranged from 5.9 to 
12.8%, while those in CSF ranged from 66.7 to 103%. Since the drug 
remained in CSF much longer than in plasma, the penetration and retention 
of docetaxel in CSF can potentially reach levels associated with significant 
antitumor activity. 
 
Despite the increasing numbers of elderly patients presenting with cancer, 
only few pharmacological studies have been conducted in this subgroup of 
patients. Furthermore, elderly patients are underrepresented in trials on 
cancer therapy. The pharmacokinetics of anticancer drugs may be altered 
with aging due to several factors, including differences in end organ function 
and body composition. Besides that, elderly patients may be intrinsically 
more susceptible to toxic effects of certain cytostatic agents. In chapter 7 
the pharmacokinetics of both unbound and total paclitaxel in 8 elderly 
women (age ≥ 70 years) with breast cancer are compared to a control group 
of 15 patients aged < 70 years. In both groups paclitaxel was administered 
once weekly at a dose of 80 or 100 mg/m2. The clearance (± SD) of unbound 
paclitaxel and total paclitaxel was 124 ± 35.0 and 13.9 ± 2.3 L/h/m2 in the 
elderly group vs. 244 ± 58.8 and 17.4 ± 4.5 L/h/m2 in the control group, 
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respectively. The total plasma clearance of Cremophor EL was 150 ± 60.7 vs. 
115 ± 39.2 mL/h/m2, respectively. These data indicate that the clearance of 
unbound paclitaxel is approximately 50% reduced in elderly patients as 
compared to younger patients, resulting in a significant increase in systemic 
exposure with age. The unexpected increase in clearance of Cremophor EL in 
the elderly may (in part) explain the altered clearance of unbound paclitaxel. 
 
In contrast to paclitaxel, a prospective study on docetaxel administered at a 
dose of 75 mg/m2 in a 3-weekly regimen in elderly patients (≥ 65 years) and 
patients < 65 years, described in chapter 8, revealed an unchanged mean (± 
SD) docetaxel clearance of 30.1 ± 18.3 vs. 30.0 ± 14.8 L/h, respectively. In 
support of this lack of age-dependence, it was shown that phenotypic activity 
of CYP3A4, as assessed using the erythromycin breath test, was not 
changing with advancing age. Although there was no significant difference 
observed in treatment-related side effects between the two age groups, the 
incidence of neutropenic fever seemed to be slightly increased in the elderly. 
 
In chapter 9, the results of a multicenter Phase II clinical trial is described 
on the chemotherapeutic treatment of elderly patients with breast cancer 
receiving single agent paclitaxel once weekly at a dose of 80 mg/m2. The 
study revealed that with this schedule a response rate of 38% can be 
achieved, with 34% of patients showing stable disease. The median duration 
of response was > 6 months and overall treatment was well tolerated with 
only mild and infrequent myelosuppression. Fatigue constituted an 
important problem and occurred in 67% of patients. 
 
Future perspectives 
 
The work presented in this thesis aimed at identifying factors involved in 
pharmacokinetic alterations for taxane drugs, including formulation 
vehicles, concomitant medication and patient demographic characteristics 
like age. However, there is still a substantial degree of interpatient variation 
in the pharmacokinetics of both drugs, ultimately leading to unpredictable 
treatment outcome (ie, toxicity and efficacy). The residual pharmacokinetic 
variability that cannot be explained by the factors evaluated in this thesis 
likely involve individual variation in plasma protein binding capacity and/or 
in hepatic metabolism by members of the cytochrome P-450 family. 
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Currently ongoing studies will focus on the role of inherited factors 
regulating the expression and function of these proteins, and will hopefully 
lead to a more predictable pharmacokinetic behavior of the taxanes. 
However, it is likely that in addition to genetic components, other 
environmental and physiological factors not studied here may influence the 
clinical pharmacology of the taxanes. Hence, it seems imperative to design 
additional prospective studies in the future employing both genotyping and 
phenotyping approaches of proteins crucial to drug elimination in order to 
eventually individualize and improve chemotherapeutic therapy with 
taxanes. 
 
Finally, the drawbacks presented by the presence of Cremophor EL and 
Tween 80 as an integral component of the pharmaceutical formulation of 
paclitaxel and docetaxel have instigated extensive research to develop 
alternative delivery systems. These alternative formulations of the taxanes 
should eventually enable a safer administration with less likelihood of 
interactions between the formulation vehicle and the active drug, and a 
reduced incidence and severity of vehicle-mediated side-effects. Such 
alternative formulations, including those involving nanoparticles, also 
should enable the drug to be administered without premedication and lead 
to a more predictable and sustained exposure of the tumor to the drugs, 
leading to a more favorable treatment outcome.  
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Samenvatting, conclusies en toekomstige ontwikkelingen 
 
Sinds de jaren 90 hebben zowel paclitaxel als docetaxel een belangrijke 
plaats verworven in de behandeling van kanker. In vele publicaties zijn de 
klinisch farmacologische eigenschappen van beide middelen besproken. 
Desondanks zijn er nog veel onopgehelderde aspecten, met name de 
interactie met andere, gelijktijdig toegediende geneesmiddelen. 
 
In hoofdstuk 2 wordt een overzicht gegeven over de onderschatte rol van de 
niet-ionogene oplosmiddelen Cremophor EL en Tween 80, die respectievelijk 
gebruikt worden om de slecht-wateroplosbare middelen paclitaxel en 
docetaxel toe te dienen. In tegenstelling tot vroegere opvattingen zijn beide 
oplosmiddelen niet inert, maar kunnen aanleiding geven tot vele 
bijwerkingen en leiden tot klinisch relevante interacties met (andere) 
geneesmiddelen. 
 
In hoofdstuk 3 worden de farmacokinetische eigenschappen van beide 
oplosmiddelen nader belicht aan de hand van een studie uitgevoerd bij 
kankerpatiënten. Deze studie leerde dat de relatieve blootstelling aan Tween 
80 veel geringer is ten opzichte van Cremophor EL t.g.v. een verschil in 
afbraaksnelheid. Tween 80 heeft een korte halfwaardetijd met een 
gemiddelde waarde (± standaard deviatie (SD)) van 0,607 ± 0,245 uur en een 
plasmaklaring van 7.70 ± 2.90 L/uur. De eliminatie van Cremophor EL was 
daarentegen beduidend langzamer, met een halfwaardetijd van 35,7 ± 18,9 
uur en een plasmaklaring van 0,216 ± 0,075 L/uur. De trage klaring van 
Cremophor EL is overeenkomstig observaties dat dit oplosmiddel vaker 
aanleiding geeft tot geneesmiddelinteracties en bijwerkingen dan Tween 80. 
Het is daarom aan te bevelen om bij de ontwikkeling van slecht-
wateroplosbare geneesmiddelen ook de farmacologische eigenschappen van 
oplosmiddelen in ogenschouw te nemen. 
 
In hoofdstuk 4 wordt de interactie van de P-glycoproteineremmer valspodar 
(PSC833; Amdray®) beschreven, om inzicht te verwerven in de toegenomen 
paclitaxel-gerelateerde beenmergtoxiciteit bij gelijktijdige toediening van 
valspodar. In een klinische studie wordt aangetoond dat er geen duidelijke 
aanwijzingen zijn voor een farmacologische interactie tussen beide 
geneesmiddelen, i.t.t. studies met andere P-glycoproteineremmers. De 
gemeten klaring van ongebonden paclitaxel bedroeg 230 ± 49,9 L/uur/m2 
(gemiddelde (± SD)) in de afwezigheid en 202 ± 49,9 L/uur/m2 in de 
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aanwezigheid van valspodar; hetgeen niet significant verschillend is. Deze 
resultaten suggereren dat het meten van paclitaxel concentraties in het 
plasma geen goede manier is om de gevolgen van P-glycoproteineremming te 
meten. 
 
In hoofdstuk 5 wordt een interactie-studie over de combinatie van docetaxel 
met ketoconazole beschreven. De combinatie van deze geneesmiddelen wordt 
momenteel ontwikkeld voor de behandeling van prostaatkanker. 
Ketoconazole is echter een krachtige remmer van het leverenzyme CYP3A4 
dat betrokken is bij de afbraak van docetaxel, waardoor farmacologische 
interacties mogelijk zijn. Inderdaad bleek de gemiddelde docetaxelklaring in 
respectievelijk af- en aanwezigheid van ketoconazole 33 L/uur (uitersten, 20 
– 50 L/uur) en 27 L/uur (uitersten, 7 – 45 L/uur). Deze significant 
vertraagde plasmaklaring van 33% resulteerde in een toename van 
docetaxelconcentraties die geassocieerd zijn met een 4-voudige toename in 
de kans op het ontwikkelen van neutropene koorts bij de aanbevolen 
standaarddosering van docetaxel. Het lijkt derhalve dat substantiële dosis 
reducties van docetaxel noodzakelijk zijn, indien het middel moet worden 
gecombineerd met remmers van CYP3A4. 
 
De doordringbaarheid van het centraal zenuwstelsel voor cytostatica blijft 
een controversieel onderwerp. In hoofdstuk 6 wordt de penetratie van 
docetaxel in het hersenvocht beschreven bij twee patiënten met borstkanker 
met leptomeningeale metastasering. Alhoewel de gemeten docetaxel- 
concentraties in het hersenvocht duidelijk lager zijn dan die in het plasma, 
bleek het farmacologisch relevante, ongebonden docetaxel in plasma te 
variëren van 5,9 tot 12,8%, terwijl die in de hersenvocht varieerde van 66.7 
tot 103%. Omdat docetaxel veel langer in het hersenvocht verbleef dan in 
plasma, zou dit kunnen leiden tot antitumoractiviteit. 
 
Ondanks de recent toegenomen prevalentie van ouderen met kanker, zijn er 
maar weinig farmacologische studies verricht in deze specifieke 
patiëntengroep. Verder zijn oudere patiënten duidelijk ondervertegen-
woordigd in klinische onderzoeken gericht op de behandeling van kanker. De 
farmacokinetiek van cytostatica zou kunnen veranderen op hogere leeftijd 
t.g.v. een aantal factoren, zoals veranderingen van orgaanfuncties en 
lichaamssamenstelling. Daarnaast zouden ouderen meer gevoelig kunnen 
zijn voor de bijwerkingen van cytostatische behandeling. In hoofdstuk 7 
wordt de farmacokinetiek van paclitaxel in 8 oudere patiënten ( 70 jaar) 
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vergeleken met die van 15 patiënten < 70 jaar. In beide groepen werd 
paclitaxel toegediend in doseringen van respectievelijk 80 of 100 mg/m2. De 
plasmaklaring van zowel vrij als totaal paclitaxel was 124 ± 35,0 and 13.,9 ± 
2,3 L/uur/m2 in de oudere groep vs. 244 ± 58,8 and 17,4 ± 4,5 L/uur/m2 in 
de groep jongere patiënten. Daarentegen was de plasmaklaring van 
Cremophor EL in de oudere groep juist hoger: 150 ± 60,7 vs. 115 ± 39,2 
mL/uur/m2. Deze resultaten tonen dat de klaring van vrij paclitaxel in de 
oudere patiënten met ca. 50% is afgenomen t.o.v. de jongeren, hetgeen zal 
leiden tot een significante toename in blootstelling aan vrij paclitaxel. De 
onverwachte toename in Cremophor EL klaring zou een mogelijke verklaring 
kunnen zijn voor de afname in vrij paclitaxel klaring. 
 
In tegenstelling tot paclitaxel, leerde een studie beschreven in hoofdstuk 8, 
dat de docetaxelklaring niet veranderd op hogere leeftijd. De gemiddelde (± 
SD) plasmaklaring van docetaxel in de ouderen was 30,1 ± 18,3 vs. 30,0 ± 
14,8 L/uur in de jongere groep. Ter verdere ondersteuning voor de 
afwezigheid van een leeftijdseffect bleek ook de fenotypische activiteit van het 
lever enzym CYP3A4, gemeten m.b.v. de erythromycineademtest, niet 
veranderd op hogere leeftijd. 
 
In hoofdstuk 9 worden de resultaten beschreven van een klinisch fase II 
onderzoek verricht in samenwerking met diverse Nederlandse instituten naar 
de chemotherapeutische behandeling van oudere borstkanker patiënten met 
paclitaxel in een eenmaal-per-week toediening van 80 mg/m2. Deze studie 
toont dat met dit schema een responspercentage van 38% kan worden 
bereikt, met daarnaast 34% van de patiënten met stabilisering van de ziekte. 
De mediane responsduur was > 6 maanden en over het algemeen werd de 
behandeling goed verdragen met relatief geringe beenmergtoxiciteit. 
Vermoeidheid vormde de belangrijkste bijwerking en trad op in 67% van de 
patiënten. 
 
Toekomstige ontwikkelingen 
 
Het werk gepresenteerd in dit proefschrift had tot doel het identificeren van 
factoren die de farmacokinetiek van taxanen kunnen beïnvloeden, zoals 
oplosmiddelen, gelijktijdig toegediende medicatie en patiëntkenmerken zoals 
leeftijd. Helaas is er nog steeds een substantiële interpatiëntvariatie in de 
farmacokinetiek van beide cytostatica, die zowel kunnen leiden tot 
onvoorspelbare toxiciteit en effectiviteit. Deze variatie wordt niet alleen 
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bepaald door de voornoemde factoren, maar waarschijnlijk ook door 
interpatiëntvariatie in metabolisme door het cytochroom P450 systeem en 
door variatie in de mate van eiwitbinding in plasma. 
 
Momenteel zijn er studies gaande die de rol van erfelijkbepaalde factoren 
verder ontrafelen, zodat hopelijk in de toekomst het farmacokinetisch gedrag 
van beide taxanen beter wordt begrepen en dus ook beter kan worden 
voorspeld. Het is echter aannemelijk dat naast de erfelijkbepaalde factoren 
ook omgevingsinvloeden en fysiologische aspecten de farmacokinetiek van 
taxanen beïnvloeden. Het lijkt derhalve noodzakelijk om in de toekomst 
studies op te zetten die zowel genotypische als fenotypische factoren van 
eiwitten en enzymen betrokken bij het taxaanmetabolisme onderzoeken, om 
uiteindelijk taxanen op geïndividualiseerde basis te kunnen toedienen. 
 
Tenslotte, de nadelen die de aanwezigheid van Cremophor EL en Tween 80 in 
de farmaceutische formulering van paclitaxel en docetaxel met zich 
meebrengen, hebben uitgebreide onderzoeken geïnitieerd om nieuwe 
toedieningsvormen te ontwikkelen. Deze alternatieve toedieningsvormen 
moeten uiteindelijk leiden tot minder oplosmiddelgerelateerde bijwerkingen 
en verminderde kans op het ontwikkelen van interacties met het actieve 
geneesmiddel. Dergelijke nieuwe formuleringen, bijvoorbeeld bestaande uit 
zogenaamde nanoparticles, moeten in de nabije toekomst toediening zonder 
pre-medicatie mogelijk maken en leiden tot langere blootstelling van de 
tumor aan het cytostaticum, met mogelijk verbeterde behandelingsuitkomst. 
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